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General Introduction and 
Aims of this Thesis
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General Introduction and Aims of this Thesis
Desmoid-type fibromatosis (DTF) is a rare, soft tissue tumour with an incidence in the 
Dutch population of 5 patients per million people per year 1. The likelihood that a doctor 
encounters a desmoid patient in his professional career is low, but early recognition, referral 
to a specialized centre, and accurate treatment are crucial. This thesis describes desmoid-
type fibromatosis in the broadest sense and aims to contribute to the knowledge of this 
rare disease.
Desmoid-type fibromatosis has been given a variety of names since its discovery about 185 
years ago 2, 3. These include: aggressive fibromatosis, desmoid tumour, deep fibromatosis, 
fibromatosis, and desmoid fibromatosis. Just like the variety of names, DTF displays a wide 
range of clinical presentations and outcomes. DTF has no metastatic potential and cannot 
undergo malignant transformation. However, it can display aggressive and invasive growth, 
and has a tendency towards local recurrence. For this reason DTF is classified as a ‘locally 
aggressive but non-metastasizing’ tumour by the World Health Organization (D48.1) 4. It 
mostly affects females aged between 20 and 40 years 1. The clinical presentation can vary 
between a small lump without significant symptoms, to a large infiltrating and debilitating 
tumour, having a significant impact on the patients’ life.  
Genetics and Molecular Biology
DTF tumours express cell surface markers and genes that are characteristic of mesenchymal 
stem cells and seem to have a mesenchymal origin 5. It is a clonal fibroblastic proliferation 
that arises in connective tissue. Since connective tissues comprises a large part of the body’s 
musculoskeletal system, DTF can develop anywhere in the body 6.
Roughly two types can be distinguished: hereditary (familiar) and sporadic DTF. The 
hereditary type occurs more frequent in patients with familial adenomatous polyposis 
(FAP), and causes intra-abdominal DTF tumours. FAP-related DTF is an autosomal 
dominant disorder caused by germline mutation of the adenomatous polyposis coli (APC) 
gene. This hereditary condition predisposes to the development of extra- and intra-intestinal 
neoplasms, including malignant colorectal carcinoma and DTF tumours 7. The cumulative 
rate of DTF in FAP patients is 20.6% at 60 years of age 8. About 10% of FAP patients die 
from intra-abdominal DTF tumours. After colorectal carcinoma, DTF is the second most 
common cause of death in FAP 9.
1
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The second type, “sporadic-DTF”, derives from a single progenitor cell 10 and is the 
focus of this thesis. In contrast to hereditary DTF, sporadic DTF is commonly localized 
extra-abdominally (trunk or extremities) or in the abdominal wall 6. As a result, sporadic 
DTF is rarely fatal but can cause substantial morbidity and thereby sincerely impairing 
quality of life. The precise aetiology remains tenuous. Several studies report correlations 
with (spontaneous or iatrogenic) trauma and hormones, although translational studies, 
investigating the biological rational of these correlations, are lacking 11. The majority of 
sporadic DTF tumours, about 85%, have mutations in the CTNNB1 (β-catenin) gene 12-14. 
These mutually exclusive mutations are located in exon 3 and most commonly cause the 
following changes: a replacement of threonine to alanine at codon 41 (T41A), a replacement 
of serine for phenylalanine (S45F), or a replacement of serine for proline (S45P) at codon 
45. These mutations block the phosphorylation and subsequent degradation of β-catenin, 
which consequently leads to its stabilization and an increased level of β-catenin in the 
cytoplasm and in the nucleus 15. This aberrant level of β-catenin is useful for the diagnosis 
of DTF as immunopositivity for β-catenin can distinguish DTF from other myofibroblastic 
proliferations 16. The group without a mutation in the CTNNB1 gene, about 5-15%, has been 
designated as “wild-type” in the past 13. However, this group decreases over time as more 
sensitive sequencing tools, such as Next Generation Sequencing, become more widely 
available and reveal other rare mutations in CTNNB1 or other genes such as APC 13, 17, 18.
Diagnosis and Treatment 
During the diagnostic work-up, imaging (i.e., magnetic resonance imaging (MRI), 
ultrasound, or computed tomography) and a histologic tissue biopsy are obtained. The 
differential diagnosis of DTF is broad and includes scar tissue, keloid, nodular fasciitis, 
low-grade fibromyxoid sarcoma, and low-grade myofibroblastic sarcoma amongst 
other soft tissue tumours 16. Once the diagnosis of DTF is confirmed, using β-catenin 
immunopositivity and sequencing of the CTNNB1 gene, treatment in a sarcoma-specialised 
centre is a necessity 19. 
The treatment of DTF has dramatically changed over the past decade. Despite a doctors’ 
natural urge to start any form of treatment immediately after diagnosis, active surveillance 
(i.e., “wait and see”) has become the first treatment strategy for asymptomatic DTF 
tumours 19. Various retrospective studies show that “active surveillance” is safe 20, and 
that a minority of patients need to switch to an “active form” of treatment 21. Furthermore, 
1
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spontaneous regression is observed in up to 20% of patients 21. Especially for DTF tumours 
located in the chest wall, head, neck and upper limb, this active surveillance approach is 
beneficial since these “unfavourable locations” are generally considered challenging to 
treat, yielding severe morbidity 22. 
Forms of ‘active treatment’ like surgery, radiotherapy and systemic therapy, are indicated 
in case of a symptomatic and/or progressive DTF tumour 19. Surgery is first in line in 
case of failure of the active surveillance approach 22, 23. Radiotherapy as a single treatment 
modality has not shown any improvement of the risk of progression compared to surgery 
with adjuvant radiotherapy 24, 25. It can decrease symptoms and cause disease stabilization 
or even a partial or a complete response in patients with inoperable DTF 26. Adjuvant 
radiotherapy is only given in cases with a high chance of recurrence, which would be 
difficult to treat due to the unfavourable tumour location.
Several systemic treatment options are available to treat symptomatic and progressive DTF, 
for which surgery and/or radiotherapy is not a suitable option. Systemic options include non-
steroidal anti-inflammatory drugs (NSAID’s) alone or in combination with anti-hormonal 
agents such as tamoxifen 27-29, low dose chemotherapy such as a doxorubicin 30, 31, or a 
combination of methotrexate low dose with either vinblastine or vinorelbine 32-36, gamma-
secretase inhibitors such as Nirogacestat 37, and tyrosine kinase inhibitors such as imatinib 
38-40, sorafenib 41, 42, pazopanib 43, 44, or nilotinib 19. There is no consensus about the sequence 
of systemic treatments and the exact working mechanisms of these systemic agents in DTF 
remains unclear. Randomized data is currently only available for tyrosin kinase inhibitors 
(sorafenib vs. placebo (phase 3) 42 and pazopanib vs. methotrexate-vinblastin (phase 2) 43 
and gamma-secretase inhibitors (Nirogacestat vs. placebo) 45. The first trial reported an 
advantage for sorafenib in the 2-year progression-free survival (PFS) over placebo (81% 
(95% confidence interval [CI], 69-96) versus 36% (95% CI, 22-57). The second trial reported 
an advantage for pazopanib over methotrexate-vinblastin in progression-free proportion 
of patients measured at 6 months (83.7% (95% CI 69.3–93.2) vs 45% (95% CI 23.1–68.5). 
Gamma-secretase inhibitors, such as Nirogacestat, form an attractive therapeutic option as 
they inhibit the final step in the Notch signalling pathway, a pathway which is also known for 
its cross talk with the Wnt signalling pathway 46. Clinical phase 1 and 2 trials of the gamma-
secretase inhibitor PF-03084014 (later named Nirogacestat) showed promising results in 
which a substantial part of patients experienced partial response or disease stabilisation 47, 48. 
These results led to a phase 3 trials of which the inclusion is already closed and the results 
1
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are currently awaited 45. If positive, these results will lead to the first officially approved 
drug for DTF tumours.
Despite all these positive scientific advances, determination of the true therapeutic value 
of the most above-mentioned treatments remains challenging, as many trials only included 
progressive, inoperable, refractory DTF tumours. 
In this thesis, we focus on three aspects of DTF. Several studies identified a prognostic role 
for the CTNNB1 mutation but so far, no biological differences have been found. The first 
part therefor focusses on the molecular origin and biology of DTF. In this part, we aim to 
explain the observed clinical behaviour of the different mutations types by identification of 
biological differences. Due to the rarity of DTF, uniform imaging protocols are lacking, and 
diagnosis can be challenging. Treatment decisions are depending on symptoms and tumour 
site and up till now, the CTNNB1 mutation is not incorporated in the clinical decision-
making. The second part, deals with simplifying the diagnostic process by the use of 
radiomics. Furthermore, it focusses on two commonly used treatments: active surveillance 
and surgery. With low mortality rates and irrelevance of traditional oncology endpoints, the 
search for novel endpoints in clinical trials continues. The third part encompasses health-
related quality of life (HRQoL) describing the disease from a patients’ perspective. Insight 
into common DTF-related HRQoL-problems will lead to the development of a DTF-specific 
HRQoL-tool and HRQoL can be used as an endpoint in clinical trials.
Part I – Genetics and Molecular Biology
Mutations in the CTNNB1 gene cause accumulation of β-catenin in the nucleus and 
consequently aberrant Wingless (Wnt)/β-catenin signalling 15. Knowledge about the 
influence of other signalling pathways in the pathogenesis of DTF is limited. In Chapter 
2, we reviewed the current available literature regarding DTF and common cell signalling 
pathways such as JAK/STAT, Notch, PI3 kinase/AKT, mTOR, Hedgehog, the oestrogen 
pathway, and the growth regulatory pathway. Additionally, we described the current 
evidence for the use of therapies targeting the aforementioned signalling pathways. As 
the Wnt/β-catenin signalling pathway is one of the most important oncogenic pathways, 
we aimed to gain more insight into the Wnt/β-catenin signalling pathway in the setting of 
DTF. Several studies indicate that there is a difference in the clinical behaviour between 
the different CTNNB1 mutation types (T41A, S45F, and S45P) and wild-type DTF 12, 49-51. 
1
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Therefore, we investigated whether we could potentially explain this difference by studying 
mRNA expression data of known Wnt target genes in Chapter 3. 
DNA methylation is an epigenetic modification that influences gene expression and 
hence, gene activity 52. Abnormal DNA methylation have been described in various solid 
tumours and sarcomas 53, 54. In Chapter 4 we examined and compared genome-wide DNA 
methylation patterns of DTF tumours containing a T41A or an S45F CTNNB1 mutation.
Part II - Diagnosis and Treatment
Radiomics, makes use of computational computer algorithms designed to link imaging 
features to molecular, pathological and clinical features 55. By the annotation of tumours on 
conventional imaging, already obtained during the routine diagnostic work-up, radiomics 
can be used to contribute to diagnosis, prognosis and treatment decision making 56, 57. 
In Chapter 5 we investigated whether radiomics can be used to differentiate extremity 
DTF from other extremity tumours such as fibromyxosarcomas, myxoid liposarcomas 
and leiomyosarcomas on pre-treatments MRI. Additionally, we investigated whether our 
radiomics model could be used to differentiate the various CTNNB1 mutation types.
In recent years, active surveillance has obtained a more prominent role in the treatment of 
asymptomatic DTF. The recommendation that active surveillance should be the front-line 
approach for treating DTF published in the first European consensus guideline (2015) 58, was 
based on the results of five retrospective studies 20, 59-62. As the results of the three prospective 
studies 63-65 are still awaited, we performed a systematic literature review described in 
Chapter 6. This review systematically evaluates the results of the active surveillance 
approach in published retrospective series.
Since DTF is a rare disease, randomized controlled trials to investigate the efficacy of certain 
treatments are scarce. For a long time, surgery remained the gold standard for treating 
DTF; however, the risk of local recurrence after surgery was high, between 20% and 68% 
66, 67. Several studies 12, 49-51 found a significant correlation between risk of recurrence and 
mutation status and claimed that the S45F mutated DTF tumours have the highest chance 
of recurrence. Often, these studies included both primary and recurrent DTF tumours, and 
1
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several patients received adjuvant therapy after surgery, distorting the true prognostic value 
of the CTNNB1 mutation. In Chapter 7, we investigated the association of the different 
CTNNB1 mutations with the risk of recurrence, in a large international cohort of primary 
DTF patients treated with surgery solely. Studies were included based on an extensive 
literature search and individual patient data was used to create a large homogenous cohort 
of DTF patients. 
Part III - Health-related Quality of Life
The rarity, the high morbidity, and the increasing use of active surveillance as a first 
line management are reasons to better study the patients’ perspective. In Chapter 8, we 
performed a systematic literature search to investigate which HRQoL-tools are being used 
for DTF in clinical practice and in research setting. Additionally, we organized focus groups 
to gain insight into the HRQoL-problems experienced by DTF patients. In Chapter 9, we 
presented the retrieved HRQoL-issues to a new, international cohort of DTF patient and to 
healthcare professionals involved in the care of DTF patients, to identify the most important 
HRQoL-issues. In Chapter 10, we describe the study protocol of the QUALIFIED study 
(The evaluation of health-related quality of life issues experienced by patients with desmoid-
type fibromatosis): an international, multicentre, cross-sectional, observational cohort study 
which evaluates HRQoL-problems in the adult DTF population.
Part IV - General Discussion and Future Perspectives
This thesis describes the many faces of DTF. We provide insights into the molecular 
biology contributing to DTF pathogenesis, we incorporate new techniques such as 
radiomics to change the diagnostic pathway, we assess the role of the CTNNB1 mutation 
in risk of recurrence, and we evaluate how DTF impacts a patients’ life. In Chapter 11, the 
results from the previous chapters are discussed. Chapter 12 outlines future perspectives 
for DTF research.
1
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Abstract
Desmoid-type fibromatosis (DTF) is a rare, soft tissue tumour of mesenchymal origin, which 
is characterized by local infiltrative growth behaviour. Besides “wait and see”, surgery and 
radiotherapy, several systemic treatments are available for symptomatic patients. Recently, 
targeted therapies are being explored in DTF. Unfortunately, effective treatment is still hampered 
by the limited knowledge of the molecular mechanisms that prompt DTF tumorigenesis.
Many studies focus on Wnt/β-catenin signalling, since the vast majority of DTF tumours 
harbour a mutation in the CTNNB1 gene or the APC gene. The established role of the Wnt/β-
catenin pathway in DTF forms an attractive therapeutic target, however, drugs targeting this 
pathway are still in an experimental stage and not yet available in the clinic.
Only few studies address other signalling pathways that can drive uncontrolled growth in 
DTF such as JAK/STAT, Notch, PI3 kinase/AKT, mTOR, Hedgehog, and the oestrogen 
growth regulatory pathways. Evidence for involvement of these pathways in DTF 
tumorigenesis is limited and predominantly based on the expression levels of key pathway 
genes or on observed clinical responses after targeted treatment. No clear driver role for 
these pathways in DTF has been identified, and a rationale for clinical studies is often 
lacking. In this review, we highlight common signalling pathways active in DTF and provide 
an up-to-date overview of their therapeutic potential.
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Introduction
Desmoid-type fibromatosis (DTF) is a clonal fibroblastic proliferation of the soft tissues 
that arises in musculoaponeurotic structures 1. It has a mesenchymal origin since DTF 
tumours express cell surface markers and genes that are characteristic of mesenchymal 
stem cells 2. The incidence in the Dutch population is 5 patients per million people per year 
3. Unfortunately, worldwide epidemiological data is lacking. The abdominal wall and the 
trunk are the most common localisations and symptoms can vary, depending on tumour 
location and size 4, 5. Roughly, two types can be distinguished: sporadic and hereditary 
DTF. The first type is considered to be a monoclonal disorder, since it derives from a single 
progenitor cell 6. This “sporadic” type is commonly localized extra-abdominally or in the 
abdominal wall 5. The precise aetiology of sporadic DTF remains tenuous. Several studies 
report correlations with (spontaneous or iatrogenic) trauma and hormonal status 7-10. The 
hereditary type occurs more frequent in patients with familial adenomatous polyposis 
(FAP), and causes intra-abdominal DTF tumours. This DTF type is an autosomal dominant 
disorder caused by germline mutation of the adenomatous polyposis coli (APC) gene, and 
is associated with the formation of hundreds of colon polyps which can transform into 
malignant colorectal tumours in time (reviewed by De Marchis et al. 11 and Lips et al. 12). 
The cumulative rate of DTF in FAP patients is 20.6% at 60 years of age 13.
Desmoid-type fibromatosis is considered to be a borderline tumour because of its 
incapability to metastasize 1. The mortality of this disease is low and seldom described in 
literature. However, local aggressive growth can cause significant morbidity by infiltrating 
surrounding structures, causing pain or functional loss. Currently, “wait and see” is the 
first line therapy in case of asymptomatic DTF. Several retrospective studies report 
that a minority of patients on a “wait and see” protocol experience progression and that 
progression usually occurs within two years after tumour development 14. Additionally, up 
to one third of patients experience disease regression without any form of treatment 15-17. 
Three prospective studies investigating a “wait and see” approach (NCT02547831, Italy; 
NTR 4714, the Netherlands; NCT01801176, France) examine the natural growth behaviour 
of DTF and their relationship with CTNNB1 mutations 18-20. Surgery is the treatment of 
choice in case of failure of the “wait and see” management 21. Radiotherapy is mainly 
used as an adjuvant treatment in case of incomplete surgical resection. Radiotherapy as 
a single treatment modality may be considered for patients in whom local control is the 
primary treatment goal 21. When both surgery and radiotherapy are not an option due to 
tumour localization (e.g., near vital structures), or because of comorbidities, several other 
treatment options are available like local cryoablation and partial systemic chemotherapy via 
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isolated limb perfusion 21. Although not widely used, as the evidence for their effect in DTF 
is only based on small patient series, some patients benefit from these local therapies for 
example when limb salvage is the treatment goal 22-25. Besides targeted drugs, other systemic 
options include more classic chemotherapeutic compounds like vinblastine, vinorelbine, 
methotrexate, doxorubicin, dacarbazin, either as a single agent or as combination therapy 
21. Although most studies describe small retrospective case series and include patients who 
received other treatments prior to their cytotoxic treatment, multiple studies indicate a 
potential effect of these drug regimens 26-29.
The aggressive growth behaviour, in combination with the high recurrence rate, creates the 
need for effective drugs targeting the molecular mechanisms that drive tumorigenesis 30, 31. 
This is especially true for large, symptomatic tumours, which cannot be treated surgically, 
or with radiotherapy. As stated above, several systemic options are available with variable 
efficacy in different patients, but no consensus about the nature and the sequence of 
systemic treatments has been established 21. As of yet, the exact working mechanisms of 
these systemic agents in DTF remain unclear.
A better understanding of the molecular mechanisms that prompt tumorigenesis and 
influence DTF progression will contribute to the development and implementation of new 
targeted therapies. This review comprehensively screened the available literature regarding 
active cell signalling and biochemical pathways and reviews pathway-specific targeted 
drugs investigated in DTF. Additionally, the challenges of DTF research, as well as the 
future perspectives, are discussed. The abbreviations used in the text, tables and figures 
are explained in Supplemental Material 1.
The Wnt/ß-catenin signalling pathway in desmoid-type  
fibromatosis
The Wnt/ß-catenin signalling pathway
The canonical Wnt/ß-catenin pathway coordinates cell fate decisions during the 
developmental process and in adult homeostasis. Target genes of this signalling pathway 
are involved in regulating the balance between self-renewal, differentiation, apoptosis, and 
in stem cell maintenance (reviewed by Nusse and Clevers 32 and Steinhart and Angers 33). 
Activation of the Wnt/β-catenin pathway involves a Wnt ligand binding to the transmembrane 
receptor Frizzled, forming a complex with a co-receptor that is the LDL receptor-related 
protein 5 or 6 (LRP5 and LRP6). The ß-catenin protein is a key mediator in the Wnt/β-
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catenin signalling pathway, and its stability is normally regulated by a degradation complex 
consisting of the tumour suppressor APC, a scaffolding protein axin, and two constitutively 
active serine-threonine kinases i.e., casein kinase 1α (CK1α/δ), and glycogen synthase 
kinase 3 (GSK3). Within this complex β-catenin is sequentially phosphorylated by CK1 and 
GSK3 on serine/threonine residues (Ser45, Thr41, Ser37, Ser33), thus forming a docking site 
for the E3 ubiquitin ligase; β-TrCP. This ubiquitinylates β-catenin, which is subsequently 
degraded by the proteasome. Activation of the Wnt/β-catenin pathway by binding of the Wnt 
ligand to the frizzled/LRP heterodimer recruits the degradation complex to the membrane 
via the dishevelled protein (DVL) disrupting the degradation complex and consequently the 
phosphorylation of β-catenin, leading to its stabilization and translocation into the nucleus. 
In the nucleus it operates as a transcriptional activator, bound to members of the T-cell 
factor/lymphoid enhancer factor (TCF/LEF) transcription factor family, and possibly to 
other co-activators of Wnt target genes (reviewed by Nusse and Clevers 32).
The Wnt/β-catenin signalling pathway in cancer
The Wnt/β-catenin signalling pathway contributes to cancer by promoting progression of 
cells through the cell cycle, by inhibiting apoptosis via the expression of anti-apoptotic 
genes, by affecting cell proliferation via the expression of growth factors and their 
corresponding receptors, by influencing cell motility through the expression of cell adhesion 
and extracellular matrix proteins and via stem cell maintenance (reviewed by Nusse and 
Clevers 32). Aberrant signalling of the Wnt/ß-catenin pathway has been implicated in 
several epithelial tumours (e.g., colorectal carcinoma 34 and endometrial carcinoma 35) and 
in mesenchymal tumours (e.g., osteosarcomas 36, 37, malignant fibrous histiocytomas and 
liposarcomas 38).
The Wnt/ß-catenin signalling pathway in desmoid-type fibromatosis
The relationship between the Wnt/β-catenin signalling pathway and DTF has been 
extensively studied. It is believed that this pathway is crucial to DTF pathogenesis because of 
the fact that the vast majority (about 85%) of DTF tumours harbour a mutation in exon 3 of 
the CTNNB1 (ß-catenin) gene, making the protein more resistant to proteolytic degradation 
39-41. Less frequently, loss-of-function mutations in the APC tumour suppressor gene are 
observed, most commonly in the context of FAP 12. In both cases, β-catenin translocates into 
the nucleus aberrantly activating target genes. This nuclear accumulation can be determined 
by immunohistochemistry (IHC), and serves as a diagnostic tool differentiating DTF from 
other bone-, soft tissue and fibrous tumours 42. The group of wild-type (WT) ß-catenin DTF, 
comprises about 15% of all DTF tumours, and is defined as “having no CTNNB1 mutations 
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in exon 3”. The number of DTF patients assigned to this group decreases over time since 
next generation sequencing is able to detect ß-catenin mutations located on exon 3, in 
tumours where the traditional Sanger sequencing method is not sensitive enough 43, 44.
Interestingly, the β-catenin mutations observed in DTF are almost exclusively confined to 
residues T41 and S45, while alterations at other N-terminal phosphorylation residues, that 
is D32-S37, are rarely observed. Recently, Rebouissou et al. showed in liver cancers that the 
T41 and S45 mutants activate the pathway only weakly compared to others 45. Apparently, 
this weak activation is ideal for DTF outgrowth in line with the “just-right” signalling 
hypothesis that postulates that each tumour type selects for an optimal level of β-catenin 
signalling that is ideal for tumour initiation and progression 46. In accordance, the APC 
mutant proteins observed in DTF retain some functionality in regulating β-catenin levels. 
The specific β-catenin mutation may be of clinical relevance since several groups reported a 
higher recurrence rate in CTNNB1 S45F mutated DTF tumours compared to other CTNNB1 
(T41A) mutated tumours and WT DTF 30, 47-49. This issue is however still under debate as 
others have reported contradictory results 41, 50.
Using a β-catenin reporter assay in primary DTF cultures, Tejpar et al. validated the 
enhanced β-catenin signalling present in DTF. They also showed that in the nucleus, 
β-catenin is mainly associated with TCF7L1 (also known as TCF3) to regulate target genes. 
Expression of TCF7 (TCF1) and LEF1 could not be identified, while solely a minority of DTF 
samples expressed TCF7L2 (TCF4) 51. Others found that several matrix metalloproteinases 
(MMP-3, MMP-7 and MMP-9) are expressed in DTF implying a role for MMP’s in DTF 
invasiveness 52, 53. In fact, Kong et al. showed that MMP inhibition decreases tumour 
invasion and motility 52. Matono et al. showed that MMP7 is more abundantly expressed in 
CTNNB1 mutated DTF compared to CTNNB1 WT, and hypothesized a correlation between 
MMP7 and prognosis as previously was demonstrated in pancreatic cancer 54, 55. The MMP-
inhibitor ilomastat (galardin /GM6001) was investigated in two studies, showing a decrease 
in DTF-cell (human and murine) migration and invasion capability 52, 53. In Apc+/Apc1638N 
mutant mice, DTF tumour volume was decreased (Table 1) 52.
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Table 1. Overview of drugs used in vitro /vivo studies targeting a signalling pathway in DTF






Murine PCC from DTF and 
NF
↓ DTF cell invasion and motility
↓ tumour volume in mice
53 Human PCC from DTF and 
normal fascia (n=7)
↔cell growth
↓ DTF cell invasion





↓ DTF cell and NF proliferation
↔ apoptosis in DTF cells and NF
↔ tumour number in mice (sulindac)










↓ DTF cell and NF proliferation
↔ apoptosis in DTF cells and NF
↔ tumour number in mice (sulindac)
↓ tumour volume in mice (sulindac)
NSAID
Sulindac
57 Human PCC from 
DTF,CRC





58 Apc-/+p53+/- , Apc+/+p53+/-,
 Apc-/+p53+/+ mice
↓ DTF tumour number
Angiostatic factor 
Endostatin
59 Human PCC from FAP-
related DTF and CRC
↑ apoptosis (CRC cultures)
↑ cell death (DTF cultures)
Benzoxazocine 
Nefopam
60 Human PCC from DTF and 
NF
Apc1638N mice
↓ cell proliferation, modest change in apoptosis
↓ ß-catenin protein level




61 Human PCC from DTF
Apc+/1638N; Gli2+/- and 
Apc+/1638N; Gli2+/+ mice
↓ tumour volume (Apc+/1638N mice)
↓ number of tumours (Apc+/1638N; Gli2+/-)
↓ number of tumour cells, viability, proliferation 
rate (DTF cells)





62 Human PCC from DTF ↓ Notch signalling (↓ NICD and Hes1 expression)
↑ cell cycle arrest




63 Human PCC from DTF and 
NF
Apc/Apc1638N, Apc1638N;
Ifnar1-/- and Apc/Apc1638N; 
Ifnar1+/+
↔ apoptosis (human vs. murine DTF and NF)
↓ cell proliferation (human/ murine DTF and NF)
2
146460_Timbergen,Milea_BNW-def.indd   27 25-11-2020   08:20
28
Table 1.  (continued)
Drug Ref.  Setting Effect





64 Human PCC from DTF ↓ DTF cell proliferation and invasion (sorafenib)
↓ mTOR signalling (↓ phospho-S6K levels 
(everolimus))
Growth regulatory signalling pathway
Cytokines
TGF-ß1
65 Human PCC from DTF, 
fibroma, NF
↔ cell proliferation in DTF, fibroma and NF cell 
culture
↑ GAG accumulation in extra-cellular matrix
↑ collagen synthesis
66 Human PCC from DTF 
and NF
↑ active unphosphorylated fraction of ß-catenin
Cytokines
rhEGF /rhTGF-ɑ
67 Human PCC from DTF Up- and down regulation of genes in response to 









69 Human PCC from DTF ↓ cell growth (tamoxifen ± oestrogen)
↔ cell growth (toremifene ± oestrogen)
Anti-oestrogen
Toremifene
70 Human PCC from DTF, 
fibroma and NF
↔ cell proliferation (3H-tymidine incorporation)
↓ GAG (DTF, fibroma and NF cultures)
↓ collagen production (3H-proline incorporation)
↓ TGF-ß1 levels in culture medium
↓ TGF-ß1 mRNA expression levels
↓ TGF-ß1 receptor affinity
71 Human PCC from DTF 
and NF
↑cell death (DTF and NF culture)
↓ collagen production (3H-proline incorporation)
↓ procollagen α1 mRNA expression (DTF culture)
↓ type I and III collagen
↑ collagenase activity
↔ MMP-1, ↑ MMP-2, ↓ TIMP-1
72 Human PCC from DTF, 
Gardner-syndrome related 
fibroblast and NF
↓ GAG synthesis and secretion
↓ active TGF-ß1, ↔ total (active + latent) TGF-ß1
↓ number TGF-ß1 receptors (DTF cells)
↓ TNF-α production
↓, decrease; ↑, increase; ↔, no effect; CRC, colorectal cancer; DFMO, Difluoromethylornithine; DFU, selective 
COX-2 blocker (5,5-dimethyl-3-(3- ūorophenyl)4-(4-methylsulphonyl)phenyl-2(5H)-furon one); DTF, desmoid-type 
fibromatosis; FAP, familial adenomatous polyposis; GAG, glycosaminoglycan; PCC, primary cell culture; NF, 
normal fibroblast; NSAID, Non-steroidal anti-inflammatory drug
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Pharmacological options targeting the Wnt/ß-catenin signalling pathway
Although many studies implicated aberrant Wnt/β-catenin signalling in DTF tumorigenesis, 
therapeutic targeting of this pathway remains challenging. Wnt/β-catenin target-genes that 
do form attractive therapeutic targets in DTF are cyclooxygenase (COX), a member of 
the COX enzyme family (COX1 and COX2) and the vascular endothelial growth factor 
(VEGF), a protein that regulates angiogenesis. A role of COX in DTF has been indicated 
by the expression of COX2 and by the expression of phosphorylated, and thus activated, 
associated growth factors receptors such as the platelet derived growth factor receptor ɑ and 
ß (PDGF-ɑ and PDGF-ß) 56, 73. Activation of their receptors (PDGFR-ɑ /PDGFR-ß) takes 
place by an autocrine/paracrine loop and is initiated by COX2 overexpression due to Wnt/ß-
catenin deregulation 56, 73. Inhibition of COX with sulindac decreased cell proliferation in 
DTF cell culture and therefore forms an attractive therapeutic target in DTF, especially 
because COX inhibitors are already widely used in the clinic 56, 57. Halberg et al. reported 
decreased DTF tumour numbers in ApcMin/+p53-/- mice treated with piroxicam, a drug 
which is a non-steroidal anti-inflammatory drug (NSAID) which works by inhibiting both 
prostaglandins and the COX enzyme (Table 1) 58.
A preclinical study by Poon et al. used the non-opioid analgesic drug nefopam 
(benzoxazocine class), and reported a decrease in ß-catenin levels and cellular proliferation 
rate, as well as a reduction in tumour number and volume in Apc+/Apc1638N mice (Table 1) 
60. The working mechanism of this drug in DTF has not been entirely clarified yet, but is 
presumably due to an inhibition of serine-9-phosphorylation of GSK3-β (Figure 1) 60.
Overexpression of VEGF has been correlated with ß-catenin nuclear staining in DTF 74. 
Additionally, microvessel density, a phenomenon correlated to angiogenesis, was shown to 
be higher in samples with VEGF overexpression. This high vascularity potentially increases 
the growth potential of DTF tumours 74. These findings reveal a possible new treatment 
strategy for DTF by interfering with angiogenesis. Endostatin, an anti-angiogenic protein 
with the ability to inhibit the Wnt/β-catenin signalling pathway in colorectal cancer cells, 
directed the induction of cell death in primary FAP-associated DTF-cells in culture 59. 
Endostatin has been proven to be well tolerated in a Phase 1 study, with minimal toxicities in 
patients with solid tumours other than DTF; however, no studies report the use of endostatin 
for DTF in the clinic 75.
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Figure 1. A schematic presentation of the Wnt/β-catenin signalling pathway and the drugs that target this 
pathway in DTF. The graph shows that ipafricept (OMP-54F28), inhibits Wnt signalling by acting as a decoy 
receptor inhibiting Wnt signalling through the Frizzled 9 receptor. NSAIDs, like meloxicam, the angiogenesis 
inhibitor endostatin and MMP inhibitors act on target genes of the Wnt signalling pathway. The drug Nefo-
pam, a non-opioid analgesic drug of the benzoxazocine class suppresses the effect of high levels of β-catenin.
The blockage of Wnt/β-catenin signalling with the truncated Frizzled 9 receptor fused to 
the IgG1 Fc region (ipafricept, OMP-54F28), was recently tested in a Phase 1 study for solid 
tumours (Table 2). In this study, two patients with DTF were included that both exhibited 
stable disease, although it is unclear if this can be directly attributed to the treatment 76.
While the above-mentioned treatments, targeting Wnt/β-catenin targets constitute attractive 
therapeutic possibilities, no prospective clinical trials using these treatment strategies in sporadic 
DTF have been designed. Experimental inhibitors of Wnt/β-catenin signalling have been 
developed, however, systemic abolition of Wnt secretion is not preferable since this will result in 
defects in gut homeostasis, affects the immune system and affects both ß-catenin-dependent and 
independent Wnt signalling (reviewed by Zimmerli et al. 90 and Enzo et al. 91). Figure 1 displays 
the Wnt/β-catenin signalling pathway and putative drug targets in the context of DTF.
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Table 2. Overview of drugs used clinical trials targeting signalling pathways in DTF
Drug Ref. Setting Tumour type N of DTF patients Efficacy in DTF
Wnt/ ß-catenin signalling pathway




76 Phase 1 Advanced 
solid tumours 
(n = 26)
2 n = 2 SD ( > 6 months)
Notch signalling pathway
PF-03084014 77 Phase 1 DTF 7 ORR 71.4% (95%CI 29-96.3%)
n = 5 PR, median TTR 9.9 months
n = 1 PD
78 Phase 2 DTF 17 n = 5 PR (after a median of 32 
cycles, 95 weeks), n=11 SD




79 Phase 2 DTF 40 n = 2 TS (<1 year)
at 3 months: n=1 CR, n=3 PR, 
n=28 SD, n = 5 PD
3-months NPRR 91% (95% CI 
77-96), 6-months NPRR 80%, 12-
months NPRR 67%
80 Phase 2 DTF 51 At 2-months: n=48 SD
2-months PFS 94%, 4-months PFS 
88%, 1 year PFS 66%
81 Phase 2 DTF 19 n = 3 PR, n = 4 SD (> 1 year), 
1-year disease control rate 36.8%,
TTF 325 days




20 DTF patients: n = 2 PR, n = 8 SD, 
n = 7 PD, n = 3 unknown.
Median TTP 9.1 months (95%CI 
2.9-17.0 months).
Imatinib (+ nilotinib) 83 Phase 2 DTF 39 OS 100%, PAR at 6 months: 65%
At 21 months: n = 7 PR, ORS 19%
n = 8 imatinib + nilotinib due to PD 
under imatinib 3-months PAR 88%
Imatinib + gemcitabine 
(I+G) or Imatinib+ 
doxorubicin (I+D)
84 Phase 1 solid tumours
(n = 16)
1 (I+G) DTF patients: ceased treatment due 
to dose-limiting toxicity (grade 2 
neutropenia)
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Table 2.  (continued)
Drug Ref. Setting Tumour type N of DTF patients Efficacy in DTF
Sunitinib 85 Phase 2 Non-GIST 
sarcomas 
(n = 53)
1 DTF patients: n = 1 NR
86 Phase 2 advanced DTF 19 Median FU 20.3 months (1.8-50.7 
months), 2-year PFS 74.7%, OS 
94.4%. n = 5 PR, n = 8 SD, n = 3 
PD, n = 3 not evaluable. Median 
duration of the response 8.2 
months (range 2.0-17.3 months)




2 DTF patients: n = 1 PR
88 Phase 3 Advanced 
and refractory 
DTF
87 2-year PFS of sorafenib 81% 
(95%CI 69-96%) vs. placebo 36% 
(95%CI 22-57%)
ORR of sorafenib 33% (95% CI 






89 Phase 2 Paediatric DTF 59 n = 4 PR, n = 1 CR
2-year PFS 36%, OS 96%
CI, confidence interval; CR, complete response; DTF, desmoid-type fibromatosis; GIST, gastro-intestinal stromal 
tumour; N, number of patients; NPRR, non-progressive response rate; NR, no response; ORR, objective response 
rate; ORS, overall response rate, OS, overall survival; PAR, progression arrest rate; PD, progressive disease; PFS, 
progression free survival; PR, partial response; SD, stable disease; TS, treatment stop; TTF, time to treatment 
failure; TTP, Time to progression; TTR, time to recurrence
The Hedgehog signalling pathway in desmoid-type  
fibromatosis
The Hedgehog signalling pathway
The Hedgehog (Hh) signalling pathway plays an essential role in embryonic development, 
in adult tissue homeostasis, tissue renewal and tissue regeneration. Precursor proteins of 
Hh ligands, including Sonic (Shh), Indian (Ihh) and Desert (Dhh), undergo autocatalytic 
cleavage and cholesterol alterations at the carboxy terminal end, and palmitoylation at their 
amino terminal end. This process results in a dually-lipidated protein, which is released 
from the secreting cell surface. Subsequently, the Hh ligands interact with cell surface 
proteins like Glypican and the proteins of the of heparin sulfate proteoglycan family 
2
146460_Timbergen,Milea_BNW-def.indd   32 25-11-2020   08:20
33
enhancing their stability and promoting internalization when bound to Patched (PTCH1). 
Binding of Hh proteins to the canonical receptor PTCH1 and to co-receptors GAS1, 
BOC and CDON initiates Hh signalling. This results in the release of PTCH1 mediated 
repression of the transmembrane protein Smoothened (SMO), a G-protein coupled receptor 
(GPCR)-like protein, which consequently leads to an accumulation of SMO in the cilia 
and phosphorylation of its cytoplasmic tail. Smoothened, regulates the downstream signal 
transduction which dissociates glioma associated oncogene (GLI) proteins, from kinesin-
family protein, KIF7 and SUFU. GLI proteins serve as bifunctional transcription factors, 
capable of activating and repressing transcription, and form a key intracellular component 
of the Hh pathway (reviewed by Wu et al. 92 and Briscoe and Thérond 93).
The Hedgehog signalling pathway in cancer
Aberrant Hh signalling in cancer is attributed to an increased endogenous Hh ligand expression, 
or to activating mutations of Hh pathway components (reviewed by Wu et al. 92). Aberrant 
uncontrolled activation of Hh has been described in numerous tumour types including: 
rhabdomyosarcoma 94, colorectal cancer 95, basal cell carcinoma 96 and medulloblastoma 97.
The Hedgehog signalling pathway and its role and therapeutic potential in des-
moid-type fibromatosis
As the Hh pathway has the ability to maintain mesenchymal progenitor cells in a less 
differentiated state with greater proliferative capacity, it is possible that it influences 
proliferation of DTF cells in a similar manner because of the mesenchymal origin of 
these cells 61. Ghanbari et al. showed that Hh signalling is active in DTF by identifying a 
significant upregulation of Hh target genes GLI1, PTCH1 and Hedgehog interacting protein 
(HHIP) in human DTF samples compared to adjacent normal tissues. Additionally it was 
demonstrated that expression of Gli1, Gli2, and Ptch1 in mouse (Apc+/1638N) tumours was 
upregulated compared to normal tissue. In vivo, pharmacological inhibition of Hh with 
triparanol, which works by interference with the posttranslational modification of Hh 
signalling molecules and with the sterol-sensing domain of the receptor PTCH1, led to a 
reduction in tumour volume in Apc +/1638N mice. Genetic approaches to reduce Hh signalling 
in DTF using Apc+/1638N;Gli2+/− mouse models, gave rise to the development of fewer and 
smaller tumours (Table 1) 61, 98. Current inhibition of the Hh signalling pathway in the clinic 
acts via the pharmacological inhibition of SMO, however no clinical trials studying Hh 
inhibitors in DTF have been carried out. Figure 2 displays the Hh pathway and proposed 
working mechanism of target drugs in DTF.
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Figure 2. A schematic presentation of the Hedgehog signalling pathway and the drugs that interfere with 
this pathway in DTF. The graph depicts that inhibition of the Hedgehog pathway, by SMO inhibitors, works 
by blockage of Smoothened (SMO), a key regulator of downstream signaling by GLI transcription factors. 
The compound triparanol is known for inhibition of the cholesterol biosynthesis but can also interfere with 
Hedgehog signalling molecules including the Hedgehog ligand receptor Patched 1.
The Notch signalling pathway in desmoid-type fibromatosis
The Notch signalling pathway
Notch signalling is essential for regulating cell-fate during tissue development and for 
managing cell proliferation, differentiation and survival, neurogenesis and homeostasis 
in adult tissues (reviewed by Artavanis-Tsakonas et al. 99). There are four mammalian 
transmembrane Notch receptors (Notch receptor family type 1-4; NOTCH 1-4). Each 
receptor is a Ca2+-stabilized heterodimer containing three domains: an extracellular 
(NECD), a transmembrane (NTMD) and an intracellular domain (NICD) (reviewed by 
Takebe et al. 100). These receptors can interact with ligands; members of the Delta-like 
(DLL1, DLL3 and DLL4), and the Jagged (JAG1 and JAG2) families. In case of ligand 
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binding, the receptor undergoes two processing steps. The first cleavage is mediated by 
a member of the disintegrin and metalloproteinase family (ADAM10 or ADAM17) and 
releases the NECD which remains bound to its ligand and is internalized by endocytosis 
in the cell that sends the signal. Subsequently in the receiving cell, a presenilin-dependent 
ɣ-secretase complex, removes the NICD from the NTMD. This NICD is translocated into 
the nucleus where it interacts with the CSL (CBF1/Suppressor of hairless/Lag-1) repressor 
complex, converting it into an activation complex that interacts with a co-activator protein 
mastermind-like 1 (MAML1). These interactions results in the transcriptional activation of 
several Notch target genes such as MYC, p21, HRT, Notch receptors, Notch ligands, cyclin 
D1, and HES-family members (reviewed by Takebe et al. 100. and Ranganathan et al. 101).
The Notch signalling pathway in cancer
Deregulation of the Notch signalling pathway is described in hematologic malignancies, 
notably T-cell acute lymphoblastic leukaemia which harbours an activating mutation in 
NOTCH 1 that result in a constitutive Notch signalling pathway activity 102. Although 
activating mutations in members of the Notch family are uncommon in solid tumours, 
Notch signalling may play a role in tumorigenesis (reviewed by Egloff and Grandis 103). For 
example, NOTCH3 transcript and protein levels are upregulated in a subset of colorectal 
cancers promoting tumour growth 104.
The Notch signalling pathway and its role and therapeutic potential in des-
moid-type fibromatosis
Inhibition of Notch signalling forms an appealing therapeutic approach. Small molecular 
inhibitors, including ɣ-secretase inhibitors (GSI), siRNAs and monoclonal antibodies 
against Notch receptors and ligands have been developed (reviewed by Yuan et al. 105). 
Particularly GSI’s are of interest as these drugs inhibit the final Notch processing step by 
which NICD is released to act in the nucleus, consequently blocking Notch signalling. A 
number of GSI’s (e.g., MK-0752 and RO4929097) have already been studied in solid cancers 
other than DTF in early phase clinical trials 106, 107.
Few studies investigated the role of the Notch signalling in DTF, however, DTF tumours 
have been shown to express NOTCH1 and its downstream target HES1 108. Preliminary 
evidence, from a phase 1 clinical trial indicated a partial response in five out of seven DTF 
patients to the oral GSI PF-03084014 (Table 2) 109. This prompted an in vitro study performed 
by Shang et al., which demonstrated a significant higher expression of nuclear HES1 in DTF 
tissues compared to scar tissue by IHC and reported expression of NOTCH1, JAGGED1 
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and HES1 in DTF cells by Western Blot analysis. Additionally, it was demonstrated that 
PF-03084014, decreased NICD and HES1 expression in a dose dependent manner in DTF 
cells, and that Notch signalling inhibition contributed to impaired DTF cell proliferation by 
inducing a cell cycle G1 arrest and decreasing migration and invasion (Table 1) 62. Two other 
clinical trials (a phase 1 trial with seven DTF patients and phase 2 trial with seventeen DTF 
patients) showed promising results with a significant part of patients experiencing partial 
response or stable disease (Table 2) 77, 78. Figure 3 displays the Notch pathway and putative 
drug targets in the context of DTF.
Figure 3. A schematic presentation of the Notch signalling pathway and the drugs that interfere with this 
pathway in DTF. The graph depicts that the Notch signalling pathway can be targeted by the use of γ-secre-
tase inhibitors e.g., PF-03084014.
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The JAK/ STAT signalling pathway in desmoid-type  
fibromatosis
The JAK/STAT signalling pathway
The Janus-activated kinase (JAK) and signal transducer and activator of transcription 
(STAT) signalling pathway regulates cell proliferation, survival, differentiation, migration 
and apoptosis, and has a role in pathogen resistance. The JAK/STAT pathway is the main 
signalling mechanism for many cytokines and growth factors. A variety of ligands e.g., 
interferon-ɑ /interferon-ß (IFN), secreted by leukocytes (IFN-ɑ), fibroblasts (IFN-ß) and 
various other cells involved in immune responses, and interleukins (IL) together with their 
cognate receptors, stimulate the pathway. Ligand binding causes receptor dimerisation and 
subsequent activation of the JAK tyrosine kinases associated with the cytoplasmic domains 
of the receptor. JAKs in close proximity are trans-phosphorylated and phosphorylate the 
receptors. The phosphorylated receptor sites can then serve as docking sites for cytoplasmic 
transcriptions factors (STATs). These STATs become phosphorylated by JAKs, dimerise and 
are translocated into the nucleus where they activate or repress the transcription of target 
genes (reviewed by O’Shea et al. 110).
The JAK/STAT signalling pathway in cancer
Dysregulation of the JAK/STAT signalling pathway has been observed in several cancers 
including haematological and solid malignancies such as breast (reviewed by Banerjee 
and Resat 111 ) and prostate cancer (reviewed by Bishop et al. 112). Hallmarks of JAK/STAT 
dysregulation are aberrant cytokine production, the occurrence of activating JAK mutations 
or mutations in other upstream oncogenes and activating mutations in STAT (reviewed by 
O’Shea et al. 110).
The JAK/STAT signalling pathway and its role and therapeutic potential in des-
moid-type fibromatosis
In both human DTF samples and murine DTF models (Apc/Apc1638N), an increased expression 
of type 1 IFN response genes (e.g., MxA, MxB, IFITI1, and IFNAR1) have been identified 
suggesting an activated JAK/STAT signalling. Genes activated by this signalling pathway, 
have been shown to have an anti-proliferative effect on DTF cells and normal fibroblasts 
(Table 1) 63. Regression of DTF after treatment with IFN has been described in several 
case reports 113-116. A retrospective study by Leithner et al. examined thirteen DTF patients 
receiving IFN-ɑ ± tretinoin (a natural metabolite of vitamin A [retinol]). This study 
indicated no evidence of disease in seven out of nine patients (adjuvant group) and a mean 
disease-free interval of 22 months (±18 months), and progressive disease in two patients. 
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Stabilization of DTF occurred in four patients which received IFN-ɑ± tretinoin 117. Despite 
these encouraging results, no prospective clinical trials in DTF have been carried out yet.
The PI3 kinase/AKT and mTOR signalling pathways in des-
moid-type fibromatosis
The PI3 kinase/ AKT and mTOR signalling pathways
The phosphoinositide 3 (PI3) kinase signalling pathway plays a critical role in various 
cellular processes like cell growth, survival, proliferation, metabolism and differentiation 
(reviewed by Engelmann et al. 118). The pathway is activated by plasma membrane proteins 
including receptor tyrosine kinases, integrins, B- and T-cell receptors, cytokine receptors 
and GPCRs and entails the formation of membrane-bound phosphatidylinositol-3,3,5-
triphosphate (PIP3) by the enzyme PI3 kinase. Proteins that harbour a pleckstrin-homology 
(PH) domain like AKT (protein kinase B or PKB) and PDK1 bind to the 3-phosphoinositides 
on the membrane. Subsequent phosphorylation of AKT at the Thr308 and Ser473 residues, 
by PDK1 and mTORC2, respectively, fully activates its serine/threonine kinase potential. 
AKT consequently phosphorylates many downstream substrates, thereby regulating various 
cellular functions (reviewed by Hers et al. 119). Importantly, AKT also leads to downstream 
activation of the mTOR complex 1 (mTORC1) pathway by phosphorylation of its negative 
regulators TSC2 and PRAS40. Activation of this complex provides a growth advantage for 
cells, as mTORC1 is critical for cell maintenance by sensing nutritional and environmental 
cues and responding by inhibiting autophagy and regulating translation thereby stimulating 
cell growth and proliferation (reviewed by Hers et al. 119. and Dowling et al. 120).
The PI3 kinase/AKT and mTOR signalling pathways in cancer
Dysregulation of the PI3 kinase/AKT signalling pathway is frequently encountered in 
cancers and facilitates tumorigenesis. Over-activation of AKT may be caused by the 
presence of gain-of-function mutations in PI3K subunits, or loss-of- function mutations 
in Phosphatase and Tensin homolog deleted from chromosome ten (PTEN) or PTEN 
expression loss. PTEN, a tumour suppressor is a lipid phosphatase, negatively regulating 
AKT by dephosphorylation of PIP3. Alternatively, overexpression or activating mutations 
in tyrosine kinase receptors and their ligands, as well as the interaction of Ras with PI3K, 
can excite AKT activity (reviewed by Brugge et al. 121and Keniry and Parsons 122).
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The PI3 kinase /AKT and mTOR signalling pathways and their role and thera-
peutic potential in desmoid-type fibromatosis
The relationship between DTF and the PI3 kinase/AKT and the mTOR signalling pathways 
has not been extensively studied. Immunohistochemical analysis of twenty-nine DTF 
tumour samples indicated the expression of ß-catenin and PDGFR-ß in all samples. No 
expression could be detected of PDGFR-α and phospho-Ser-473, suggesting inactive AKT 
signalling 123. Meazza et al. showed that a substantial part of paediatric DTF cases had 
an E17K mutation in either AKT1 (eight out of twenty-eight 28; 31%), however no AKT1 
mutations were observed in adult DTF cases (n = 33) 124. Interestingly, DTF patients with 
an E17K AKT1 mutation had a longer recurrence free survival rate in agreement with the 
mutation-induced stimulation of downstream AKT signalling.
Recently, Rosenberg et al. reported the anti-tumour effect of sorafenib, a multi-kinase inhibitor 
that targets multiple tyrosin kinases (e.g., VEGFR, c-Kit and PDGFR) expressed on patient 
derived DTF cell lines (Table 1). It was found that sorafenib decreased proliferation and invasion 
in a dose dependent manner and that the Ras/MEK/ERK and the PI3kinase/AKT/mTOR 
signalling pathways were affected. Additionally, they investigated the efficacy of everolimus, 
an mTOR inhibitor, as monotherapy and in combination with sorafenib, and found no synergistic 
or additive inhibitory effect on cellular proliferation (Table 1) 64. Cates et al. compared the 
expression profiles of selected receptor- and non-receptor tyrosine kinases and downstream 
effectors of signalling activity in DTF (n = 27), reactive scars (n = 14) and fibrous tissue (n = 6) 
(Table 1). PDGFR-β, FAK 1 and MET were detected by IHC in almost all DTF and scar tissues 
and in at least half (PDGFR-β, FAK1) or none (MET) of the fibrous control tissue. Of note, AKT 
was phosphorylated in 56% of DTF samples, but significantly higher levels were observed in 
scar tissues and only low levels were observed in a subset of fibrous tissues 125.
Inhibition of various tyrosine kinases including PDGFR, with imatinib is a promising 
treatment strategy for DTF. Imatinib is effective in other solid tumours of mesenchymal origin 
like gastro-intestinal stromal tumours (GISTs) and dermatofibrosarcoma protuberans, in which 
it targets KIT or PDGFR-ɑ /PDGFR-ß (reviewed by Kosela-Paterczy et al. 126, 127). The efficacy 
of imatinib (either alone or combined with other treatment) was observed in several early phase 
clinical studies with DTF patients (Table 2) 79-84. Chugh et al. and Penel et al. reported a 1-year 
progression free survival (PFS) of 66% and 67% respectively. However, the results of these 
studies should be interpreted with caution, since the majority of patients included in these 
trials received other treatments prior to treatment with imatinib (Table 2). Additionally, the 
relevant targets of imatinib in DTF remain unclear 81, 123. Two phase 2 clinical trials including 
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DTF patients studied the effect of sunitinib (Table 2). George et al. did not detect a response 
to sunitinib in the single DTF patient that was included in their study 85. In contrast, a study 
by Jo et al. showed a 2-year PFS of 75% in nineteen patients with advanced DTF 86. A phase 
1 study, investigating the use of sorafenib in paediatric solid malignancies, of which two 
patients had DTF, showed a partial response on sorafenib in one patient 87. Recently published 
results from the phase 3 clinical trial (NCT02066181; sorafenib versus placebo for advanced 
and refractory DTF) showed a 2-year PFS rate of 81% (95% confidence interval [CI] 69-96) 
with an objective response rate (ORR) of 33% (95% CI, 20-48) in the sorafenib group versus 
2-year PFS of 36% (95% CI, 22-57) and an ORR of 20% (95% CI, 8-38) in the placebo group 
88. The biological mechanisms underlying the activity of sorafenib in DTF remain unclear 
because sorafenib targets multiple tyrosine kinases thereby affecting multiple pathways.
The use of imatinib, sunitinib and sorafenib, led to study the tyrosine kinase inhibitor (TKI) 
pazopanib in the setting of DTF. Pazopanib targets the VEGFR1-3, PDGFR-ɑ and PDGFR-ß, 
amongst others. A retrospective study by Szucs et al., described a partial response in three 
out of eight patients with DTF and stable disease in five out of eight patients with a median 
PFS of 13.5 months 128. Another retrospective study in adolescents and young adults with 
DTF by Agresta et al. reported tumour reduction after pazopanib use with only mild 
toxicities (Table 2) 129. One clinical trial is currently ongoing to investigate TKIs in the 
setting of DTF: pazopanib (NCT01876082, phase 2 study) (Table 3) 130.
Table 3. Overview of ongoing clinical trials with targeted drugs in DTF
Drug Ref. NCT number Setting Current status
PI3 kinase/AKT/ mTOR signalling pathway
Receptor Tyrosin Kinase 
inhibitor
Imatinib + vactosertib
131 NCT03802084 Phase 1/2 clinical trial Not yet recruiting
mTOR inhibitor
Sirolimus
132 NCT01265030 Phase 1 clinical trial
Phase 2 clinical trial 






133 NCT01981551 Phase 2 clinical trial Active, not recruiting
134 NCT03785964 Phase 3 clinical trial Not yet recruiting
Growth regulatory signalling pathway
PDGF-ɑ /PDGF-ß /VEGFR
Pazopanib
130 NCT01876082 Phase 2 clinical trial Recruiting
NCT, national clinical trial
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The growth factor regulatory signalling pathways in desmoid-
type fibromatosis
The growth regulatory signalling pathways
The superfamily of transforming growth factor-ß (TGF-ß) regulates cell proliferation, 
differentiation, apoptosis and development. Two ligand subfamilies are recognized; 
the TGF-β nodal subfamily, and bone morphogenetic protein (BMP) subfamily. Ligand 
binding of either TGF-β ligands or BMP ligands facilitates the oligomerisation of type I 
and type II serine/threonine receptor kinases. In case of signalling, intracellular effectors, 
R-SMAD’s, are phosphorylated in the cytoplasm whereupon they partner with SMAD4 and 
translocate to the nucleus. In the nucleus they regulate, in conjunction with transcription 
factors/corepressors or co-activators, the transcription of TGF-ß target genes. Growth factor 
signalling pathways are initiated by various growth factors (e.g., insulin-like growth factors, 
platelet-derived growth factor, and hepatocyte growth factor) and induce phosphorylation of 
downstream targets via activation of their associated receptor tyrosine kinases. The signal is 
transduced through various intracellular intermediate molecules, frequently including PI3 
kinase/AKT and Ras/Raf/MAPK pathways to ultimately affect gene expression (reviewed 
by Massague et al. 135).
The growth factor regulatory signalling pathways and their role and therapeutic 
potential in desmoid-type fibromatosis
The role of TGF-ß in DTF has been established by the expression of TGF-ß target genes 
(e.g., several collagen types and metalloproteinases) and by the upregulation of TGF-ß 
signalling pathway components (phospho-SMAD2 and phospho-SMAD3, ɑ-SMA and PAI1) 
in comparison to normal fascia 66. Mignemi et al. investigated TGF-ß signalling comparing 
DTF tissue with hypertrophic scars and fibrous tissue in human samples. It was discovered 
that the levels of TGF-ß receptor type 1 were similar in DTF and scar tissue, but that this 
receptor could not be detected in fibrous tissue. Phosphorylated SMAD2/3 could be detected 
in the majority of DTF samples (74%) but only in a minority of scar tissues (29%) and not 
at all in fibrous tissue 136. Additionally, TGF-ß stimulates β-catenin transcriptional activity, 
which indicates that this growth factor might play an important role in the development 
of DTF 66. Multiple studies reported overexpression of platelet derived growth factors and 
their associated receptors (PDGFɑ, PDGFRɑ, PDGFß and PDGFRß) in neoplastic fibrous 
proliferations including DTF and myofibromatoses 137, 138.
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Various studies investigated the effect of TFG-ß and epidermal growth factor (EGF) on 
DTF cell lines and stimulation with these cytokines caused up- and down regulation of 
various target genes (e.g., SMAD4), changes in β-catenin levels, and increased production 
of glycosaminoglycan and collagen. Additionally, treatment with EGF increased DTF cell 
motility (Table 1) 65-68.
Cross-talk between the insulin-like growth factor (IGF) and the oestrogen receptor (ER) 
mediated signalling has been demonstrated in breast-cancer cells. Activation of MAPK, 
which is located downstream of IGF-1, enhances ER induced transcription via ER 
phosphorylation. Therefore, it is presumed that growth factor signalling pathways and the 
oestrogen pathways complement and overlap each other (reviewed by Dhingra et al. 139). 
Toremifene, a drug which also inhibits collagen synthesis and protein kinase C, works on 
both the growth factor regulatory signalling pathway and the oestrogen pathway and will 
be discussed in the next section.
The role of the oestrogen driven pathway in desmoid-type 
fibromatosis
The oestrogen driven pathway
Oestrogens affect various physiological processes that concern the development of the 
reproductive system and several reproductive functions. The role of oestrogens in cancer has 
been described in breast cancer and uterine tumours (reviewed by Dhingra et al. 139). Two 
subtypes of oestrogen receptors (ER) haven been identified: ER-ɑ (ESR1) and ER-ß (ESR2) 
to which oestrogens can bind. Without the ligand, the intracellular ER is considered to be 
in an inactive state, forming a complex with two heat shock proteins (Hsp90 and Hsp56) 
and various other proteins. Upon binding of the ligand oestrogen, Hsp90 is detached from 
the complex which leads to ER phosphorylation. Next, the ER dimerises and translocates 
to the nucleus where it can interact with specific DNA sequences, oestrogen response 
elements (ERE), causing transcriptional activation (reviewed by Dhingra et al. 139. and 
Picariello et al. 140).
The oestrogen driven pathway and its role and therapeutic potential in des-
moid-type fibromatosis
The role of sex hormones, particularly oestrogen, in DTF tumorigenesis is primarily 
based on clinical observations, and prompted the use of anti-hormonal agents. DTF arises 
frequently in females at the reproductive age 4. Moreover, tumour growth during pregnancy, 
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accelerated tumour growth by using oral contraceptives and tumour regression in menopause 
are reported 10, 141. Although DTF does not express ER-α, Deyrup et al. discovered that 
DTF tumours express ER-ß 142. The involvement of oestrogens in DTF offers a variety of 
interesting hormone-related drugs which can be a potential treatment for DTF. Tamoxifen 
is most extensively studied in the setting of DTF and is often used in various dosages in 
combination with other drugs, frequently NSAIDs, like sulindac (reviewed by Bocale et al. 
143). A meta-analysis by Bocale and Rotelli et al. verified that tamoxifen, administered as a 
single agent, gave an overall response rate (partial or complete response) of 58% (22 out of 
38 patients). In combination with NSAIDs, this response rate decreased to 35% 143. Likewise, 
toremifene has been shown to have an anti-tumour effect in DTF 71, 144. Although it does not 
influence cell proliferation, toremifene decreased the total amount of glycosaminoglycan’s 
(GAG), TGFß1, collagen and fibronectin levels and it diminished the affinity of type I 
and II TGFβ1 receptors for 125I-TGF-ß1 (Table 1) 65, 70. Toremifene in retrospective clinical 
studies, administered alone or in combination with other drugs like melatonin, sulindac 
or IFN-ɑ, yielded an overall complete and partial response rate of 56%. When comparing 
tamoxifen and toremifene, used as a single agent, no differences in overall response rate 
were found (reviewed by Bocale et al. 143). Raloxifene, a drug initially developed for treating 
chronic osteoporosis, was administered to thirteen patients with FAP-related DTF which 
were refractory to other treatments. Eight patients displayed a complete remission and a 
partial response was seen in five cases 145. Despite a clear involvement of oestrogens in DTF, 
response rates to anti-oestrogen agents vary and the number of prospective clinical studies 
is still limited. One phase 2 trial combined sulindac (NSAID) with tamoxifen in pediatric 
DTF patients and showed a 1-year PFS of 36% (Table 2) 89.
Future directions and conclusion
This review aims to provide a summary of the current knowledge of important, cancer-
related signalling pathways in the setting of DTF. The role of Wnt/β-catenin signalling in 
DTF has been firmly established in numerous studies, showing the presence of β-catenin 
signalling enhancing mutations in the vast majority of tumours. Therapeutic options 
targeting the Wnt/β-catenin signalling pathway remain scarce and are not yet widely tested 
in the clinical setting for DTF. Several clinical trials, targeting other signalling pathways, 
like Notch and Hedgehog, are currently ongoing, but few study the contribution of these 
pathways to DTF tumorigenesis.
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A major challenge remains to study DTF in the preclinical setting. This is partly due to the 
rarity of the tumour type, but also to the limited availability of pure DTF cell lines and other 
cell and animal models 3. Culturing a fresh DTF resection specimen, inevitably leads to an 
overgrowth of WT fibroblasts and concomitant loss of DTF tumour cells. Separating tumour 
cells from their surrounding stromal cells remains challenging and time consuming. Even if 
a “pure” DTF cell line is obtained, DTF tumour cells often reach senescence after several 
passages. To our knowledge, no studies investigating the effect of immortalization protocols 
on primary DTF cells have been published yet. Experimenting with primary cultures 
consisting of both stromal cells and tumour cells is an alternative but has its drawbacks. 
Additionally, representative cellular and animal models of DTF (e.g., organoids or mice 
expressing mutated CTNNB1) in relevant tissues are difficult to generate and expensive 
to maintain. The existing Apc+/Apc 1638N mouse model has already been proven as a useful 
model for FAP-associated DTF and is often used as a tumour model for non-FAP related 
DTF (Table 1) 61, 146. A mouse DTF model based on specific β-catenin mutations is, to our 
knowledge, currently not available. A recently developed genetically engineered Xenopus 
tropicalis model harbouring a mutated APC, may yield another DTF tumour model that 
can be exploited as a platform to define novel therapeutic targets and preclinical validation 
studies 147. Well-defined preclinical models are as necessary as well-annotated large series 
of DTF tumour samples, to better understand DTF biology and to provide experimental 
support and rationale for translational research investigating the inhibition of signalling 
pathways in DTF.
Additionally, signalling pathways are often seen as separate entities, however, in reality 
cross-talk occurs between different pathways. The precise interactions between different 
signalling- and biochemical pathways is complex and still poorly understood. Aberrant 
signalling of one pathway can often be corrected via compensatory mechanisms in another 
pathway 148. In DTF tumours and cell lines, the Wnt, Notch and Hh pathways have been 
shown to be involved in cross-talk, implicating optimal therapeutic efficacy, is reached 
when all interacting pathways are inhibited in a combinatorial approach 149. Future studies 
should not focus on individual signalling cascades but rather on the simultaneous inhibition 
of multiple pathways.
Furthermore, clinical studies to evaluate the efficacy of systemic and targeted treatments 
without any randomization procedures remain challenging in current clinical practice as 
they are often difficult to interpret. Due to the unpredictable growth behaviour of DTF with 
reports of spontaneous regression without treatment and stable disease, it is difficult to 
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distinguish the true treatment effects from natural growth behaviour. Moreover, the design 
of randomized controlled trials might be restricted by the rarity of the disease and the small 
number of DTF patients with an indication for systemic treatment. Despite these challenges, 
future studies should include signalling pathways other than Wnt/β-catenin signalling to 
uncover additional driver genes and pathways in DTF and to clarify the potential working 
mechanisms of target drugs in the setting of DTF.
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Sporadic desmoid-type fibromatosis (DTF) is a rare soft tissue tumour of mesenchymal origin. 
It is characterized by local invasive growth and unpredictable growth behaviour. Three distinct 
mutations involving the CTNNB1 (β-catenin) gene have been identified in the vast majority of 
DTF tumours, which cause activation of the Wnt signalling pathway and impacts prognosis. 
This study examines whether the different CTNNB1 mutants (T41A, S45F) occurring in DTF 
tumours differentially affect Wnt signalling activity, which might explain the different disease 
course between DTF patients harbouring different CTNNB1 mutations.
Materials and methods
Real-time polymerase chain reaction (RT-PCR) on 61 formalin fixed paraffin embedded 
DTF samples with known CTNNB1 status was used to measure the relative mRNA 
expression level of Wnt target genes AXIN2, DKK1 and CCND1. Additionally, publicly 
available mRNA expression data retrieved from the Gene Expression Omnibus of 128 
DTF samples were used for an unsupervised cluster analyses based on the expression of a 
selection of Wnt targets.
Results
No statistically significant difference in relative expression levels of Wnt target genes 
AXIN2, DKK1 and CCND1 was identified between either CTNNB1 wild-type, S45F or 
T41A mutated DTF samples. Moreover, the hierarchical cluster analyses using selected Wnt 
targets did not discriminate between different CTNNB1 mutation types.
Conclusions
No differences in the expression levels of Wnt target genes were observed between the 
different CTNNB1 mutation types in DTF tumours. Further studies are needed to decipher 
the mechanism accounting for the diverse disease courses between DTF patients with 
different CTNNB1 variants.
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Introduction
Sporadic desmoid-type fibromatosis (DTF) is a soft tissue tumour characterized by local 
invasive growth and unpredictable growth behaviour with phases of progression, stable 
disease and even spontaneous regression 1-4. The incidence in the Dutch population is 
approximately five cases per million people per year 5. Affected patients are mostly females, 
with a peak incidence between the second and fourth decade of life 6-9. Sporadic DTF 
has a mesenchymal origin, arising in musculoaponeurotic structures and can develop 
at practically any location in the body 10. The most common site is the abdominal wall 
whereas the predominant extra-abdominal sites are the trunk and the proximal part of 
the extremities 7, 11. Treatment includes conservative management via active surveillance, 
surgical resection, radiotherapy or systemic therapy. The latter option comprises non-
steroidal anti-inflammatory drugs (NSAIDs), anti-hormonal agents such as tamoxifen, 
low dose chemotherapy such as a combination of methotrexate with either vinblastine or 
vinorelbine, and tyrosine kinase inhibitors such as imatinib, sorafenib, or nilotinib 12. No 
recommendations about the sequence of existing systemic treatment options can be given 
yet, although the recent results of a randomized phase 3 trial suggest a possible role of 
sorafenib in symptomatic patients 13. Recurrence rates after treatment are high with a 5-year 
local recurrence rate of 49% after surgery 9.
The CTNNB1 (β-catenin) gene is mutated in the vast majority of sporadic DTF tumours 9, 
14-22. Normally, β-catenin acts as a key mediator in the Wingless (Wnt) signalling pathway 
by operating as a transcriptional activator through binding in the nucleus to members of 
the TCF/LEF transcription factor family. The CTNNB1 mutations, found in DTF, mainly 
affect two codons in exon 3; substituting threonine at position 41 with alanine (T41A) and 
replacing serine at position 45 with either phenylalanine (S45F) or proline (S45P) 8, 9. These 
mutations prevent its phosphorylation, poly-ubiquitination and subsequent proteasomal 
degradation. Instead, β-catenin is stabilized and translocated into the nucleus where it 
drives transcription of Wnt target genes. The Wnt signalling cascade is involved in several 
biological processes like embryonic development and maintenance and regeneration of adult 
cells 23, 24. The aberrant activation of the Wnt signalling pathway, as in DTF, is observed in 
various malignancies like colorectal cancer, breast cancer and non-small cell lung cancer, 
and is considered to be a driver of tumorigenesis 14, 25-28. The CTNNB1 genotype-phenotype 
relation has been extensively investigated in liver cancer, providing evidence that different 
CTNNB1 mutations are linked to different levels of β-catenin activation. The S45 mutation 
leads to a weak activation and T41 mutations are associated with a moderate activation 
which may yield differences in clinical behaviour 29. Desmoid tumours that harbor a S45F 
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mutation exhibit a higher recurrence rate after primary resection than wild-type (WT) 
and T41A mutant tumours 9, 20, 30, 31 and were shown to be more resistant for the NSAID 
meloxicam 32. However, others report conflicting results and could not reveal an impact of 
CTNNB1 mutations on outcome 18, 22. The molecular mechanisms, underlying a CTNNB1 
genotype-phenotype relationship, are not known, although Hamada et al. reported that 
S45F desmoid cells have a stronger nuclear β-catenin staining in a preclinical model and 
observed an upregulation of Wnt target genes AXIN2 and CCND1 compared to WT and 
T41A cells 33.
Here we examined whether the CTNNB1 mutants, encountered in DTF, differentially affect 
Wnt signalling activity in human desmoids and whether this may explain the variable 
clinical behaviour between the different CTNNB1 mutants.
Materials and methods
Dutch and French dataset
A Dutch, formalin fixed paraffin embedded (FFPE) DTF cohort (n=64), with CTNNB1 
mutation status determined with Sanger sequencing, previously described by van 
Broekhoven et al. was available for this study 20. Samples were derived from patients with 
sporadic, aggressive fibromatosis who underwent surgical excision of their tumour. Clinical 
characteristics included: sex, tumour localization (extra-abdominal, abdominal wall or 
intra-abdominal), age at diagnosis and tumour size in millimetres.
Additionally, the clinical and molecular data from a French, fresh frozen DTF sample 
set (n = 128), containing a total of 54613 probe sets, previously described by Salas et al. 
were accessed through the Gene Expression Omnibus (series matrix file, accession number 
GSE58697) 34. This file contains data normalized using the GCRMA algorithm. The data 
on the CTNNB1 mutations status of these tumours were kindly provided by dr. Frederic 
Chibon, Cancer Research Center of Toulouse, France. Clinical data included: sex, age at 
the time of diagnosis, tumour size in millimetres, tumour localization, and tumour status 
(primary or recurrent). The patient and tumour characteristics of both sample sets are listed 
in Table 1.
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RNA Isolation and RT-qPCR
Total RNA was extracted from two to four tissue sections (20 µm) of DTF FFPE tumour 
samples using the RecoverAllTM total nucleic acid isolation kit (Ambion/ Life Technologies) 
according to the manufacturer’s recommendations. Total RNA quality and concentration 
were determined using a Nanodrop-2000 (Isogen Life Science). The 260nm/280nm ratio 
was ≥1.80 for all RNA preparations. The mRNA expression of AXIN2, CCND1 and DKK1 
was assessed by RT-qPCR. In brief: 50 ng RNA was reverse transcribed with RevertAid™ 
H Minus (Thermo Fischer Scientific, EP0452) to generate cDNA. The resulting 4 μL cDNA 
was subsequently pre-amplified for 15 cycles in a final volume of 8 μL using Taqman 
PreAmp mastermix (Thermo Fisher Scientific) in combination with 100-fold diluted primer-
probe combinations for AXIN2, CCND1, Dickkopf 1 (DKK1) and Peptidylprolyl Isomerase 
A (PPIA), (Thermo Fisher Scientific; Assay Ids Hs00610344_m1, Hs00765553_m1, 
Hs00183740_m1 and Cat # 4333763F, respectively). Next, for each sample, four individual 
- gene transcript specific - real time PCRs were carried out in a Mx3000P (Agilent) for 40 
cycles using SensiFast Probe Lo-ROX master mix (BioLine) according the manufacturer’s 
recommendation and the same four primer-probe combinations. A 10 ng/μL down to 0.04 
ng/μL serially diluted RNA sample isolated from MCF7 cells and expressing all targets 
was used in each experiment to monitor the efficiencies of the RT-qPCRs and a minus RT 
sample as a negative control. All targets were amplified with an equal efficiency (98%-
110%). Finally, levels of the target genes were normalized on the stable expressed PPIA 
mRNA levels using the delta Cq normalization method.
Statistical analysis of AXIN2, CCND1 and DKK1 expression in WT and 
CTNNB1 DTF mutants
The relative expression values of AXIN2, CCND1 and DKK1 were measured by RT-PCR 
on FFPE samples, in the Dutch DTF cohort. Median values and the maximum interquartile 
range (IQR) were calculated. Because of non-normally distributed data, a Kruskal-Wallis 
test was performed to identify differences in ranked expression levels of AXIN2, CNND1 
and DKK1 (p-value < 0.05, confidence interval 95%) between DTF with various CTNNB1 
mutation types (T41A, S45F) and DTF with no mutations in exon 3 of CTNNB1 (WT). A 
Bonferroni correction was used to correct for multiple testing.
To validate the results of the RT-PCR data, the most variable probes of AXIN2, CCND1 
and DKK1, were selected based on the highest IQR using log2 transformed data of the total 
French cohort. Because of a non-normal distribution, a Kruskal-Wallis test was performed 
to identify differences in ranks of expression levels of AXIN2, CNND1 and DKK1 (p-value 
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< 0.05, confidence interval 95%) between DTF with various CTNNB1 mutation types (T41A, 
S45F) and DTF with no mutations in exon 3 of CTNNB1 (WT).
Selection of Wnt target genes
To rule out that the limited set of Wnt genes analysed so far caused a selection bias affecting 
the outcome of our analyses, the number of Wnt targets genes was increased. Wnt target 
genes used in a hierarchical unsupervised cluster analyses using, transcript expression 
data from DTF tumours, were selected using the mammalian Wnt target genes listed on 
the Wnt homepage (https://web.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes) as a 
reference 35. Supplemental Table 1 summarizes the mammalian Wnt target genes that were 
selected, the corresponding Affymetrix probe sets and alias terms (https://www.ncbi.nlm.
nih.gov/gene/). Since DTF tumours are of mesenchymal origin, they may express Wnt target 
genes partly different from those observed in epithelial cancers. Therefore, unsupervised 
hierarchical cluster analyses were repeated using a list of putative mesenchymal Wnt target 
genes in desmoids published by Denys et al 36. Gene names, corresponding Affymetrix 
probe sets and alias terms are shown in Supplemental Table 2.
Hierarchical cluster analysis
For hierarchical cluster analysis, the retrieved normalized mRNA expression data of the 
128 DTF samples of the French cohort 26 were log2 transformed to minimize outliers. 
Next, Wnt target genes were selected based on their names and alias terms as described 
in paragraph 2.4. In case of multiple probes representing a single gene, the probe with the 
highest variability, based on the maximum IQR, using the entire dataset, was selected for 
further analyses. An unsupervised hierarchical cluster analysis was performed using median 
centred expression data with Cluster 3.0 for Windows (Human Genome Center, University 
of Tokyo, 2002) and Java Treeview, version 1.1.6rv, for visualization. The clustering was 
based on the centred correlation as a distance metric using average linkage.
Ethical approval
This study was part of a protocol entitled “Translational research on soft tissue sarcomas” 
which was assessed by the Medical Ethics Committee of the Erasmus MC, Rotterdam, the 
Netherlands (MEC-2016-213).
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Results
No difference in AXIN2, CCND1 and DKK1 expression between wild-type and 
CTNNB1 mutated desmoids
To examine whether different CTNNB1 mutations in desmoid tumours cause differential 
expression of Wnt target genes, the transcript levels of AXIN2, CCND1 and DKK1 were 
determined by RT-PCR. In total, 64 FFPE samples from the Dutch cohort were available 
for the RT-PCR analysis. The cohort included 23 males (35.9%) and 41 females (64.1%). 
Mutational status was as follows; 11 tumours (17.2 %) were WT for exon 3, 38 (59.4%) 
tumours harboured a T41A mutation, 12 (18.8%) tumours harboured a S45F mutation and 
3 (4.7%) tumours harboured a S45P mutation. Because of the low prevalence, the desmoids 
with the S45P mutation were not included in the RT-PCR analysis leaving a total of 61 
patients. The tumour and patient characteristics are summarized in Table 1. The relative 
expression values of AXIN2, CCND1 and DDK1 transcripts were measured and the median 
expression levels and the maximum IQR were calculated (Table 2). A Kruskal-Wallis test 
shows that the mean rank of the relative expression levels was not statistically significantly 
different between groups for AXIN2 and DKK1 (Table 2). The mean rank of the relative 
expression level for CCND1 showed a significant difference between groups, however failed 
significance after Bonferroni correction for multiple testing between mutation groups (Table 
2). A dot plot depicting the relative expression levels of individual samples of AXIN2, 
CCND1 and DKK1 is shown in Figure 1.
Table 2. Relative expression values of Wnt target genes AXIN2, CCND1 and DKK1 for the Dutch and French 
subgroups (tumours harbouring a T41A, S45F or wild-type CTNNB1 gene mutation
A. Dutch cohort, subgroup data 
(n = 61) a,b
Median (IQR) p-value c
AXIN2 1.48 (1.12) 0.273
CCND1 0.61 (0.86) 0.029 d
DKK1 0.02 (0.04) 0.319
B. French cohort, subgroup data
(n = 93)a
Median using log2 transformed 
data (IQR)
p-value c
AXIN2 (224498_x_at) 4.80 (1.48) 0.058
CCND1 (208711_s_at) 5.89 (0.80) 0.486
DKK1 (204602_at) 5.20 (1.17) 0.652
a T41A, S45F and wild-type CTNNB1 tumours included; b compared to house keeper gene Peptidylprolyl Isomerase A; c 
calculated p-values using the Kruskal-Wallis test; d non-significant after Bonferroni correction for multiple testing.
IQR, interquartile range; AXIN2, Axin 2; CCND1, Cyclin D1; DKK1, Dickkopf1; CI, confidence interval
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Figure 1. Dot plot depicting the individual data relative expression levels measured with realtime qPCR of 
Wnt target genes AXIN2, DKK1 and CCND1 in DTF harbouring either a S45F or T41A CTNNB1 mutation 
or wild-type DTF.
Next, mRNA expression data from the French cohort were used to validate these findings. The 
patient and tumour characteristics of this cohort are listed in Table 1. Ninety-three desmoid 
samples; CTNNB1 WT (n = 14); T41A (n = 45) and S45F (n = 34) were selected for subsequent 
analysis. First, the Affymetrix probe sets for AXIN2 (222696_at, 224176_at, 222695_s_at, 
224498_x_at) CCND1 (208712_at, 208711_s_at) and DKK1 (204602_at) were identified and 
the probes that displayed the most variable expression values after log 2 transformation, 
based on the highest IQR, were selected for further analysis (224498_x_at, 208711_s_at and 
204602_at). A Kruskal-Wallis test showed no significantly differences between the mean ranks 
of the groups with T41A or S45F mutations and WT CTNNB1 (Table 2).
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Figure 2A (part 1). Hierarchical clustering based on Wnt target mRNA expression in desmoid tumours does 
not discriminate wild-type and CTNNB1 S45F and T41A mutants. Heat map  depicting an unsupervised 
hierarchical cluster analysis of 93 desmoid-type fibromatosis samples harbouring T41A or S45F CTNNB1 
mutations and wild-type tumours using the  mRNA expression levels of selected mammalian Wnt target 
genes. Red and green represent relative high and low expresion levels, respectively. Tumour status (prima-
ry or recurrent); tumour size (<40 mm, 40-69 mm, 70-104 mm, >104 mm); age at diagnosis presented in 
categories based on the median and the 25th and 75th percentiles (age < 27 years, 27-37 years 38-55 years 
and > 55 years); tumour site (intra-abdominal, extra-abdominal and abdominal wall); sex and CTNNB1 
mutation status are indicated.
3
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Figure 2A (part 2). Hierarchical clustering based on Wnt target mRNA expression in desmoid tumours does 
not discriminate wild-type and CTNNB1 S45F and T41A mutants. Heat map  depicting an unsupervised 
hierarchical cluster analysis of 93 desmoid-type fibromatosis samples harbouring T41A or S45F CTNNB1 
mutations and wild-type tumours using the  mRNA expression levels of selected mammalian Wnt target 
genes. Red and green represent relative high and low expresion levels, respectively. Tumour status (prima-
ry or recurrent); tumour size (<40 mm, 40-69 mm, 70-104 mm, >104 mm); age at diagnosis presented in 
categories based on the median and the 25th and 75th percentiles (age < 27 years, 27-37 years 38-55 years 
and > 55 years); tumour site (intra-abdominal, extra-abdominal and abdominal wall); sex and CTNNB1 
mutation status are indicated.
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Figure 2B. Heat map depicting an unsupervised hierarchical cluster analysis of 93 desmoid-type fibroma-
tosis samples harbouring T41A, S45F CTNNB1 mutations and wildtype tumours using selected the mRNA 
expression levels of a set of putative mesenchymal Wnt target genes. Red and green represent relatively high 
and low expression levels, respectively. Tumour status (primary or recurrent); tumours size (<40 mm, 40-69 
mm, 70-104 mm, >104 mm); age at diagnosis presented in categories based on the median and the 25th and 
75th percentiles (age < 27 years, 27-37 years 38-55 years and > 55 years); tumour site (intra-abdominal, 
extra-abdominal and abdominal wall); sex and CTNNB1 mutation status are indicated.
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Hierarchical cluster analyses based on Wnt target gene expression does not 
discriminate between wild-type and CTNNB1 mutant desmoids
The total dataset contained 54613 probes, of which 107 probes were selected as mammalian 
Wnt targets and 47 were selected as mesenchymal Wnt targets. The hierarchical clustering 
using mammalian Wnt targets (Figure 2A) did not discriminate WT and mutated DTF 
(T41A and S45F) tumours, nor showed a discriminative pattern based on sex, age at the time 
of diagnosis, tumour size or tumour status (primary or recurrent tumour). An additional 
hierarchical clustering, using expression data from all 128 desmoid samples (including WT 
tumours as well as T41A, S45F, S45P mutated tumours, rare mutations classified as “other”, 
and tumours with an unknown mutation type), showed similar results (Supplemental Figure 
1A). Cluster analyses using putative mesenchymal Wnt targets 36 in a subgroup containing 
samples that are CTNNB1 WT, T41A and S45F (Figure 2B) and the cluster analysis using 
all samples (Supplemental Figure 1B), also showed that the desmoid samples did not cluster 
according to CTNNB1 mutational status, neither did the observed cluster appear to be driven 
by clinicopathological parameters like sex, age at time of diagnosis, tumour size or tumour 
status (primary or recurrent tumour).
Discussion
This study evaluated whether the potentially more aggressive clinical behaviour of S45F 
mutated DTF, compared to T41A mutants and WT desmoids, could be explained by a 
differential Wnt signalling activity. As aberrant Wnt/β-catenin signalling plays a pivotal 
role in the initiation and development of DTF, variable activity of Wnt signalling may affect 
cancer-related biological processes like cancer stem cell maintenance and invasiveness in 
a different manner 37-39. We therefore examined and compared Wnt target expression levels 
using different independent DTF sample sets that included DTF designated as WT as well 
as T41A and S45F CTNNB1 mutants. No evidence was found that WT tumours, T41A 
and S45F tumours have a differential activation of Wnt/β-catenin signalling. This finding 
contrasts with Hamada et al. who reported a significant increase of AXIN2, CCND1 and 
c-MYC transcript levels in S45F DTF isolated single cell lines compared to human skin 
fibroblasts and WT and T41A cells 33.
A study conducted by Meneghello et al. showed upregulated (two to six fold) mRNA 
expression of AXIN2 measured by RT-PCR but also reported that desmoid cells had 
downregulated mRNA expression of CCND1 (two-four fold) when comparing DTF samples 
with connective tissue of non-desmoid patients 17. In addition, Jilong et al. compared β-catenin 
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mutated tumours with WT tumours and found that CCND1 was expressed more frequently 
in β-catenin mutated DTF 16. Saito et al. found a statistically significant correlation between 
nuclear staining of β-catenin and CCND1 overexpression 16, 40. Although the literature on 
Wnt target expression in desmoids is limited and somewhat contradictory, both AXIN2 and 
CCND1 seem to be overexpressed in DTF. Interestingly, by studying genotype-phenotype 
correlations of CTNNB1 mutations in liver cancer, others have found that T41 mutations were 
associated with moderate activity whereas S45 mutations led to a weak β-catenin activation 
which could be compensated by S45 mutant allele duplication 29.
None of our hierarchical cluster analyses, based on the expression of different Wnt target 
gene sets, discriminated CTNNB1 mutated (S45 and T41) from WT DTF samples, neither 
were S45F and T41A clearly separated. A possible confounder in our analyses is that the WT 
group, now defined by the absence of mutations in exon 3 of CTNNB1, needs to be screened 
more thoroughly for CTNNB1 mutations. It was demonstrated that a fair part of the DTF, 
designated as WT by Sanger sequencing, contain low frequency CTNNB1 mutations that 
are only detected by whole exome sequencing or contain novel intra-genic deletions of the 
CTNNB1 gene 19, 41. Moreover, in the WT group, other genomic alterations occurred like 
APC loss, chromosome 6 loss and BMI1 mutations which are all linked to Wnt/β-catenin 
activation 19. In our analyses, we could not distinguish between WT and S45F/T41A mutant 
DTF corresponding to observations of Crago et al. 19. In contrast, Colombo et al. reported 
that CTNNB1-mutated and WT DTF had different gene expression profiles 42. In our cluster 
analyses, distinct clusters of samples were discerned based on the expression levels of 
putative Wnt target genes that were not related to CTNNB1 mutational status. Unfortunately, 
we were not able to identify the origin of the cluster pattern as it could not be explained by 
factors like sex, age at the time of diagnosis, tumour size and tumour status (primary or 
recurrent tumour). Other clinicopathological factors, not included in this study, for example 
immune cell infiltration could potentially explain the observed cluster pattern and could 
be the subject of future studies. Interestingly in this respect is a recent publication from 
Colombo et al. describing that T41A and S45F mutated DTF displayed a different expression 
of inflammation related genes 42.
No indications were found in this study for a differential Wnt/β-catenin signalling activity 
between the T41A and S45F mutants thereby failing to explain the reported different clinical 
behaviour of the two DTF mutant groups. A more thorough investigation into the molecular 
consequences of different CTNNB1 mutations is necessary, focusing on protein-protein 
interactions and identifying their genomic binding sites. Irrespective of the specific CTNNB1 
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mutation present in DTF, it is clear that Wnt/β-catenin signalling is activated which plays 
an essential role in carcinogenesis. Inhibition of this pathway may provide a vulnerability 
in DTF that can therapeutically be exploited. However, drugs should operate at the level 
of β-catenin, interacting with transcription co-factors or target specific key downstream 
factors to avoid serious adverse effects 43, 44. Additionally, other signalling pathways like 
Notch1 and Hedgehog have also been implicated to play a role in DTF development and 
may be therapeutically targeted by small molecules 45, 46. Future studies are needed to gain 
more insight into the role of these additional signalling pathways, the cross-talks between 
each pathway and their contribution to the DTF tumorigenesis.
Conclusions
Our study demonstrated no difference between either WT, S45F or T41A mutated DTF 
tumours regarding the investigated Wnt target gene expression levels. Apparently a 
differential Wnt/β-catenin signalling activity does not determine the observed differences 
in clinical behaviour between S45F and T41A DTF mutants.
3
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Supplemental Table 1. Selection of putative mammalian Wnt targets. Selected probes for the cluster analysis 
are marked by an asterisk (*)
Gene name Gene title Alias terms Affymetrix Code
ATOH1 atonal bHLH 
transcription factor 1
ATH1; HATH1; MATH-1; 
bHLHa14
221336_at*




protein /// PMF1-BGLAP 
readthrough
OC; OCN, osteocalcin 206956_at*
BIRC5 baculoviral IAP repeat 
containing 5
Survivin, API4; EPR-1 202095_s_at*; 1555826_at; 
202094_at; 210334_x_at;
BMP4 bone morphogenetic 
protein 4
ZYME; BMP2B; OFC11; 
BMP2B1; MCOPS6
211518_s_at*
BTRCP beta-transducin repeat 
containing E3 ubiquitin 
protein ligase
FWD1; FBW1A; FBXW1; 





CACNA1G calcium channel, 
voltage-dependent, T 
type, alpha 1G subunit





CCND cyclin D1 BCL1; PRAD1; U21B31; 
D11S287E
208711_s_at*;208712_at;
cyclin D2 No alias terms 200951_s_at*; 200952_s_at
200953_s_at; 231259_s_at
cyclin D3 No alias terms 1562028_at*; 201700_at
CD44 CD44 molecule IN; LHR; MC56; MDU2; 
MDU3; MIC4; Pgp1; CDW44; 









CDC25 cell division cycle 25A CDC25A2, CDC25C cell 
division cycle 25C; PPP1R60
204696_s_at*; 1555772_a_at;
204695_at
CDH1 cadherin 1, type 1 E-cadherin; cadherin 1, UVO; 
CDHE; ECAD; LCAM; Arc-1; 
BCDS1; CD324
201130_s_at*; 201131_s_at
CDKN2A cyclin-dependent kinase 
inhibitor 2A
ARF; MLM; P14; P16; P19; 
CMM2; INK4; MTS1; TP16; 
CDK4I; CDKN2; INK4A; 





CDX1 caudal type homeobox 1 No alias terms 206430_at*
CDX4 caudal type homeobox 4 No alias terms 221340_at*
CLD1 claudin 1 CLDN1; SEMP1; ILVASC 218182_s_at*; 222549_at
3
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Supplemental Table 1. (continued)
Gene name Gene title Alias terms Affymetrix Code
COX2 cytochrome c oxidase 
subunit II
No alias terms 1553569_at*; 1553570_x_at
CTLA4 cytotoxic T-lymphocyte-
associated protein 4
CD; GSE; GRD4; ALPS5; 









CCN1; GIG1; IGFBP10 210764_s_at*; 201289_at
Dickkopf dickkopf WNT 
signalling pathway 
inhibitor 1















EDA ectodysplasin A ED1; HED; EDA1; EDA2; 
HED1; ODT1; XHED; ECTD1; 
XLHED; ED1-A1; ED1-A2; 









EFNB ephrin-B1 CFND; CFNS; EFB1; EFL3; 
EPLG2; Elk-L; LERK2
202711_at*
ephrin-B2 EFNB2 HTKL; EPLG5; 
Htk-L; LERK5
202669_s_at*; 202668_at
ephrin-B3 No alias terms 205031_at*; 210883_x_at
EMP1 epithelial membrane 
protein 1










FGF18 fibroblast growth factor 
18
ZFGF5; FGF-18 206987_x_at*; 206986_at;
211029_x_at; 211485_s_at;
214284_s_at; 231382_at;
FGF20 fibroblast growth factor 
20
RHDA2; FGF-20 220394_at*
FGF4 fibroblast growth factor 
4
HST; KFGF; FGF-4; HST-1; 
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Supplemental Table 1. (continued)
Gene name Gene title Alias terms Affymetrix Code
FGF9 fibroblast growth factor 
9
GAF; FGF-9; SYNS3; HBFG-9; 
HBGF-9,
239178_at*; 206404_at
FN fibronectin fibronectin 1;FN; CIG; FNZ; 






FOXN1 forkhead box N1 WHN; RONU; FKHL20 207683_at*; 1558687_a_at;
FST follistatin FS 204948_s_at*; 207345_at
226847_at
FZD7 frizzled class receptor 7 FzE3 203706_s_at*; 203705_s_at
GAST gastrin GAS 208138_at*
GJA1 gap junction protein 
alpha 1
Connexin 43; CX 43, HSS; 
CMDR; CX43; EKVP; GJAL; 
ODDD; AVSD3; EKVP3; 
HLHS1; PPKCA
201667_at*
GREM gremlin 1, DAN family 
BMP antagonist
GREM1; DRM; HMPS; 
MPSH; PIG2; CRAC1; 
CRCS4; DAND2; HMPS1; 
IHG-2; DUP15q; C15DUPq; 
GREMLIN; CKTSF1B1
218468_s_at*; 218469_at




Tcf-1 HNF1 homeobox A HNF1A; HNF1; LFB1; TCF1; 
HNF4A; MODY3; TCF-1; 
HNF-1A; IDDM2
210515_at*; 216930_at
ID2 inhibitor of DNA 
binding 2, dominant 
negative helix-loop-helix 
protein
GIG8; ID2A; ID2H; bHLHb26; 201566_x_at*; 201565_s_at
ID2 /// ID2B inhibitor of DNA 
binding 2, dominant 
negative helix-loop-
helix protein /// inhibitor 




No alias terms 213931_at*
IGF1 insulin-like growth 
factor 1 
(somatomedin C)






factor 2 /// INS-IGF2 
readthrough





IL6 interleukin 6 CDF; HGF; HSF; BSF2; IL-6; 
BSF-2; IFNB2; IFN-beta-2
205207_at*
IRX1 iroquois homeobox 1 IRX-1; IRXB1 230472_at*
3
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Supplemental Table 1. (continued)
Gene name Gene title Alias terms Affymetrix Code
IRX3 iroquois homeobox 3 IRX-3 229638_at*
ISL1 ISL LIM homeobox 1 Isl-1; ISLET1 206104_at*










JAG2 jagged 2 HJ2; SER2 32137_at*; 209784_s_at
C-JUN jun proto-oncogene AP-1 transcription factor 
subunit ,AP1; p39; AP-1;
201465_s_at*; 201464_x_at;
201466_s_at; 213281_at;
L1CAM L1 cell adhesion 
molecule
S10; HSAS; MASA; MIC5; 




LBH limb bud and heart 
development
No alias terms 221011_s_at*
LEF1 lymphoid enhancer-
binding factor 1









FEX; HG38; GPR49; GPR67; 
GRP49
213880_at*; 210393_at
MET MET proto-oncogene, 
receptor tyrosine kinase












No alias terms 220541_at*
MMP3 matrix 
metallopeptidase 3
Stromelysin, SL-1; STMY; 








GELB; CLG4B; MMP-9; 
MANDP2
203936_s_at*
MSI1 musashi RNA binding 
protein 1
No alias terms 206333_at*
MYCBP2 MYC binding protein 
2, E3 ubiquitin protein 
ligase
No alias terms 201959_s_at; 1557370_s_at;
201960_s_at
NANOG Nanog homeobox No alias terms 231079_at*; 220184_at
NEUROD1 neuronal differentiation 
1
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Supplemental Table 1. (continued)
Gene name Gene title Alias terms Affymetrix Code
NEUROG1 neurogenin 1 AKA; ngn1; Math4C; bHLHa6; 
NEUROD3
208497_x_at*
NKX2-2 NK2 homeobox 2 NKX2B; NKX2.2 206915_at*
NOS2 nitric oxide synthase 2, 
inducible
NOS2, NOS; INOS; NOS2A; 
HEP-NOS
210037_s_at*





RS; RGS; ARP1; Brx1; IDG2; 
IGDS; IHG2; PTX2; RIEG; 
ASGD4; IGDS2; IRID2; Otlx2; 
RIEG1
207558_s_at*
PLAU plasminogen activator, 
urokinase
urokinase receptor , CD87; 
UPAR; URKR; U-PAR
211668_s_at*; 205479_s_at
PLAUR plasminogen activator, 
urokinase receptor




POSTN periostin, osteoblast 
specific factor











G/H synthase and 
cyclooxygenase)
COX2; COX-2; PHS-2; 









EAP1; PTTG; HPTTG; TUTR1200677_at*
RET ret proto-oncogene PTC; MTC1; HSCR1; MEN2A; 




RHOU ras homolog family 
member U
ARHU; G28K; WRCH1; 
hG28K; CDC42L1
223169_s_at*; 223168_at
RUNX2 runt-related transcription 
factor 2
CCD; AML3; CCD1; CLCD; 






SALL4 spalt-like transcription 
factor 4
DRRS; HSAL4; ZNF797 229661_at*
SFRP2 secreted frizzled-related 
protein 2
FRP-2; SARP1; SDF-5 223121_s_at*; 223122_s_at
SIX3 SIX homeobox 3 HPE2 242054_s_at*; 206634_at
244288_s_at
3
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Supplemental Table 1. (continued)
Gene name Gene title Alias terms Affymetrix Code
SNX9 sorting nexin 9 SDP1; WISP; SH3PX1; 
SH3PXD3A
223027_at*; 223028_s_at
SOX17 SRY box 17 VUR3; SRY-box 17 SOX 17 219993_at*; 230943_at
SOX9 SRY box 9 CMD1; SRA1; CMPD1; 
SRXX2; SRXY10, SRY-box 9
202936_s_at*; 202935_s_at
SP5 Sp5 transcription factor No alias terms 235845_at*
STRA6 stimulated by retinoic 
acid 6
MCOPS9; MCOPCB8; PP142961569334_at*; 1569335_a_at;
221701_s_at
TBX1 T-box 1 Brachyury (Tbox1);
TBX1 T-box 1; DGS; TGA; 
VCF; CAFS; CTHM; DGCR; 









TCF4 transcription factor 4 ITF2; PTHS; SEF2; FECD3; 
ITF-2; SEF-2; TCF-4; SEF2-1; 






TERT telomerase reverse 
transcriptase
TP2; TRT; CMM9; EST2; 
TCS1; hTRT; DKCA2; DKCB4; 
hEST2; PFBMFT1
1555271_a_at*; 207199_at
TIAM1 T-cell lymphoma 
invasion and metastasis 
1
TIAM-1 213135_at*; 206409_at
TNFRSF11Atumor necrosis factor 
receptor superfamily, 
member 11a, NFKB 
activator
RANK ligand; FEO; OFE; 
ODFR; OSTS; PDB2; RANK; 
CD265; OPTB7; TRANCER; 
LOH18CR1
207037_at*; 238846_at
TNFRSF19 tumor necrosis factor 
receptor superfamily, 
member 19




TNFRSF9 tumor necrosis factor 
receptor superfamily, 
member 9
ILA; 4-1BB; CD137; CDw137;
TNF family 41BB ligand
238950_at*; 207536_s_at
211786_at
TWIST1 twist family bHLH 
transcription factor 1
CRS; CSO; SCS; ACS3; CRS1; 
BPES2; BPES3; SWCOS; 
TWIST; bHLHa38
213943_at*





VEGF vascular endothelial 
growth factor A
VPF; MVCD1 211527_x_at*; 210512_s_at;
210513_s_at; 212171_x_at
3
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Supplemental Table 1. (continued)






vascular endothelial growth 
factor C, VRP; Flt4-L; 
LMPH1D
209946_at*
WISP WNT1 inducible 
signaling pathway 
protein 1





WISP WNT1 inducible 
signalling pathway 
protein 2
CCN5; CT58; CTGF-L 205792_at*
3
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Supplemental Table 2. Selection of putative mesenchymal Wnt targets. Selected probes for the cluster 
analysis are marked by an asterisk (*)
Gene name Gene Title Alias terms Affymetrix Code
ACAN aggrecan AGC1; SEDK; AGCAN; 




ACAP1 ArfGAP with coiled-coil, 
ankyrin repeat and PH 
domains 1
No alias terms 205212_s_at*
ALCAM activated leukocyte cell 
adhesion molecule
MEMD; CD166 1569362_at*; 201951_at;
201952_at





ARL4C ADP-ribosylation factor 
like GTPase 4C
No alias terms 213759_at*; 202206_at;
202207_at; 202208_s_at
ATF5 activating transcription 
factor 5
ATFX; HMFN0395 230938_x_at*; 204998_s_at; 
204999_s_at;
217389_s_at
BRF2 butyrate response factor 2 BRFU; TFIIIB50, BRF2 
BRF2, RNA polymerase III 
transcription initiation factor 
subunit
218954_s_at*; 218955_at
CLEC2B C-type lectin domain 
family 2, member B
CLEC2B C-type lectin domain 
family 2 member B; AICL; 
IFNRG1; CLECSF2; HP10085
209732_at*
CREB1 cAMP responsive element 
binding protein 1




CRIP1 cysteine-rich protein 1 
(intestinal)
CRHP; CRIP; CRP1; CRP-1; 
CRIP1 cysteine rich protein 1
205081_at*
CRLF1 cytokine receptor-like 
factor 1
CLF; NR6; CISS; CISS1; CLF-1; 
zcytor5, CRLF1 cytokine 
receptor like factor 1
206315_at*
CRYAB crystallin alpha B MFM2; CRYA2; CTPP2; 
HSPB5; CMD1II; CTRCT16; 
HEL-S-101; CRYAB crystallin 
alpha B
209283_at*
CTS cathepsin CTSK; cathepsin K; CTSO; 
PKND; PYCD; CTS02; CTSO1; 
CTSO2
203758_at*
EFEMP1 EGF containing fibulin-
like extracellular matrix 
protein 1
DHRD; DRAD; FBNL; MLVT; 
MTLV; S1-5; FBLN3; FIBL-3
201843_s_at*; 201842_s_at;
228421_s_at
ENG endoglin END; HHT1; ORW1 201809_s_at*; 201808_s_at
3
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Supplemental Table 2. (continued)
Gene name Gene Title Alias terms Affymetrix Code
FLNB filamin B, beta AOI; FH1; SCT; TAP; LRS1; 
TABP; FLN-B; FLN1L; ABP-





No alias terms 201422_at*
IGFBP6 insulin like growth factor 
binding protein 6
IBP6 203851_at*
ITPR3 inositol 1,4,5-trisphosphate 
receptor, type 3





JUNB jun B proto-oncogene AP-1; JUNB ; AP-1 
transcription factor subunit
201473_at*
KRT18 keratin 18, type I K18; CK-18; CYK18 201596_x_at*
KRT7 keratin 7, type II K7; CK7; SCL; K2C7 1558394_s_at*; 1558393_at; 
209016_s_at
LGALS3BP lectin, galactoside-binding, 
soluble, 3 binding protein
galectin 3 binding protein; 






mab-21-like 1 (C. elegans) 
/// microRNA 548f-5
MAB21L1 mab-21 like 
1CAGR1; Nbla00126
206163_at*
MDK midkine (neurite growth-
promoting factor 2)
MK; ARAP; NEGF2 midkine 209035_at*
MFGE8 milk fat globule-EGF factor 
8 protein
BA46; HMFG; MFGM; 
SED1; hP47; EDIL1; MFG-E8; 
SPAG10; OAcGD3S; HsT19888
1558960_a_at*; 210605_s_at
MMP3 matrix metallopeptidase 3 SL-1; STMY; STR1; CHDS6; 
MMP-3; STMY1
205828_at*
MYRL2 myosin light chain 2 
myosin regulatory light 
chain 2, smooth muscle 
isoform
MLC2; CMH10; MLC-2s/v; 
MYL2
209742_s_at*
NID2 nidogen 2 (osteonidogen) NID-2 204114_at*
NRG1 neuregulin 1 NRG; GGF; HGL; HRG; NDF; 
ARIA; GGF2; HRG1; HRGA; 





PENK proenkephalin PE; PENK-A; proenkephalin 213791_at*
PODXL podocalyxin-like PC; PCLP; Gp200; PCLP-1 201578_at*
PTGIS prostaglandin I2 
(prostacyclin) synthase
CYP8; PGIS; PTGI; CYP8A1 208131_s_at*; 210702_s_at;
211892_s_at;
PTK7 protein tyrosine kinase 7 
(inactive)
CCK4; CCK-4 1555324_at*; 207011_s_at;
3
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Supplemental Table 2. (continued)
Gene name Gene Title Alias terms Affymetrix Code
PTX3 pentraxin 3, long TSG-14; TNFAIP5 206157_at*
QSCN6 Quiescin Q6 No Alias terms 230523_at*; 201482_at
SEMA3C sema domain, 
immunoglobulin domain 
(Ig), short basic domain, 
secreted, (semaphorin) 3C
semaphorin 3C, SemE; SEMAE 203788_s_at*; 203789_s_at
SFRP1 secreted frizzled-related 
protein 1
No Alias terms 202037_s_at*; 202035_s_at;
202036_s_at; 228413_s_at;





SLC7A8 solute carrier family 7 
(amino acid transporter 
light chain, L system), 
member 8
LAT2; LPI-PC1 216604_s_at*; 202752_x_at;
216092_s_at; 216603_at;
217248_s_at
SPARCL1 SPARC like 1 SC1; MAST9; PIG33; MAST 9 200795_at*
TNFAIP6 tumor necrosis factor, 
alpha-induced protein 6
No alias terms 206025_s_at*; 206026_s_at
TNFRSF11B tumor necrosis factor 
receptor superfamily, 
member 11b




TRO trophinin MAGED3; MAGE-d3 205028_at*; 210882_s_at;
211700_s_at; 211701_s_at;
WNT5A wingless-type MMTV 
integration site family, 
member 5A
hWNT5A;, Wnt family 
member 5a
205990_s_at*; 213425_at
ZIC1 Zic family member 1 ZIC; CRS6; ZNF201 206373_at*; 234716_at;
236896_at
3
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Supplemental Figure 1A (part 1). Hierarchical clustering based on Wnt target mRNA expression in des-
moid tumors does not discriminate wild-type, samples with an unknown CTNNB1 status, rare CTNNB1 
mutants and CTNNB1 S45F, S45P, T41A mutants. Heat map depicting an unsupervised hierarchical cluster 
analysis of 128 desmoid-type fibromatosis samples harbouring T41A or S45F CTNNB1 mutations and wild-
type tumours using the mRNA expression levels of selected mammalian Wnt target genes. Red and green 
represent relative high and low expresion levels, respectively. Tumour status (primary or  recurrent); tumour 
size (<40 mm, 40-69 mm, 70-104 mm, >104 mm); age at diagnosis presented in categories based on the 
median and the 25th and 75th percentiles (age < 27 years, 27-37 years 38-55 years and > 55 years); tumour 
site (intra-abdominal, extra-abdominal and abdominal wall); sex and CTNNB1 mutation status are indicated.
3
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Supplemental Figure 1A (part 2). Hierarchical clustering based on Wnt target mRNA expression in des-
moid tumours does not discriminate wild-type, samples with an unknown CTNNB1 status, rare CTNNB1 
mutants and CTNNB1 S45F, S45P, T41A mutants. Heat map depicting an unsupervised hierarchical cluster 
analysis of 128 desmoid-type fibromatosis samples harbouring T41A or S45F CTNNB1 mutations and wild-
type tumours using the mRNA expression levels of selected mammalian Wnt target genes. Red and green 
represent relative high and low expresion levels, respectively. Tumour status (primary or  recurrent); tumour 
size (<40 mm, 40-69 mm, 70-104 mm, >104 mm); age at diagnosis presented in categories based on the 
median and the 25th and 75th percentiles (age < 27 years, 27-37 years 38-55 years and > 55 years); tumour 
site (intra-abdominal, extra-abdominal and abdominal wall); sex and CTNNB1 mutation status are indicated.
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Supplemental Figure 1B. Hierarchical clustering based on Wnt target mRNA expression in desmoid tu-
mours does not discriminate wild-type,samples with an unknown CTNNB1 status, rare CTNNB1 mutants 
and CTNNB1 S45F, S45P, T41A mutants. Heat map depicting an unsupervised hierarchical cluster analysis 
of 128 desmoid-type fibromatosis samples harbouring wild-type, CTNNB1 samples, samples with an un-
known CTNNB1 status, samples with rare CTNNB1 mutations and CTNNB1 S45F, S45P, T41A mutants, 
using selected the mRNA expression levels of a set of putative mesenchymal Wnt target genes. Red and 
green represent relatively high and low expression levels, respectively. Tumour status (primary or recurrent); 
tumour size (<40 mm, 40-69 mm, 70-104 mm, >104 mm); age at diagnosis presented in categories based on 
the median and the 25th and 75th percentiles (age < 27 years, 27-37 years 38-55 years and > 55 years); tumour 
site (intra-abdominal, extra-abdominal and abdominal wall); sex and CTNNB1 mutation status are indicated.
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The majority of desmoid-type fibromatosis (DTF) tumours harbour a β-catenin mutation, 
affecting specific codons in CTNNB1 exon 3. S45F tumours are reported to have a higher 
chance of recurrence after surgery and more resistance to systemic treatments compared to 
wild-type (WT) and T41A tumours. The aim of this pilot study was to examine the genome-
wide DNA methylation profiles of S45F and T41A mutated DTF, to explain the observed 
differences in clinical behaviour between these DTF subtypes.
Material and methods
Genome-wide analysis of DNA methylation was performed using MeD-seq on formalin 
fixed, paraffin embedded primary DTF samples harbouring a S45F (n = 14) or a T41A 
(n = 15) mutation. Differentially methylated regions (DMRs) between S45F and T41A DTF 
were identified and used for a supervised hierarchical cluster analysis. DMRs with a fold 
change  ≥1.5 were considered to be differentially methylated and differences between S45F 
and T41A tumours were quantitatively assessed. The effect of DMRs on the expression 
of associated genes was assessed using an mRNA expression dataset. Protein-protein 
interactions between wild-type β-catenin and mutant variants and DNA methyltransferase 
1 (DNMT1) were examined by immunoprecipitation experiments.
Results
MeD-seq analyses indicated 354 regions that displayed differential methylation. Cluster 
analysis yielded no distinct clusters based on mutation, gender, tumour site or tumour size. 
A supervised clustering based on DMR between small (≤34 mm) and large (>87 mm) DTF 
distinguished the two groups. Only ten DMRs displayed a fold change of ≥1.5 and six of 
them were found associated with of the following genes: NLRP4, FOXK2, PERM1, CCDC6, 
NOC4L and DUX4L6. The effects of DMR on gene expression yielded a significance 
difference (p < 0.05) in the expression between S45F and T41A for CCDC6 and FOXK2 
but not for all Affymetrix probes sets used to detect these genes. Immunoprecipitation did 
not reveal an association of wild-type β-catenin or mutant variants with DNMT1.
Conclusion
This study demonstrated that S45F and T41A DTF tumours did not exhibit gross differences 
in DNA methylation patterns. This implies that distinct DNA methylation profiles are not the 
sole determinant for the divergent clinical behaviour of different DTF mutant subtypes.
4
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Introduction
Desmoid-type fibromatosis (DTF) is a rare, non-metastasizing, invasive, mesenchymal soft 
tissue sarcoma 1, 2. The presence 3of nuclear β-catenin distinguishes DTF from other soft 
tissue tumours and scar tissue 4 and is caused by the fact that the majority of tumours (> 85%) 
harbor a mutation at specific sites in the β-catenin (CTNNB1) gene 5. These mutually exclusive 
mutations in exon 3 of the CTNNB1 gene result in substitution of serine at position 45 with 
phenylalanine (S45F), or less commonly proline (S45P), or lead to a replacement of threonine 
at position 41 with alanine (T41A) 5, 6. The tumour is categorized as wild-type (WT) in case no 
CTNNB1 exon 3 mutations are found. This WT group is considered heterogeneous as these 
tumours may contain other CTNNB1, outside of exon 3, or APC mutations 5. Despite the shared 
molecular basis in the majority of DTF patients, the clinical presentation and disease course 
varies. Several studies indicate a prognostic role for the CTNNB1 mutation and some claim that 
S45F tumours have a higher risk of recurrence after surgery in comparison to T41A tumours 
6-8 or that S45F tumours are more resistant to treatment with e.g., sorafenib 9, doxorubicin 10 or 
meloxicam 11. Currently, there is no biological rationale for the reported clinical differences in 
behaviour – particularly the risk of recurrence - of DTF with these mutation types. A recent 
pilot study revealed differences in the metabolomics profiles associated with T41A and S45F 
DTF cell lines also suggesting that - up to a certain extent - the biology of DTF with these 
CTNNB1 mutations indeed differs 12.
The CTNNB1 mutations that are predominantly observed in DTF, prevent phosphorylation 
and subsequent degradation of β-catenin, a key player in the Wnt/β-catenin signalling 
pathway. This leads to stabilisation and translocation of β-catenin into the nucleus, causing 
aberrant Wnt/β-catenin signalling. However, CTNNB1 has a complex role in the cell, and is 
involved in protein-interaction networks related to cell adhesion and transcription. Nuclear 
β-catenin recruits transcription factors of the TCF family and interacts with epigenetic and 
chromatin modifiers 13,14. Song et al. reported a protein interaction between CTNNB1 and the 
DNA methyltransferase DNMT1 in cancer cells which stabilizes each protein and regulates 
downstream CTNNB1 and DNMT1 functions suggesting a cross-regulation between Wnt 
signalling and DNA methylation 15.
Changes in the DNA methylation pattern have been described in various solid tumours, 
including various mesenchymal neoplasms such as chondrosarcoma, Ewing sarcoma and 
rhabdomyosarcoma 16-21. These distinct methylation patterns could be of diagnostic value 
and capable of discerning tumour subtypes, may yield clinically relevant biomarkers that 
can direct treatment choices, and can potentially reveal novel treatment opportunities 22-26. 
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The findings of Song et al. prompted us to hypothesize that the different mutations found 
in CTNNB1 in DTF affect interacting DNMT1 differently consequently causing altered 
DNA methylation patterns.
This study investigates DNA methylation patterns of the two most common mutation types 
of DTF (S45F and T41A), aiming to provide insight in the biological underpinnings of the 
different clinical behaviour of these DTF mutants.
Materials and Methods
Patient and sample selection
Patients with histologically proven, primary DTF and a S45F or T41A CTNNB1 mutation 
were identified in the Erasmus MC pathology database. Corresponding formalin-fixed 
paraffin-embedded (FFPE) tumour tissue blocks were collected from the Erasmus MC 
tissue bank. Similarly, clinicopathological characteristics such as sex, age at diagnosis, 
tumour site (extra-abdominal, intra-abdominal, or abdominal wall), and largest tumour size 
(in millimetres [mm]) on imaging were obtained from the patient files. The CTNNB1 exon 
3 mutations were previously determined for diagnostic purposes essentially as described 
by Dubbink et al. 27. In short: Tumour DNA was extracted from FFPE tumour tissue using 
proteinase K and 5% Chelex®-100 chelating resin (Bio-Rad). Sequence analysis of CTNNB1 
exon 3 was performed by bidirectional sequencing of PCR-amplified DNA fragments using 
M13-tailed forward and reverse primers. The selected patients did not receive any treatment 
before the specimens were obtained. An expert soft tissue sarcoma pathologist confirmed 
the diagnosis by examining hematoxylin-eosin stained sections of the FFPE samples.
DNA isolation
DNA was isolated from five consecutive FFPE DTF sections of 10µm using the Allprep DNA/
RNA kit according to the manufacturer’s recommendations (Qiagen, Hilden, Germany). 
The DNA quality and the concentrations were determined using a Nanodrop-2000 (Isogen 
Life Science, Utrecht, and the Netherlands). The 260nm/280nm ratio was ≥ 1.80 for all 
DNA preparations.
MeD-seq sample preparations
Methylated DNA sequencing (MeD-seq) was used to analyse genome wide DNA 
methylation. MeD-seqprovides single-nucleotide resolution by exploiting the properties of 
the DNA methylation dependent restriction enzyme LpnPI 28. This enzyme generates DNA 
4
146460_Timbergen,Milea_BNW-def.indd   94 25-11-2020   08:20
95
fragments of 32 base pairs (bp) by cutting 16 bp downstream from the methylated CpG 
sites, which allows specific focus on the methylated regions. The MeD-seq analyses were 
essentially carried out as previously described 28, 29. In brief: DNA samples were digested 
by LpnPI (New England Biolabs, Ipswich, MA, USA), resulting in snippets of 32 bp around 
a fully-methylated recognition site that contains a CpG. These short DNA fragments were 
further processed using a ThruPlex DNA–seq 96D kit (cat#R400407, Rubicon Genomics 
Ann Arbor, MI, USA) and a Pippin system. Stem-loop adapters were blunt-end ligated to 
repaired input DNA and amplified to include dual indexed barcodes using a high-fidelity 
polymerase to generate an indexed Illumina NGS library. The amplified end product was 
purified on a Pippin HT system with 3% agarose gel cassettes (Sage Science, Beverly, MA, 
USA). Multiplexed samples were sequenced on Illumina HiSeq2500 systems for single 
read of 50 bp according to the manufacturer’s instructions. Dual indexed samples were 
demultiplexed using bcl2fastq software (Illumina, San Diego, CA, USA).
MeD-seq data analysis
Data processing was carried out using specifically created scripts in Python. The proprietary 
Python script is used in the context of an exclusive license from the Erasmus Medical Center 
with Methylomics BV. Raw fastq files were subjected to Illumina adaptor trimming and 
reads were filtered based on LpnPI restriction site occurrence between 13-17 bp from either 
5’ or 3’ end of the read. Reads that passed the filter were mapped to hg38 using bowtie2. 
Genome-wide individual LpnPI site scores were used to generate read count scores for the 
following annotated regions: transcription start sites ((TSS), 1 kb before and 1 kb after), 
CpG-islands and gene bodies (1kb after TSS till Transcription End Site (TES)). Gene and 
CpG-island annotations were downloaded from ENSEMBL (www.ensembl.org). Detection 
of DMRs was performed between two datasets containing the regions of interest (TSS, gene 
body or CpG-islands) using the Chi-square test on read counts. Significance at a p-value of < 
0.05 was called by either Bonferroni or FDR using the Benjamini-Hochberg procedure.
In addition, a genome-wide sliding window was used to detect sequentially differentially 
methylated LpnPI sites. Statistical significance was called between LpnPI sites in 
predetermined groups using the Chi-square test. Neighbouring significantly called LpnPI 
sites were binned and reported. Annotation of the overlap of genome-wide detected DMRs 
was reported for TSS, CpG-islands and gene body regions. DMR thresholds were based on 
LpnPI site count. Fold changes of read counts are mentioned in the figure legends before 
performing hierarchical clustering. The differentially methylated datasets generated and 
analysed during the current study have been deposited to the Sequence Read Archive (SRA) 
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data repository under accession number PRJNA604749. The DMRs with a fold change ≥1.5 
were considered to be differentially methylated and were analysed separately. Non-normal 
distributed values were analysed using a Mann-Whitney U test to identify statistically 
significant differences in the normalized read counts between the two mutation types. A 
p-value of < 0.05 was considered to be statistically significant. SPSS Statistics (version 24) 
was used for the Mann-Whitney U tests (IBM, Armonk, New York, USA). The DMRs of 
interest were loaded in the Integrative Genomics Viewer (IGV) using the Hg 38 platform 
to visualize regions of interest 30.
Validation MeD-seq results using an mRNA expression dataset
Expression data, generated on an Affymetrix platform (Human Genome U133 Plus 2.0 
array) of PERM1, DUX4L6, CCDC6, NOC4L, FOXK2 and NLRP4 in DTF samples 
(n = 128) were obtained from a publicly available dataset in the Gene Expression Omnibus 
(accession number GSE58697) 31 Information regarding the CTNNB1 mutational status was 
kindly provided by dr. Frederic Chibon, Cancer Research Center of Toulouse, France. Only 
patients with an S45F or T41A mutation were selected for validation purposes. A Mann-
Whitney U test was performed on non-normal distributed data to identify differences in 
mRNA expression levels of the selected genes corresponding to the identified DMRs. A 
p-value of < 0.05 was considered statistically significant. SPSS Statistics (version 24) was 
used for all statistical analyses.
Cell lines, cell transfection
The human cell lines HEK293T (embryonic kidney cells) and HCT116 (colon cancer cells) 
were maintained in DMEM (Gibco Life Technologies) supplemented with 10% fetal bovine 
serum (Greiner bio-one) and 100 IU/ml penicillin and 100 μg/ml streptomycin at 37°C 
in a humidified atmosphere containing 5% CO2. For transfections cells were cultured in 
6-well plates to 70% confluence. Next the cells in each well were transfected with 1 µg 
of different N-terminal FLAG tagged β-catenin plasmids or empty pcDNA 5’UT-FLAG 
vector using ViaFect™ (Promega) as transfection agent. The construction of the different 
expression plasmids is described by Liu et al. 32. The CTNNB1 plasmid variants used 
express FLAG tagged versions of either the wild-type (WT), T41A, S45P, exon 3 deletion 
or K335I β-catenin.
Cell lysates, Immunoprecipitation and Western blotting
At 48 h post-transfection cells were washed with ice-cold PBS and lysed in 500 µl of 
lysis buffer 25 mM Tris-HCl pH 7.5; 150 mM NaCl; 1 mM EDTA; 1% NP-40 and 5% 
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glycerol (Pierce IP lysis buffer) containing Halt Protease and Phosphatase inhibitor single-
use cocktail (ThermoFisher Scientific). Wells were cleaned by scraping and the cell lysates 
collected and centrifuged at 11.000 x g for 10 minutes at 4°C to pellet insoluble cell debris. 
From the cleared lysates 10% was used as input control which is prepared for SDS-PAGE 
by adding an equal volume of 2 x Laemmli sample buffer with 0.1 M DTT (Laemmli/
DTT). FLAG-tagged β-catenin is immunoprecipitated from the remainder of the lysates 
using prewashed ANTI-FLAG M2 Affinity Gel (Sigma-Aldrich, cat. No. A2220) for 2 h 
at 4°C. FLAG-beads were washed with lysis buffer for three times and resuspended in 
Laemmli/DTT.
Input and IP samples were heated to 95°C for 5 minutes and subjected to SDS-PAGE 
and electroblotted onto polyvinylidene difluoride (PVDF) membranes. Membranes were 
blocked in TBS/0.1% Tween’20 supplemented with 5% (w/v) BSA and incubated overnight 
at 4°C with rabbit monoclonal anti-DNMT1 (1:1000 DNMT1 XP®, D63A6, Cell Signaling 
Technology), mouse monoclonal anti-FLAG® M2 antibody (1:1000 Sigma-Aldrich, cat 
no. F1804) or mouse monoclonal anti-β-actin (1:10.000, Sigma-Aldrich, cat no. A5441). 
The primary antibodies were diluted in blocking buffer. HRP conjugated goat-anti-rabbit, 
goat-anti-mouse were used as secondary antibodies in TBS/0.1% Tween’20 supplemented 
with 5% (w/v) non-fat dried milk. Enhanced chemiluminescence (SuperSignal™ West Pico 
Plus Chemilumininescent Substrate, Thermo Scientific) was used to visualize the bound 
antibodies in a ChemiDoc MP Imager (Bio-Rad).
Ethical approval
This study was part of a protocol entitled “Translational research on soft tissue sarcomas” 
which was assessed by the Medical Ethics Committee of the Erasmus MC, Rotterdam, the 
Netherlands (MEC-2016-213).
Results
Clinical characteristics of the patients included in the MeD-Seq analysis
The vast majority of  DTF tumours contain mutations in exon 3 of the CTNNB1 (β-catenin) gene. 
Interestingly, the mutations are almost exclusively confined to residues T41 and S45 preventing 
the phosphorylation of these residues and consequently stabilizing CTNNB1 and activating 
Wnt/β-catenin signalling. Although having similar effects, the T41A and S45F mutated DTF 
tumours were reported to display a different clinical behaviour for which the underlying 
biological mechanism is still unclear. Epigenetic alterations may be important in this respect, 
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particularly in view of the reported interaction between CTNNB1 and DNMT1 15. Therefore, the 
genome-wide DNA methylation profiles of DTF tumours were explored, comparing CTNNB1 
S45F and T41A mutated tumours. To this end, 29 FFPE samples of primary untreated DTF 
tumours were analysed using MeD-seq. Fifteen samples harboured a CTNNB1 T41A mutation 
and 14 samples a CTNNB1 S45F mutation, both mutations that are commonly observed. The 
patients had a median age of 36 years (interquartile range 26-47 years) and females were in the 
majority (n = 19, 66%). Most tumours were located extra-abdominally (69%) and had a median 
size of 55 mm (interquartile range 34-87 mm) (Table 1).
Table 1. Clinical characteristics of patients and tumour samples (n = 29) included in this study
Total group
 n = 29
T41A n (%) S45F n (%)
Sex Female 19 (66%) 11 (73%) 8 (57%)
Male 10 (34%) 4 (27%) 6 (43%)
Tumour location Extra-abdominal 20 (69%) 7 (47%) 13 (93%)
Abdominal wall 6 (21%) 5 (33%) 1 (7%)
Intra-abdominal 3 (10%) 3 (20%) 0
Median age at diagnosis in years (IQR) 36 (26-47) 38 (33-48) 31 (20-45)
Median size in mm (IQR) a,b 55 (34-87) 53 (29-59) 68 (50-103)
abased on initial imaging; b n = 3 missing values; IQR, interquartile range
Differentially methylated regions between S45F and T41A DTF samples identi-
fied by MeD-seq
A genome-wide MeD-seq analysis was carried out using DNA isolated from 29 FFPE DTF 
samples. A total of 365 differentially methylated regions (DMRs) were found to be significantly 
different between S45F, and T41A DTF tumours. After excluding DMRs located on the X- 
and Y-chromosomes, a group of 354 DMRs remained. Of these 354 DMRs, 97 (27%) DMRs 
were hypomethylated in S45F (versus T41A), and 257 (83%) were hypermethylated in S45F 
(vs. T41A). Supplemental Materials 1 provides an overview of all 354 DMRs. A supervised 
hierarchical clustering of the DTF samples based on all detected DMRs, did not reveal clearly 
separated groups based on CTNNB1 mutational status (Figure 1). Likewise, no distinct cluster 
patterns were observed on basis of sex (Figure 1), tumour site (Supplemental Figure 1) and 
tumour size (Supplemental Figure 2). As a meta-analysis by our group revealed tumour size 
to be an independent predictor for recurrence 7 a supervised cluster analysis was performed 
based on DMRs between small DTF (n = 6, ≤ 34 mm) and large tumours (n = 6, > 87 mm). 
Interestingly, the small and large DTF tumours were almost completely distinguished only 
one small tumour grouped together with the large tumours (Supplemental Figure 3).
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Figure 1. Supervised hierarchical clustering based on differentially methylated regions (DMRs) between 
S45F and T41A mutated DTF tumours together with clinicopathological features: sex, tumour site, age, and 
tumour size. The heat map depicts the methylation in 354 DMRs, including all fold changes and excluding 
DMRs present on sex chromosomal regions, in S45F and T41A DTF samples. The cluster tree on top indicates 
distinct subgroups of DTF samples. Grouping, however, is not based on CTNNB1 mutation type (T41A or 
S45F) nor on clinicopathological parameters such as sex, tumour site, age, or tumour size.
Within both CTNNB1 mutation groups, there appeared to be a considerable heterogeneity 
in DNA methylation between tumour samples. When considering all 354 DMRs it was 
noticed that the vast majority displayed relatively small fold changes (<1.5) between the 
different DTF mutant groups. Only ten DMRs had fold changes ≥1.5. Table 2 lists the 
chromosomal position of the DMRs with a fold change ≥1.5 including the start and end 
positions, the observed fold change, the overlapping genes associated with the DMR, the 
location of the DMR with respect to the gene body and the methylation status in the S45F 
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Figure 2. Read counts for DMRs in individual S45F and T41A DTF. Plots showing the normalized read 
counts for selected DMRs (fold-change ≥1.5) associated with NLRP4, FOXK2, PERM1, CCDC6, NOC4L 
and DUX4L6. The whiskers represent the minimum and maximum read counts. Dots (S45F) or squares 
(T41A) indicate individual data points, the horizontal line designates the median level. A Mann Whitney U 
test was used to assess statistical significance.
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and T41A samples. Most genes, with the exception of DUX4L6, present with DMRs in 
the gene body. The DMRs and their location were visualized by loading the MeD-seq 
data into the Integrative Genomics Viewer (IGV) (Supplemental Figure 4A-E). The IGV 
graphs present the methylation patterns in a quantitative way in each DTF sample that was 
analysed. It was observed that the methylation profiles within a CTNNB1 mutant class may 
differ considerable, with samples displaying almost a complete absence of methylation 
whereas other samples appear (partly) methylated. Figure 2 depicts the actual normalized 
read counts of the DMRs and associated genes detected between S45F and T41A DTF 
samples. A more stringent statistical analysis of the raw data revealed that only the DMR 
associated with CCDC6 remained statistically significant (p = 0.04).













19 2.68 55850028-55850071 + - NLRP4 postTSS1KB-TES
17_GL383563v3_alt 2.27 130411-131133 - + -
17 1.85 82585430-82587461 - + FOXK2 postTSS1KB-TES
16 1.79 85410202-85410284 + - -
1 1.77 977947-977974 - + PERM1 postTSS1KB-TES
21 42956670-42958541 + - -
10 1.70 59882022-59883084 - + CCDC6 postTSS1KB-TES
10 1.69 42089321-42090999 + - -
12 1.65 132149685-132150607 + - NOC4L postTSS1KB-TES
4 1.50 190075267-133745860 + - DUX4L6 TSS
DMRs located on sex (X- and Y) chromosomes were excluded; TSS, Transcription Start Site; TES, Transcription 
End Site; postTSS1KB-TES, indicates the region starting at 1 Kb after the TSS till the TES thus corresponding to 
the gene body without promoter region. - hypomethylation, + hypermethylation
Effects of DMRs on gene expression levels
Next, the effect of the initially detected DMRs with a fold change ≥ 1.5 on the expression 
of the associated genes was examined. DMR associated genes NLRP4, FOXK2, PERM1, 
CCDC6, NOC4L and DUX4L6 were identified in a publicly available mRNA expression 
dataset of 34 S45F and 45 T41A DTF samples. It was noted that the same genes are detected 
by multiple probes on the Affymetrix platform used (Table 3). A Mann-Whitney U test 
indicated that no significant expression differences were observed between S45F and T41A 
mutant DTF for most genes with the exception of CCDC6 (p = 0.034, 1 out of 2 probes) and 
FOXK2 (p = 0.004, 1 out of 4 probes) (Table 3). It was noted that the expression of CCDC6 
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and FOXK2 in T41A samples was downregulated suggesting that the hypermethylation 
observed in T41A samples reduces mRNA expression.
Table 3. Expression levels of genes identified by DMRs between S45F and T41A DTF samples. Transcript 
levels are derived from publicly available Affymetrix based mRNA expression data (GSE58697) of 45 T41A 
and 34 S45F tumours.. Some genes are represented by multiple probe sets. Mann-Whitney U test was used to 
assess statistical significance in transcript levels of the respective genes between S45F and T41A tumours.
Gene name Probe number Median (IQR) p-value
CCDC6 204716_at 203 (126-239) 0.034
225010_at 617 (554.6-703.4) 0.579
FOXK2 242937_at 17 (15-21) 0.004
242938_s_at 34 (32-39) 0.384
226224_at 149 (141-158) 0.373
203064_s_at 112 (101-127) 0.533
DUX4L6 216472_x_at 11 (8-14) 0.362
208201_at 15 (11-20) 0.510
NLRP4 242334_at 2.7 (1.2-4.2) 0.149
NOC4L 218860 50 (44-55) 0.628
PERM1 224501_at 1 (1-1) 0.415
CTNNB1 (β-catenin) – DNMT1 protein interaction.
To verify whether the observed DMRs between S45F and T41A DTF samples could be the 
result of a differential regulatory interaction between β-catenin mutants and DNMT1, an 
immunoprecipitation experiment was performed. FLAG-tagged wild-type β-catenin and 
different β-catenin mutants (T41A, S45P, exon 3 deletion mutant, K335I) were transiently 
expressed in HEK293T and HCT116 cells. Western blot analysis of total lysates of the 
transfectants demonstrated expression of DNMT1 as well as the FLAG-tagged version of 
β-catenin and β-actin as loading control (Figure 3, Supplemental Figure 5). When FLAG-
tagged β-catenin was immunoprecipitated no DNMT1 was co-precipitated. We tentatively 
conclude that we cannot verify a protein-protein interaction between β-catenin wild-type 
or mutants and DNMT1.
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Figure 3. DNMT1 is not co-precipitated with wild-type or mutant CTNNB1 (β-catenin). HEK293T cells 
were transfected with plasmids driving the expression of FLAG-tagged wild-type β-catenin (WT) or FLAG-
tagged mutant versions of β-catenin (T41A; S45P; Exon 3 deletion mutant; K335I). As a control cells were 
transfected with the empty vector. At 48 h post-transfection cell lysates were prepared from which the FLAG-
tagged β-catenin variants were immunoprecipitated. Western Blot analysis was used to examine DNMT1, 
β-catenin and β-actin protein expression in the total lysates and immunoprecipitates.
Discussion
DNA methylation patterns are a good representation and reflection of molecular changes in 
the early stages of human cancer. The correlation between cancer and aberrant methylation 
patterns are described by various studies 22, 23, 26. DNA hypomethylation of gene promoter 
regions is usually associated with tumour formation, activation of oncogenes and chromosomal 
instability 33, 34. In addition, DNA hypermethylation of gene promoter regions may alter gene 
expression and can cause tumour suppressor silencing and promote cancer progression 
35. Also, gene body methylation is a widespread phenomenon, however, its functional 
consequences are less clear 36, 37. There is experimental evidence that gene body methylation 
is also associated with transcriptional activity and can affect gene expression 3, 38. Aberrant 
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methylation has been the subject of various sarcoma-related publications. A study by Röhrich 
et al. based the classification of peripheral nerve sheath tumours (benign versus malignant) on 
methylation patterns 39. Tombolan et al. was able to distinguish metastatic and non-metastatic 
rhabdomyosarcomas based on their methylation patterns 18.
In this study, we hypothesized a role for aberrant methylation patterns based on the 
differences in clinical behaviour between the different CTNNB1 mutations found in 
DTF. To our knowledge, this is the first study that explored DNA methylation patterns 
in DTF. Whole genome DNA methylation was examined using MeD-seq. This is a novel 
and powerful technique to perform genome-wide DNA methylation analysis 28. Since this 
technique focusses the sequencing resources on methylated regions only, and because the 
restriction enzyme LpnPI is restricted by a short template size, the generated fragments 
are consistent in size which results in accurate identification of DMRs genome-wide 28. 
The MeD-Seq method compared very favourable to other methods such as whole-genome 
bisulfite sequencing, MeDIP and the 450K Infinium bead-chip technology 28. Furthermore, 
MeD-seq uses single base pair resolution which allows us to identify methylation on one 
specific CG site. In case of marker development, this would create the opportunity to use 
information from this single nucleotide for primer selection.
Here we focused on differences between CTNNB1 T41A and S45F mutated tumours as they 
occur frequently, are mutually exclusive and are reported to exhibit a divergent clinical 
behaviour. Overall, the detected differences in DNA methylation were few, subtle and 
unable to discriminate between S45F and T41A tumours in a cluster analysis. Only some 
DMRs were found to be differentially methylated with a fold change ≥ 1.5, and only a 
single DMR, related to the CCDC6 gene had a fold change of ≥ 2. Most of the DMRs (fold 
change ≥ 1.5) appeared to be situated within gene bodies. The relatively small fold changes 
in DMRs observed, the intertumoural heterogeneity and the low amount of statistically 
significant DMRs identified in this study, suggests that there is no distinct difference in 
DNA methylation patterns between S45F and T41A DTF tumours. In the current study the 
effects of differential methylation on gene expression were assessed using an independent 
Affymetrix mRNA expression dataset which only revealed significant expression differences 
between S45F and T41A tumours for CCDC6 (p = 0.034) and FOXK2 (p = 0.004) but not 
for all probes capable of detecting these genes. To explain these observations, one may 
speculate that gene body methylation affects differential splicing yielding splice products 
that hybridize only with some capture probe. To obtain biological insight why different 
β-catenin mutants would affect DNA methylation differently, the interaction between 
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β-catenin and DNMT1, as reported by Song et al., was investigated 15. Despite the use of 
similar immunoprecipitation conditions and an identical cell line (HCT116) DNMT1 was 
not pulled-down with wild-type β-catenin or any of the β-catenin mutants tested.
No distinct cluster patterns were seen based on tumour size when a hierarchical clustering 
was performed using all 354 DMRs between S45F and T41A samples. Interestingly, when 
only the smallest and largest tumours were considered, DNA methylation patterns almost 
perfectly discriminated the two groups. Although tumour size depends on the measuring 
methods (radiological imaging or the dimensions of freshly resected surgical specimen) 
and can therefore be fairly subjective, our data suggest larger tumours display a different 
methylation pattern compared to smaller tumours. The phenomena that methylation patterns 
differ between tumour sizes has previously been described by Nishida et al., and may 
suggest that stepwise progression of methylation alterations may take place during the 
development of tumours 40.
This study has several limitations. The first limitation is the relatively small DTF sample 
size. DTF samples are challenging to obtain due to the rarity of these tumours and the 
current tendency to use an active surveillance approach instead of surgical resection 41. 
Furthermore, obtaining paired control tissue such as fascia from which desmoids are 
believed to arise, is challenging as it would require an additional resection of adjacent 
fascia next to the tumour site. Due to the retrospective nature of the current study, we were 
not able to obtain paired control tissue samples. Furthermore, we opted not to include WT 
DTF samples as control as they comprise a heterogeneous group which often contains rare 
CTNNB1 mutations or alterations in other genes 5.
Future research should focus on the integrated genomic and molecular characterization of 
DTF samples and include appropriate control tissues to further delineate and understand 
the biological mechanisms and epigenetic changes involved in the pathogenesis of DTF. 
The functional significance of the observed differential gene body methylation of CCDC6 
in T41A and S45F DTF should be further validated and investigated. Exploration of the 
dynamic changes in DNA methylation patterns and their consequences for gene expression 
from tumour onset to tumour progression and/or regression is of interest too and may 
provide an explanation for the different clinical behaviours of DTF tumours.
4
146460_Timbergen,Milea_BNW-def.indd   105 25-11-2020   08:20
106
Data Availability Statement
The datasets generated for this study can be found in the Sequence Read Archive (SRA) 
data repository under accession number PRJNA604749.
Conflict of Interest
The authors declare no conflict of interest or financial interests except for R.B., J.B., W.V.I. 
and J.G., who report being shareholder in Methylomics B.V., a commercial company that 
applies MeD-seq to develop methylation markers for cancer staging.
Funding
This research received no external funding.
Acknowledgments
We thank G.J.L.H. van Leenders (Department of Pathology, Erasmus MC) for his assistance 
with the selection and pathological assessment of the DTF tumour tissues.
4
146460_Timbergen,Milea_BNW-def.indd   106 25-11-2020   08:20
107
References
1. Fletcher CDM, Bridge JA, PCW H, F M. World Health Organization, International Agency for Research 
on Cancer. WHO classification of tumours of soft tissue and bone. Press: Lyon: IARC; 2013 2013.
2. Wu C, Amini-Nik S, Nadesan P, Stanford WL, Alman BA. Aggressive fibromatosis (desmoid tumor) 
is derived from mesenchymal progenitor cells. Cancer Res. 2010;70(19):7690-7698.
3. Arechederra M, Daian F, Yim A, Bazai SK, Richelme S, Dono R, et al. Hypermethylation of gene body 
CpG islands predicts high dosage of functional oncogenes in liver cancer. Nat Commun. 2018;9(1):3164.
4. Ng TL, Gown AM, Barry TS, Cheang MCU, Chan AKW, Turbin DA, et al. Nuclear beta-catenin in 
mesenchymal tumors. Mod Pathol. 2005;18(1):68-74.
5. Crago AM, Chmielecki J, Rosenberg M, O’Connor R, Byrne C, Wilder FG, et al. Near universal 
detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by 
whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015;54(10):606-615.
6. Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, et al. Specific mutations 
in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am 
J Pathol. 2008;173(5):1518-1527.
7. Timbergen MJM, Colombo C, Renckens M, Kim HS, Rosmalen JV, Salas S, et al. The Prognostic Role 
of beta-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only: A Meta-analysis 
of Individual Patient Data. Ann Surg. 2019. Online ahead of print.
8. Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le Cesne A, et al. CTNNB1 45F mutation 
is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an 
independent, multicenter validation study. Cancer. 2013;119(20):3696-3702.
9. Braggio D, Koller D, Jin F, Siva N, Zewdu A, Lopez G, et al. Autophagy inhibition overcomes sorafenib 
resistance in S45F-mutated desmoid tumors. Cancer. 2019.
10. Braggio D, Zewdu A, Londhe P, Yu P, Lopez G, Batte K, et al. beta-catenin S45F mutation results in 
apoptotic resistance. Oncogene. 2020;39(34):5589-5600.
11. Hamada S, Urakawa H, Kozawa E, Arai E, Ikuta K, Sakai T, et al. Characteristics of cultured desmoid 
cells with different CTNNB1 mutation status. Cancer Med. 2016;5(2):352-360.
12. Mercier KA, Al-Jazrawe M, Poon R, Acuff Z, Alman B. A Metabolomics Pilot Study on Desmoid 
Tumors and Novel Drug Candidates. Sci Rep. 2018;8(1):584.
13. Mosimann C, Hausmann G, Basler K. Beta-catenin hits chromatin: regulation of Wnt target gene 
activation. Nat Rev Mol Cell Biol. 2009;10(4):276-286.
14. Yakulov T, Raggioli A, Franz H, Kemler R. Wnt3a-dependent and -independent protein interaction 
networks of chromatin-bound beta-catenin in mouse embryonic stem cells. Mol Cell Proteomics. 
2013;12(7):1980-1994.
15. Song J, Du Z, Ravasz M, Dong B, Wang Z, Ewing RM. A Protein Interaction between beta-Catenin 
and Dnmt1 Regulates Wnt Signaling and DNA Methylation in Colorectal Cancer Cells. Mol Cancer 
Res. 2015;13(6):969-981.
16. Liu P, Shen JK, Xu J, Trahan CA, Hornicek FJ, Duan Z. Aberrant DNA methylations in chondrosarcoma. 
Epigenomics. 2016;8(11):1519-1525.
17. Sheffield NC, Pierron G, Klughammer J, Datlinger P, Schonegger A, Schuster M, et al. DNA methylation 
heterogeneity defines a disease spectrum in Ewing sarcoma. Nat Med. 2017;23(3):386-395.
18. Tombolan L, Poli E, Martini P, Zin A, Millino C, Pacchioni B, et al. Global DNA methylation profiling 
uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic 
rhabdomyosarcoma. BMC Cancer. 2016;16(1):886.
19. Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Mori Y, et al. A multicenter, double-blinded validation 
study of methylation biomarkers for progression prediction in Barrett’s esophagus. Cancer Res. 
2009;69(10):4112-4115.
4
146460_Timbergen,Milea_BNW-def.indd   107 25-11-2020   08:20
108
20. Martínez-Galán J, Torres B, del Moral R, Muñoz-Gámez JA, Martín-Oliva D, Villalobos M, et al. 
Quantitative detection of methylated ESR1 and 14-3-3-σ gene promoters in serum as candidate 
biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy Cancer Biology and 
Therapy. 2008;7(6):958-965.
21. Li M, Gao F, Xia Y, Tang Y, Zhao W, Jin C, et al. Filtrating colorectal cancer associated genes by 
integrated analyses of global DNA methylation and hydroxymethylation in cancer and normal tissue. 
Scientific Reports. 2016;6:31826.
22. Skvortsova K, Stirzaker C, Taberlay P. The DNA methylation landscape in cancer. Essays Biochem. 
2019;63(6):797-811.
23. Klutstein M, Nejman D, Greenfield R, Cedar H. DNA Methylation in Cancer and Aging. Cancer Res. 
2016;76(12):3446-3450.
24. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based 
classification of central nervous system tumours. Nature. 2018;555(7697):469-474.
25. Locke WJ, Guanzon D, Ma C, Liew YJ, Duesing KR, Fung KYC, et al. DNA Methylation Cancer 
Biomarkers: Translation to the Clinic. Front Genet. 2019;10:1150.
26. Pan Y, Liu G, Zhou F, Su B, Li Y. DNA methylation profiles in cancer diagnosis and therapeutics. Clin 
Exp Med. 2018;18(1):1-14.
27. Dubbink HJ, Hollink I, Avenca Valente C, Wang W, Liu P, Doukas M, et al. A novel tissue-based 
ß-catenin gene and immunohistochemical analysis to exclude familial adenomatous polyposis among 
children with hepatoblastoma tumors. Pediatr Blood Cancer. 2018;65(6):e26991.
28. Boers R, Boers J, de Hoon B, Kockx C, Ozgur Z, Molijn A, et al. Genome-wide DNA methylation 
profiling using the methylation-dependent restriction enzyme LpnPI. Genome Res. 2018;28(1):88-99.
29. Chaves I, van der Eerden B, Boers R, Boers J, Streng AA, Ridwan Y, et al. Gestational jet lag predisposes 
to later-life skeletal and cardiac disease. Chronobiology International. 2019;36(5):657-671.
30. Robinson JT, Thorvaldsdóttir H, Wenger AM, Zehir A, Mesirov JP. Variant Review with the Integrative 
Genomics Viewer. Cancer Research. 2017;77(21):e31-e34.
31. Salas S, Brulard C, Terrier P, Ranchere-Vince D, Neuville A, Guillou L, et al. Gene Expression Profiling 
of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival. Clin Cancer 
Res. 2015;21(18):4194-4200.
32. Liu P, Liang B, Liu M, Lebbink JHG, Li S, Qian M, et al. Oncogenic Mutations in Armadillo Repeats 
5 and 6 of beta-Catenin Reduce Binding to APC, Increasing Signaling and Transcription of Target 
Genes. Gastroenterology. 2020;158(4):1029-1043 e1010.
33. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, et al. Induction of tumors in 
mice by genomic hypomethylation. Science. 2003;300(5618):489-492.
34. Kawano H, Saeki H, Kitao H, Tsuda Y, Otsu H, Ando K, et al. Chromosomal Instability Associated 
with Global DNA Hypomethylation is Associated with the Initiation and Progression of Esophageal 
Squamous Cell Carcinoma. Annals of Surgical Oncology. 2014;21(4):696-702.
35. Man CH, Fung TK, Wan H, Cher CY, Fan A, Ng N, et al. Suppression of SOX7 by DNA methylation 
and its tumor suppressor function in acute myeloid leukemia. Blood. 2015;125(25):3928-3936.
36. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev 
Genet. 2008;9(6):465-476.
37. Zilberman D. An evolutionary case for functional gene body methylation in plants and animals. Genome 
Biol. 2017;18(1):87.
38. Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. Gene body methylation can alter gene 
expression and is a therapeutic target in cancer. Cancer Cell. 2014;26(4):577-590.
39. Rohrich M, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A, et al. Methylation-based classification 
of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol. 2016;131(6):877-887.
4
146460_Timbergen,Milea_BNW-def.indd   108 25-11-2020   08:20
109
40. Nishida N, Nishimura T, Nakai T, Chishina H, Arizumi T, Takita M, et al. Genome-wide profiling 
of DNA methylation and tumor progression in human hepatocellular carcinoma. Dig Dis. 
2014;32(6):658-663.
41. Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, et al. An update on the management 
of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients 
EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft 
Tissue and Bone Sarcoma Group (STBSG). Ann Oncol. 2017;28(10):2399-2408.
4
146460_Timbergen,Milea_BNW-def.indd   109 25-11-2020   08:20
110
Supplemental Figure 1. Supervised hierarchical clustering based on differentially methylated regions 
(DMRs) between DTF tumour locations. DTF samples were obtained from tumours at extra-abdominal 
sites, intra-abdominal sites or the abdominal wall.
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Supplemental Figure 2. Supervised hierarchical clustering based on differentially methylated regions 
(DMRs) between DTF tumour sizes. Tumour sizes were based on initial imaging data obtained at diagnosis. 
The following size classes were analysed ≤ 34 mm; >35mm ≤ 55 mm; ≥56 mm ≤ 87 mm; > 87 mm.
Supplemental Figure 3. Supervised hierarchical clustering based on differentially methylated regions 
(DMRs) between DTF tumour size extremes. Tumour sizes were based on initial imaging data obtained at 
diagnosis. The smallest tumours ≤ 34 mm were compared to the largest tumours > 87 mm.
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Supplemental Figure 5. DNMT1 is not co-precipitated with wild-type or mutant CTNNB1 (β-catenin). 
HCT116 cells were transfected with plasmids driving the expression of FLAG-tagged wild-type β-catenin 
(WT) or FLAG-tagged mutant versions of β-catenin (T41A; S45P; Exon 3 deletion mutant; K335I). As a 
control cells were transfected with the empty vector. At 48 h post-transfection cell lysates were prepared 
from which the FLAG-tagged β-catenin variants were immunoprecipitated. Western Blot analysis was used 
to examine DNMT1, β-catenin and β-actin protein expression in the total lysates and immunoprecipitates.
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Diagnosing desmoid-type fibromatosis (DTF) requires an invasive tissue biopsy with 
β-catenin staining and CTNNB1 mutational analysis, and is challenging due to its rarity. 
The aim of this study was to evaluate radiomics for distinguishing DTF from soft tissue 
sarcomas (STS), and in DTF, for predicting the CTNNB1 mutation types.
Materials and methods
Patients with histologically confirmed extremity STS (non-DTF) or DTF and at least a 
pretreatment T1-weighted (T1w) MRI scan were retrospectively included. Tumours were 
semi-automatically annotated on the T1w scans, from which 411 features were extracted. 
Prediction models were created using a combination of various machine learning 
approaches. Evaluation was performed through a 100x random-split cross-validation. The 
model for DTF versus non-DTF was compared to classification by two radiologists on a 
location matched subset.
Results
The data included 203 patients (72 DTF, 131 STS). The T1w radiomics model showed a 
mean AUC of 0.79 on the full dataset. Addition of T2w or T1w post-contrast scans did not 
improve the performance. On the location matched cohort, the T1w model had a mean AUC 
of 0.88 while the radiologists had an AUC of 0.80 and 0.88, respectively. For the prediction 
of the CTNNB1 mutation types (S45F, T41A and wild-type), the T1w model showed an AUC 
of 0.61, 0.56, and 0.74.
Conclusions
Our radiomics model was able to distinguish DTF from STS with high accuracy similar to 
two radiologists, but was not able to predict the CTNNB1 mutation status.
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Introduction
Sporadic desmoid-type fibromatosis (DTF) is a rare borderline, soft tissue tumour arising in 
musculoaponeurotic structures 1. Worldwide epidemiological data is lacking, but population 
studies in Scandinavia and the Netherlands show a low incidence of 2.4–5.4 cases per 
million per year 2, 3. Early recognition and diagnosis of DTF is therefore challenging.
On MRI, DTF can display a wide variety of enhancement patterns 4. DTF has imaging 
characteristics that are often associated with soft tissue sarcomas (STS), such as crossing 
fascial boundaries, an invasive growth pattern, little central necrosis, mildly hyperintense 
on T1-weighted (T1w) MRI, and hyperintense and heterogeneous on T2-weighted (T2w) 
MRI with hypointense bands 5. Hence, the distinction between DTF and STS, i.e., non-DTF, 
can be difficult. An invasive tissue biopsy, with additional immunohistochemical staining 
for β-catenin and mutation analysis of the CTNNB1 (β-catenin) gene, is therefore currently 
required to differentiate DTF from non-DTF 6.
As DTF is a borderline tumour who is unable to metastasize, and requires a different 
treatment regimen than malignant STS, this distinction is highly relevant. Differentiation 
between DTF and STS based on imaging would be beneficial because of the rarity of DTF, 
making clinical and pathological recognition challenging. Furthermore, DTF exhibits an 
aggressive growth pattern and growth might be stimulated after (surgical) trauma, including 
biopsies 7. Avoiding (multiple) harmful biopsies which potentially cause tumour growth is 
therefore of great importance.
Several studies have addressed the prognostic role of the CTNNB1 mutation in DTF 8-10, as 
serine 45 (S45F) tumours appear to have a higher risk of recurrence after surgery compared 
to threonine 41 (T41A) and wild-type (WT) (i.e. no CTNNB1 mutation 11) tumours 12. 
Obtaining the CTNNB1 mutation status is for diagnostic purposes and to guide the clinical 
work-up, but, for now, the CTNNB1 mutation status has no therapeutic consequences 13. The 
majority of DTF harbours a CTNNB1 mutation at either T41A or S45F 8. Assessment of the 
mutation status is currently done by Sanger Sequencing or Next Generation Sequencing, 
which are time consuming and expensive.
In radiomics, large amounts of quantitative imaging features are related to clinical outcome 
14. Radiomics may serve as a non-invasive surrogate to contribute to diagnosis, prognosis 
and treatment planning 15, 16. Based on the results of previous studies in cancer 17, we 
hypothesized that radiomics may also be useful in DTF.
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This study investigated whether a radiomics model based on MRI is able to 1) distinguish 
DTF from non-DTF in the extremities, and 2) to predict the CTNNB1 mutation status of 
DTF. Additionally, in the DTF versus non-DTF distinction, we evaluated which of the 
included MRI sequences has the highest predictive value.
Material and methods
Data collection
Approval by the Erasmus Medical Center (MC) institutional review board (MEC-2016-339) 
was obtained. Patients diagnosed or referred to the Erasmus MC between 1990-2018 with a 
histologically proven primary or recurrent DTF were included. This resulted in a multicentre 
imaging dataset as patients referred to our sarcoma expert institute often received imaging at 
their referring hospital. The most frequently used imaging modality prior to treatment was 
T1w-MRI, and its availability was used as an inclusion criterion 18. When available, other 
sequences such as T2w, T1w post-contrast, dynamical contrast enhanced (DCE), proton 
density (PD) and diffusion weighted imaging (DWI) MRI were collected.
For the differential diagnosis (DTF versus non-DTF), histologically confirmed malignant 
extremity STS were included. Benign STS were excluded, because this distinction is 
clinically less relevant. Non-extremity STS were excluded because of the infrequent use 
of MRI. Although DTF tumours commonly occur in the abdominal wall, their differential 
diagnosis is broad and includes pseudo-tumours such as myositis, nodular fasciitis and 
hematomas, and tumours such as lipomas, STS, endometriosis, carcinomas, lymphomas 
and metastasis 19. Hence, we decided to focus on the distinction between DTF and STS, 
and included patients with a histologically proven primary fibromyxosarcoma, myxoid 
liposarcoma or leiomyosarcoma of the extremities. Similar to the DTF, patients with at least 
a pre-treatment T1w-MRI were retrospectively included.
Sex, age at diagnosis, and tumour site were collected. For the DTF, in case of a missing 
CTNNB1 mutation status, Sanger Sequencing was performed after review of formalin-fixed 
paraffin-embedded tumour sections by a pathologist. Cases with a known CTNNB1 mutation 
did not undergo additional review by a pathologist. Poor scan quality (e.g., artefacts), poor 
DTF DNA quality with failure of sequencing, and CTNNB1 mutation other than S45F, T41A 
or WT led to exclusion.
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Radiomics feature extraction
The tumours were all manually segmented once on the T1w-MRI by one of two clinicians 
under supervision of a musculoskeletal radiologist (4 years of experience). A subset of 
30 DTF tumours was segmented by both clinicians, in which intra-observer variability 
was evaluated through the pairwise Dice Similarity Coefficient (DSC), with DSC > 0.70 
indicating good agreement 20. To transfer the segmentations to the other sequences, all 
sequences were automatically aligned to the T1w-MRI using image registration with the 
Elastix software 21. For each lesion, per MRI sequence, 411 features quantifying intensity, 
shape and texture were extracted. Details can be found in Supplemental Materials 1 and 
Supplemental Table 1.
Decision model creation
To create a decision model from the features, the WORC toolbox was used, see Figure 1 
22-24. In WORC, the decision model creation consists of several steps, e.g., feature selection, 
resampling, and machine learning. WORC performs an automated search amongst a 
variety of algorithms for each step and determines which combination of algorithms 
maximizes the prediction performance on the training set. More details can be found in 
Supplemental Materials 2.
Evaluation
Evaluation of all models was done through a 100x random-split cross-validation. In each 
iteration, the data was randomly split in 80% for training and 20% for testing in a stratified 
manner, to make sure the distribution of the classes in all sets was similar to the original 
(Supplemental Figure 1). Within the training set, model optimization was performed using 
an internal cross-validation (5x). Hence, all optimization was done on the training set to 
eliminate any risk of overfitting on the test set.
For the differential diagnosis cohort, a binary classification model was created using a 
variety of machine learning models. For the DTF cohort (predicting the CTNNB1 mutation), 
a multiclass classification model was created using random forests.
5
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Performance was evaluated using the Area Under the Curve (AUC) of the Receiver 
Operating Characteristic (ROC) curve, balanced classification accuracy (BCA), sensitivity, 
specificity, negative predictive value (NPV), and positive predictive value (PPV). For the 
multiclass models, we reported the multiclass AUC 25 and overall BCA 26. The positive 
classes included: DTF in the differential diagnosis, and the presence of the mutation in 
the mutation analysis. The 95% confidence intervals were constructed using the corrected 
resampled t-test, thereby taking into account that the samples in the cross-validation splits 
are not statistically independent 27. Both the mean and the confidence intervals are reported. 
ROC confidence bands were constructed using fixed-width bands 28.
To assess the predictive value of the various features, models were trained based on: 1) 
volume; 2) age and sex; 3) T1w-MRI imaging; 4) T1w-MRI imaging, age and sex. Model 
1 was created to verify that the imaging models were not solely based on volume. Model 
2 was created to evaluate potential age and gender biases. In model 4, the imaging and 
clinical characteristics are combined by using both the imaging features and age and sex 
as features for a total of 413 features. This allows WORC to combine the imaging and 
clinical characteristics in the most optimal way. Additionally, a model was made for each 
combination of T1w-MRI and one of the other included MRI sequences (e.g., based on T1w-
MRI and T2w-MRI) to evaluate the added value of these other sequences. When a sequence 
was missing for a patient, feature imputation was used to estimate the missing values.
The code for the feature extraction, model creation and evaluation has been published 
open-source 29.
Model insight
To explore the predictive value of individual features, the Mann-Whitney U univariate 
statistical test was used. P-values were corrected for multiple testing using the Bonferroni 
correction, and were considered statistically significant at a p-value < 0.05. Feature 
robustness to variations in the segmentations was assessed on the subset of 30 DTF 
segmented by two observers using the intra-class correlation coefficient (ICC), were an 
ICC > 0.75 indicated good reliability 30. To evaluate model reliability, a separate model was 
trained using only these features with a good reliability. To gain insight into the models, the 
patients were ranked based on the consistency of the model predictions. Typical examples 
for each class consisted of the patients that were correctly classified in all cross-validation 
iterations; atypical vice versa.
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Classification by radiologists
To compare the models with clinical practice, the tumours were classified by two 
musculoskeletal radiologists (5 and 4 years of experience), which had access to all available 
MRI sequences, age, and sex. They were specifically instructed to distinguish between STS 
and DTF. Classification was made on a ten-point scale to indicate the radiologists’ certainty. 
As only extremity STS were selected for the non-DTF group, a location-matched database 
was used. This included all extremity DTF and the same number of non-DTF. Agreement 
between the radiologists was evaluated using Cohen’s kappa. The radiomics models were 
evaluated as well in this cohort. In each cross-validation iteration, these models were trained 
on 80% of the full dataset, but tested only on patients from the location-matched cohort in 
the other 20% of the dataset. The DeLong test was used to compare the AUCs 31.
Results
Study selection and population
The dataset included 203 patients; see Table 1 for the clinical characteristics. The differential 
diagnosis cohort consisted of 64 fibromyxosarcomas, 31 leiomyosarcomas, 36 myxoid 
liposarcomas, and 72 DTFs (65 primary, 7 recurrent), of which 61 were suitable for the 
mutation analysis.
The dataset originated from 68 scanners, resulting in a large heterogeneity in the acquisition 
protocols, see Table 2. From the 72 patients in the DTF cohort, there were 30 T1w post-
contrast (42%), 49 T1w post-contrast FatSat (68%), 34 T2w (47%), 33 T2w FatSat (46%), 3 
proton density (PD) (4%), 18 DCE (25%) and 3 DWI (4%) MRI scans. Due to the limited 
availability of the PD, DCE, and DWI sequences, besides the T1w-MRI, only the T1w post-
contrast and T2w (with/without FatSat) sequences were analysed.
On the subset of 30 DTF that was segmented by both observers, the mean DSC was 
0.77 (standard deviation of 0.20), indicating good agreement. An example of the image 
registration results is depicted in Figure 2.
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Table 1. Clinical characteristics of both cohorts.








































































Tumour size in cma 
median (IQR) 
6.3 (4.1-9.8) 7.0 (4.9-12.9) 8.3 (5.2-9.4) 12.8 (8.5-15.3) 6.3 (4.1-9.5)
Volume in cl median 
(IQR)













































DTF, desmoid-type fibromatosis; IQR, interquartile range; cm, centimetre; cl, centilitre; MRI, magnetic resonance 
imaging; FS, FatSat; PC, post-contrast. 
a maximum diameter automatically measured in three planes.
Percentages might not add up to 100% in total because of rounding.
5
146460_Timbergen,Milea_BNW-def.indd   131 25-11-2020   08:21
132









General Electrics 27 13
Toshiba 4 2
Setting (Unit) Mean Std. Min Max
Slice thickness (mm) 4.66 1.45 1.0 11.0
Repetition time (ms) 619 533 0.0 4620
Echo time (ms) 14 7 2.0 94.0
T, tesla; Std, standard deviation; mm, millimetre; ms, milliseconds
Figure 2. Segmentations on various MRI sequences before and after applying image registration in a des-
moid-type fibromatosis case. The arrows are at the same position in each image and point at two details where 
the (mis)alignment is evident. (1) Original T1-weighted (T1w) MRI; (2) Original T2w-MRI; (3) Registered 
T2w-MRI; (4) Original T1w post-contrast MRI ; (5) Registered T1w post-contrast MRI
Differential diagnosis
The performance of models 1-6 for the differential diagnosis is shown in Table 3. Model 1, based 
on volume, showed little predictive value (mean AUC of 0.69). Model 2, based on age and sex, 
performed better (mean AUC of 0.86). Model 3, based on T1w-MRI, had a mean AUC of 0.79, 
thus performing worse than age and sex, but better than volume alone. Model 4, combining the 
T1w-MRI, age, and sex, showed little improvement in terms of mean AUC (0.88) over model 2. 
Addition of a T2w-MRI, i.e. model 5, or T1 post-contrast MRI, i.e. model 6, both with or without 
FatSat, both yielded a minor overall improvement over model 3 (mean AUC of 0.84 and 0.84, 
respectively). These observations were confirmed by the ROC curves in Figure 3. The models 
using either only non-FatSat or FatSat scans, both for the T2w and T1w post-contrast MRI, faired 
similar, see Supplemental Table 2. 
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Comparison with radiologists
As described in the methods, for the comparison with radiologists, a location-matched 
cohort consisting of all extremity DTFs and an equal amount of extremity non-DTF was 
used. To this end, all 20 extremity DTFs and 20 randomly selected extremity non-DTFs were 
included in the location-matched cohort. The performance of radiomics and the radiologists 
in this cohort is shown in Table 4: model 1 and 5-6 were omitted from the results for 
brevity. The AUCs of the r0adiomics models (model 2: 0.93; model 3: 0.88; model4: 0.98) 
were generally higher than both radiologists 1 (0.80) and 2 (0.88). This is confirmed by the 
ROC curves in Figure 4. Cohen’s kappa between the two radiologists was 0.40, indicating 
intermediate observer agreement. A DeLong power analysis of the AUCs resulted in a power 
of only 0.1. Due to the limited power, the p-values of the DeLong test were omitted.
Figure 4. Receiver operating characteristic curves of the radiomics models based on age and sex (model 
2); imaging (model 3); and imaging, age and sex (model 4); and those of the radiologists (Rad1 and Rad2), 
in the location-matched cohort.
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Table 4. Performance of the two radiologists and the radiomics models in differentiating between DTF (n=20) 






T1w + Age + Sex
Rad 1 Rad 2
AUC 0.93 [0.84, >1] 0.87 [0.73, >1] 0.98 [0.92, >1] 0.80 0.88
BCA 0.85 [0.71, 1.00] 0.71 [0.56, 0.87] 0.88 [0.77, 0.99] 0.75 0.90
Sensitivity 0.79 [0.57, >1] 0.49 [0.21, 0.77] 0.78 [0.57, 1.00] 0.65 0.90
Specificity 0.90 [0.71, >1] 0.93 [0.78, >1] 0.98 [0.91, >1] 0.85 0.89
NPV 0.82 [0.61, >1] 0.65 [0.43, 0.76] 0.82 [0.64, >1] 0.71 0.89
PPV 0.91 [0.72, >1] 0.81 [0.47, >1] 0.98 [0.91, >1] 0.81 0.90
T1w: T1-weighted; AUC: area under the receiver operator characteristic curve; BCA: balanced classification 
accuracy; PPV: positive predictive value; NPV: negative predictive value
CTNNB1 mutation status stratification
Table 5 depicts the performance of the radiomics models for the CTNNB1 mutation 
stratification. Model 4, using T1w-MRI, age, and sex, had a high specificity (S45F: 0.83, 
T41A: 0.59 and WT: 0.72), but a sensitivity similar to guessing (S45F: 0.15, T41A: 0.49 
and WT: 0.56). This indicates a strong bias in the models towards the negative classes, i.e. 
not-S45F, not-T41A and not-WT. As model 4 did not perform well, models 1, 2, and 3 were 
omitted from the results, as these contain a subset of these features. Adding the T2w or T1w 
post-contrast imaging, i.e. models 5 and 6, did not improve the performance. Hence, the 
models using either only non-FatSat or FatSat scans were omitted, as these contain subsets 
of the scans from models 5 and 6.
Model insight
As the CTNNB1 mutation status stratification models did not perform well, the model 
insight analysis was only conducted for the differential diagnosis. The p-values from the 
Mann-Whitney U test between the DTF and non-DTF patients of all features are shown 
in Supplemental Table 3. In the feature importance analysis, 76 T1w-MRI features had 
significant p-values (5.4x10-8 to 4.8x10-2). These included two intensity features (entropy 
and peak), two shape features (radial distance and volume), and 72 texture features. The 
p-value of age (1x10-11) was lower than that of all imaging features. The ICC values of all 
T1w-MRI features are shown in Supplemental Table 4. Of the 411 features, 270 (66%) had 
an ICC > 0.75 and thus good reliability. Only using these features with a good reliability in 
model 3 did not alter the performance.
5




























































































































































































































































































































































































































































































































































































































































146460_Timbergen,Milea_BNW-def.indd   137 25-11-2020   08:21
138
As we are mostly interested in which imaging features define typical DTF, and not 
age and sex, the patient ranking was conducted for model 3. Of the 203 patients, 104 
tumours (24 DTFs, 80 non-DTFs) were always classified correctly by model 3, i.e. in all 
100 cross-validation iterations. Nineteen tumours (17 DTFs, 2 non-DTFs) were always 
classified incorrectly. In Figure 5, MRI slices of such typical and atypical examples of 
DTFs are shown.
Figure 5. The typical examples (A and B) are two cases always classified correctly by the T1-weighted 
(T1w) imaging model; the atypical examples (C and D) are two cases always classified incorrectly by the 
T1w imaging model.
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Discussion
This study showed that radiomics based on T1w-MRI can distinguish DTF from STS. 
Adding T2w or T1w post-contrast MRI did not substantially improve the model. The DTF 
CTNNB1 mutation status could not be predicted through radiomics. To our knowledge, this 
is the first study to evaluate the DTF differential diagnosis and mutation status through an 
automated radiomics approach.
Age and sex appeared to be strong predictors for the diagnosis of DTF, performing better 
than T1w-MRI. The combination of imaging, age and sex did not improve the model. 
This implies that age and sex are sufficient for distinguishing DTF from STS. In line 
with previous nationwide DTF cohort studies, females represented the majority of our 
cohort, with a lower median age compared to the median age of the patients from the 
non-DTF group 2, 32. The relation in our database may however be too strong, and thereby 
not representative of clinical practice. For example, above 63 years of age, our database 
included 60 non-DTF and only a single DTF. While the peak incidence of DTF is between 
20 to 40 years, DTF can affect patients of all ages with reported ranges from 2 to 90 years 
32. Simply classifying all tumours in patients above 63-years as non-DTF, regardless of 
any tumour (imaging) information, is unfeasible. Such a model cannot be applied in the 
general population, while the model purely based on T1w-MRI imaging, as it does not use 
any population-based information. Our cohort might be biased due to the focus on MRI 
and the extremity as a site, while other modalities (e.g., CT or ultrasound) may be used for 
certain tumour sites or for certain types of patients. Further research should include the 
expansion of our dataset to make especially the age distribution more representative.
To estimate the clinical value of our model, we compared the performance with the 
assessment of two radiologists. The model based on imaging performed similar to the 
radiologists. The model combining age, sex and imaging features, using the same dataset as 
the radiologist, had a higher AUC than the musculoskeletal radiologists. However this model 
may suffer from the selection bias as mentioned in the previous section. The agreement 
between the radiologists was intermediate, indicating observer dependence in the prediction. 
The radiomics model is observer independent, assuming the segmentation is reproducible 
as indicated by the high DSC and ICCs, and will always give the same prediction on the 
same image.
The DTF differential diagnosis is highly important for treatment decisions, but difficult 
on imaging due to its rarity, while using invasive biopsies brings risks such as tumour 
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growth. The use of our T1w-MRI radiomics model may therefore aid early recognition and 
diagnosis of DTF, thus shortening the diagnostic delay by enabling direct referral to an 
STS expertise centre. Since all routine MRI protocols include a T1w-MRI, our radiomics 
method is generalizable, feasible and applicable for use in daily clinical practice. After 
further model optimization, it may serve as a quick, non-invasive, and low-cost alternative 
for a biopsy, currently limited to extremities due to the used dataset.
Additionally, we investigated the predictive value of sequences other than T1w-MRI. 
The number of available sequences was however limited due to the multicentre imaging 
dataset. Although T2w-MRI is often used to correlate DTF signal intensity with prognosis 
or response to therapy 33-36, in the current study T2w-MRI added little predictive value to the 
T1w-MRI, similar to the T1w post-contrast MRI. This may however be attributed to the fact 
that these sequences were only available for a subset of the patients. Our cohort contained 
too few patients with PD, DCE, or DWI sequences to be analysed. However, there is little 
to no indication of the added value of these sequences in DTF 37-39.
The second aim of this study was to predict the DTF CTNNB1 mutation status. Our 
radiomics model was not able to stratify the CTNNB1 mutation type, which is in line with 
the absence of literature linking DTF MRI appearance to the CTNNB1 mutation.
The current study enclosed several limitations. First, due to the rarity of DTF, the DTF 
sample size was limited and possibly too small for the mutation stratification model to 
learn from. This also resulted in little statistical power for the mutation analysis, as shown 
by the large width of our confidence intervals, and for the comparison with the radiologists 
in the differential diagnosis. Besides primary tumours, the DTF cohort contained also 
recurrent tumours. As this number was low, and to our knowledge, there are no indications 
that recurrent DTF appear different on MRI than primary DTF, the expected influence is 
small. Within the DTF cohort, the WT group was relatively large and might have been 
subjected to incorrect allocation, as Sanger Sequencing is not always sensitive enough to 
detect all mutations 11. The results of the CTNBB1 mutation status stratification showed a 
strong bias towards the majority classes, which may be attributed to the class imbalance. 
Although we exploited commonly used imbalanced learning strategies such as resampling 
and ensembling. other strategies may improve the performance. Second, only extremity 
DTFs were included for comparison with STS. This was due to the limited availability 
of MRI in non-extremity soft tissue tumours. However, this is not representative for the 
entire DTF population, which also occurs frequently in the abdominal wall and trunk 3. 
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Third, the current radiomics approach requires manual annotations. While accurate, this 
process is also time consuming and subject to some observer variability as indicated by our 
DSC, and thus limits the transition to clinical practice. Automatic segmentation methods, 
for example deep learning, may help to overcome these limitations 40. Lastly, the dataset 
originated from 68 different scanners, which resulted in substantial heterogeneity in the 
acquisition protocols. The lack of standard imaging parameters can be problematic as these 
can affect the appearance of the tumour and thus the radiomics performance. However, our 
method was successfully able to create diagnostic models despite these differences. As these 
models were trained on a variety of imaging protocols, there is an increased chance that 
the reported performance can be reproduced in a routine clinical setting when using other 
MRI scanners. Using a single-scanner with dedicated tumour protocols may improve the 
model performance, but will limit the generalizability.
Future work should firstly focus on the prospective validation of our findings. Although 
we did use a multicentre imaging dataset and performed a rigorous cross-validation 
experiment strictly separating training from testing data, we did not validate our model on 
an independent, external dataset. Afterwards, the radiomics model could be used to predict 
clinical outcomes of DTF receiving active surveillance or systemic treatment.
Conclusions
Our radiomics approach is capable of distinguishing DTF from non-DTF tumours on T1w-
MRI, and can potentially aid diagnosis and shorten diagnostic delay. The performance of 
the model was similar to that of two experienced musculoskeletal radiologists. The model 
was not able to predict CTNNB1 mutation status of DTF tumours. Further optimization and 
external validation of the model is needed to incorporate radiomics in clinical practice.
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Supplemental Material 1. Radiomics feature extraction
This Supplemental material is similar to 1, but details relevant for the current study are 
highlighted.
A total of 411 radiomics features were used in this study. All features were extracted using 
the defaults for MRI scans from the Workflow for Optimal Radiomics Classification (WORC) 
toolbox 2, which internally uses the PREDICT 3 and PyRadiomics 4 feature extraction 
toolboxes. The code to extract the features for this specific study has been published open-
source 5. An overview of all features is depicted in Supplemental Table 2. For details on the 
mathematical formulation of the features, we refer the reader to Zwanenburg et al. (2020) 6. 
More details on the extracted features can be found in the documentation of the respective 
toolboxes, mainly the WORC documentation 7.
The features can be divided in several groups. Twelve histogram features were extracted 
using the histogram of all intensity values within the Regions of Interest (ROIs), i.e. the 
tumours, and included several first-order statistics such as the mean, standard deviation and 
kurtosis. To create the histogram, the images were binned using a fixed number of 50 bins. 
Seventeen shape features were extracted based only on the ROI, i.e. not using the image, 
and included shape descriptions such as the volume, compactness, roundness and circular 
variance. The orientation of the ROI was described by three features, which represent the 
three major axis angles of a 3-D ellipse fitted to the ROI. Lastly, 379 texture features were 
extracted using the Gray Level Co-occurrence Matrix (144 features), Gray Level Size 
Zone Matrix (16 features), Gray Level Run Length Matrix (16 features), Gabor filters (72 
features), Laplacian of Gaussian filters (36 features), vessel (i.e. tubular structure) filters 
(36 features) 8, local phase filters (36 features) 9, Local Binary Patterns (18 features), and 
the Neighborhood Grey Tone Difference Matrix (5 features).
Most of the texture features include parameters to be set for the extraction. Beforehand 
the values of the parameters which will result in features with the highest discriminative 
power for the classification at hand (e.g. DTF vs non-DTF) is not known. Including these 
parameters in the workflow optimization, see Supplemental Material 2, would lead to 
repeated computation of the features, resulting in a redundant decrease in computation 
time. Therefore, alternatively, these features are extracted at a range of parameters as is 
default in WORC. The hypothesis is that the features with high discriminative power will be 
selected by the feature selection methods and/or the machine learning methods as described 
in Supplemental Material 2. The parameters used are described in Supplemental Table 1.
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The dataset used in this study is highly heterogeneous in terms of acquisition protocols. 
Especially the variations in slice thickness may cause feature values to be highly dependent 
on the acquisition protocol as this varied between 1.0 mm and 11 mm,. Hence, extracting 
robust 3D features may be hampered by these variations, especially for low resolutions. To 
overcome this issue, all features were extracted per 2D axial slice and aggregated over all 
slices. Afterwards, several first-order statistics over the feature distributions were evaluated 
and used in the machine learning approach. The images were not resampled, as this would 
result in interpolation errors. Due to variations in especially the magnetic field strength, 
echo time, and repetition time, the image contrast highly varies, which would affect the 
feature values. To partially overcome this, each 3D MRI was normalized using z-scoring 
before feature extraction. These settings are also the default in WORC.
Supplemental Material 2. Adaptive workflow optimization for 
automatic decision model creation
This Supplemental Material is similar to 1, but details relevant for the current study are 
highlighted.
The Workflow for Optimal Radiomics Classification (WORC) toolbox 2 makes use of 
adaptive algorithm optimization to create the optimal performing workflow from a variety 
of methods. WORC defines a workflow as a sequential combination of algorithms and their 
respective parameters. To create a workflow, WORC includes algorithms to perform feature 
scaling, feature imputation, feature selection, oversampling, and machine learning. If used, 
as some of these steps are optional as described below, these methods are performed in the 
same order as described in this Supplemental materials. More details can be found in the 
WORC documentation 7.
Feature scaling was performed to make all features have the same scale, as otherwise the 
machine learning methods may focus only on those features with large values. This was 
done through z-scoring, i.e., subtracting the mean value followed by division by the standard 
deviation, for each individual feature. In this way, all features had a mean of zero and a 
variance of one.
In the analysis including the T2w or T1w post contrast sequences, in case of a missing 
sequence, feature imputation was used to estimate replacement values for the missing 
sequence. Strategies for imputation included 1) the mean; 2) the median; 3) the most frequent 
value; and 4) a nearest neighbour approach.
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Feature selection was performed to eliminate features which were not useful to distinguish 
between the classes, e.g., DTF vs. non-DTF. These included; 1) a variance threshold, in 
which features with a low variance (<0.01) are removed. This method was always used, as 
this serves as a feature sanity check with almost zero risk of removing relevant features; 
2) optionally, a group-wise search, in which specific groups of features (i.e. intensity, 
shape, and the subgroups of texture features as defined in Supplemental material 1) are 
selected or deleted. To this end, each feature group had an on/off variable which is randomly 
activated or deactivated, which were all included as hyperparameters in the optimization; 
3) optionally, individual feature selection through univariate testing. To this end, for each 
feature, a Mann-Whitney U test is performed to test for significant differences in distribution 
between the labels (e.g., DTF vs non-DTF). Afterwards, only features with a p-value above 
a certain threshold are selected. A Mann-Whitney U test was chosen as features may not 
be normally distributed and the samples (i.e., patients) were independent; and 4) optionally, 
principal component analysis (PCA), in which either only those linear combinations of 
features were kept which explained 95% of the variance in the features or a limited amount 
of components (between 10 – 50). These feature selection methods may be combined by 
WORC, but only in the mentioned order.
Oversampling was used to make sure the classes were balanced in the training dataset. 
These included; 1) random oversampling, which randomly repeats patients of the minority 
class; and 2) the synthetic minority oversampling technique (SMOTE) 10, which creates new 
synthetic “patients” using a combination of the features in the minority class. Randomly, 
either one of these methods or no oversampling method was used.
Lastly, machine learning methods were used to determine a decision rule to distinguish 
the classes. These included; 1) logistic regression; 2) support vector machines; 3) random 
forests; 4) naive Bayes; and 5) linear and quadratic discriminant analysis.
Most of the included methods require specific settings or parameters to be set, which may 
have a large impact on the performance. As these parameters have to be determined before 
executing the workflow, these are so-called “hyperparameters”. In WORC, all parameters 
of all mentioned methods are treated as hyperparameters, since they may all influence the 
decision model creation. WORC simultaneously estimates which combination of algorithms 
and hyperparameters performs best. A comprehensive overview of all parameters is 
provided in the WORC documentation 7.
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By default in WORC, the performance is evaluated in a 100x random-split train-test cross-
validation. In the training phase, a total of 100,000 pseudo-randomly generated workflows is 
created. These workflows are evaluated in a 5x random-split cross-validation on the training 
dataset, using 85% of the data for actual training and 15% for validation of the performance. 
All described methods were fit on the training datasets, and only tested on the validation 
datasets. The workflows are ranked from best to worst based on their mean performance on 
the validation sets using the F1-score, which is the harmonic average of precision and recall. 
Due to the large number of workflows executed, there is a chance that the best performing 
workflow is overfitting, i.e. looking at too much detail or even noise in the training dataset. 
Hence, to create a more robust model and boost performance, WORC combines the 50 best 
performing workflows into a single decision model, which is known as ensembling. These 
50 best performing workflows are re-trained using the entire training dataset, and only 
tested on the test datasets. The ensemble is created through averaging of the probabilities, 
i.e., the chance of a patient being DTF or non-DTF, of these 50 workflows.
A full experiment consists of executing 50 million workflows (100,000 pseudo-randomly 
generated workflows times a 5x train-validation cross-validation times 100x train-test 
cross-validation), which can be parallelized. The computation time of training or testing 
a single workflow is on average less than a second, depending on the size of the dataset 
both in terms of samples (i.e., patients) and features. The largest experiment in this study, 
i.e. the differential diagnoses including 203 patients with both a T1w and T2w MRI had a 
computation time of approximately 32 hours on a 32 CPU core machine. The contribution of 
the feature extraction to the computation time is negligible. The code for the model creation, 
including more details, has been published open-source as well 5.
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Supplemental Table 1. Overview of the 411 features used in this study. GLCM and GLCMMS features were 
calculated in four different directions (0, 45, 90, 135 degrees) using 16 gray levels and pixel distances of 1 
and 3. LBP features were calculated using the following three parameter combinations: 1 pixel radius and 
8 neighbours, 2 pixel radius and 12 neighbours, and 3 pixel radius and 16 neighbours. Gabor features were 
calculated using three different frequencies (0.05, 0.2, 0.5) and four different angles (0, 45, 90, 135 degrees). 
LoG features were calculated using three different widths of the Gaussian (1, 5 and 10 pixels). Vessel features 
were calculated using the full mask, the edge, and the inner region. Local phase features were calculated on 
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GLCM, gray level co-occurrence matrix; GLCMMS, GLCM multislice; NGTDM, neighbourhood gray tone 
difference matrix; GLSZM, gray level size zone matrix; GLRLM, gray level run length matrix; LBP, local binary 
patterns; LoG, Laplacian of Gaussian; std, standard deviation.
Supplemental Table 2. Performance of the radiomics models for the DTF differential diagnosis based 
on T1w and T2w non-FatSat imaging features; T1w and T2w FatSat imaging features; T1w and T1w post-
contrast non-FatSat imaging features; and T1w and T1w post-contrast FatSat imaging features. Outcomes 
are presented with the 95% confidence interval.
T1w + T2
non-FatSat
T1w + T2w 
FatSat
T1w + T1w post-
contrast non-FatSat
T1w + T1w post-
contrast FatSat
AUC 0.83 [0.76, 0.89] 0.83 [0.77, 0.89] 0.80 [0.74, 0.85] 0.82 [0.75, 0.88]
BCA 0.64 [0.58, 0.71] 0.66 [0.59, 0.72] 0.73 [0.67, 0.79] 0.72 [0.66, 0.79]
Sensitivity 0.32 [0.19, 0.44] 0.34 [0.20, 0.47] 0.60 [0.49, 0.72] 0.59 [0.48, 0.70]
Specificity 0.97 [0.92, >1] 0.97 [0.94, 1.00] 0.85 [0.79, 0.92] 0.86 [0.79, 0.94]
NPV 0.74 [0.70, 0.77] 0.74 [0.70, 0.78] 0.79 [0.74, 0.84] 0.79 [0.74, 0.83]
PPV 0.87 [0.68, >1] 0.88 [0.71, >1] 0.71 [0.60, 0.82] 0.72 [0.61, 0.84]
T1w, T1-weighted images, T2w, T2-weighted images; AUC, area under the receiver operator characteristic curve; 
BCA, balanced classification accuracy; PPV, positive predictive value; NPV, negative predictive value
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Supplemental Table 3. P-values after Bonferroni correction of features in a Mann-Whitney U test between 
desmoid type fibromatosis (DTF) and non-DTF patients. Only the features with significant p-values (p < 
0.05) are depicted. Besides the feature names, several of the labels also include the parameters used. More 
details on the features can be found in Supplementary Material 1. 
Feature label P-value Feature label P-value
tf_Gabor_0.5A1.57mean_Features_0 5,39E-08 tf_GLRLM_RunPercentage_Features_0 2,36E-05





logf_energy_sigma1_Features_0 1,64E-06 vf_Frangi_full_peak_SR(1.0, 10.0)_SS2.0_
Features_0
4,89E-05
logf_peak_sigma5_Features_0 1,69E-06 vf_Frangi_edge_peak_SR(1.0, 10.0)_SS2.0_
Features_0
4,89E-05















tf_GLSZM_LargeAreaEmphasis_Features_0 5,66E-06 tf_Gabor_0.5A1.57kurt_Features_0 6,82E-05
hf_peak_Features_0 7,41E-06 hf_entropy_Features_0 2,29E-04
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Supplemental Table 3. (continued) 
Feature label P-value Feature label P-value



























































GLCM, gray level co-occurrence matrix; GLCMMS, GLCM multislice; NGTDM, neighbourhood gray tone 
difference matrix; GLSZM, gray level size zone matrix; GLRLM, gray level run length matrix; LBP, local binary 
patterns; LoG, Laplacian of Gaussian; std, standard deviation.
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Supplemental Table 4. Intra-class correlation coefficient (ICC) values of all features among segmentations 
of two clinicians in a set of 30 desmoid type fibromatosis patients. Only the features with an ICC > 0.75, 
which are considered as reliable, are included. Besides the feature names, several of the labels also include 
the parameters used. More details on the features can be found in Supplemental Material 1.
Feature label ICC Feature label ICC
tf_Gabor_0.05A0.79std_M0 0,75 tf_GLCMMS_ASMd1.0A0.79mean_M0 0,81




tf_GLCM_ASMd1.0A2.36_M0 0,76 tf_GLCMMS_dissimilarityd1.0A0.79mean_M0 0,81
logf_mean_sigma1_M0 0,76 tf_GLCMMS_energyd1.0A1.57mean_M0 0,81
tf_Gabor_0.5A2.36skew_M0 0,76 tf_GLCMMS_ASMd1.0A2.36mean_M0 0,81






tf_GLCMMS_contrastd1.0A0.0std_M0 0,76 tf_GLCMMS_homogeneityd1.0A0.0std_M0 0,82
tf_Gabor_0.5A0.79mean_M0 0,76 tf_GLCMMS_dissimilarityd1.0A0.0std_M0 0,82
tf_GLCM_ASMd1.0A0.0_M0 0,76 tf_GLCMMS_homogeneityd1.0A0.79mean_M0 0,82
phasef_phasesym_median_WL3_N5_M0 0,77 tf_Gabor_0.2A2.36std_M0 0,82
tf_GLCM_ASMd1.0A1.57_M0 0,77 tf_GLCMMS_homogeneityd1.0A2.36mean_M0 0,83
tf_LBP_skew_R8_P24_M0 0,77 tf_GLCMMS_energyd1.0A0.0mean_M0 0,83




tf_Gabor_0.5A0.79skew_M0 0,77 tf_GLCMMS_correlationd1.0A0.0std_M0 0,83
tf_GLCMMS_ASMd1.0A1.57mean_M0 0,78 tf_GLCMMS_energyd1.0A1.57std_M0 0,83
tf_GLCMMS_contrastd1.0A0.79std_M0 0,78 tf_Gabor_0.5A2.36std_M0 0,84
tf_GLCMMS_contrastd1.0A0.79mean_M0 0,78 tf_GLCMMS_energyd1.0A0.79mean_M0 0,84
tf_Gabor_0.5A0.79std_M0 0,78 hf_median_M0 0,84
tf_GLSZM_SmallAreaLowGrayLevelEmphasis_M0 0,79 vf_Frangi_inner_max_SR(1.0, 10.0)_SS2.0_M0 0,84
tf_GLCMMS_dissimilarityd1.0A2.36mean_M0 0,79 tf_GLCMMS_energyd1.0A0.79std_M0 0,84
tf_GLCMMS_ASMd1.0A0.0mean_M0 0,79 tf_Gabor_0.5A2.36mean_M0 0,84
tf_Gabor_0.05A0.79min_M0 0,79 tf_GLCMMS_energyd1.0A2.36std_M0 0,84
hf_entropy_M0 0,79 tf_GLCMMS_homogeneityd1.0A0.79std_M0 0,84
tf_Gabor_0.5A0.0kurt_M0 0,79 tf_GLCMMS_homogeneityd1.0A2.36std_M0 0,84
tf_GLCMMS_ASMd1.0A2.36std_M0 0,80 tf_GLCMMS_homogeneityd1.0A1.57mean_M0 0,84
tf_GLCMMS_homogeneityd1.0A1.57std_M0 0,80 tf_GLSZM_ZoneEntropy_M0 0,84
tf_GLCMMS_dissimilarityd1.0A2.36std_M0 0,80 vf_Frangi_inner_range_SR(1.0, 10.0)_SS2.0_M0 0,85
tf_GLSZM_SmallAreaEmphasis_M0 0,80 tf_GLCMMS_energyd1.0A2.36mean_M0 0,85
tf_GLCMMS_ASMd1.0A0.79std_M0 0,80 phasef_phasecong_kurtosis_WL3_N5_M0 0,85
tf_GLCMMS_dissimilarityd1.0A1.57std_M0 0,80 tf_GLCMMS_correlationd1.0A0.79mean_M0 0,85
tf_GLCMMS_ASMd1.0A0.0std_M0 0,80 logf_median_sigma1_M0 0,85
tf_Gabor_0.5A0.0std_M0 0,80 tf_Gabor_0.2A1.57min_M0 0,85
tf_GLCMMS_contrastd1.0A0.0mean_M0 0,80 tf_Gabor_0.2A1.57kurt_M0 0,86
vf_Frangi_edge_std_SR(1.0, 10.0)_SS2.0_M0 0,80 tf_GLCMMS_correlationd1.0A0.0mean_M0 0,86
vf_Frangi_full_std_SR(1.0, 10.0)_SS2.0_M0 0,80 tf_GLCMMS_dissimilarityd1.0A0.0mean_M0 0,86
tf_GLCMMS_ASMd1.0A1.57std_M0 0,81 tf_GLCMMS_homogeneityd1.0A0.0mean_M0 0,86
tf_LBP_mean_R8_P24_M0 0,81 tf_GLCMMS_correlationd1.0A0.79std_M0 0,86
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Supplemental Table 4. (continued)
Feature label ICC Feature label ICC
tf_Gabor_0.5A0.0max_M0 0,86 tf_Gabor_0.2A1.57std_M0 0,91
tf_GLCMMS_correlationd1.0A1.57std_M0 0,87 phasef_phasecong_skewness_WL3_N5_M0 0,91
tf_LBP_mean_R15_P36_M0 0,87 hf_min_M0 0,91
tf_Gabor_0.05A1.57kurt_M0 0,87 tf_Gabor_0.2A0.79kurt_M0 0,91
sf_cvar_avg_2D_M0 0,87 phasef_phasesym_max_WL3_N5_M0 0,91
vf_Frangi_inner_std_SR(1.0, 10.0)_SS2.0_M0 0,87 phasef_phasesym_range_WL3_N5_M0 0,91
phasef_phasecong_mean_WL3_N5_M0 0,87 tf_Gabor_0.2A0.79std_M0 0,91
tf_LBP_std_R3_P12_M0 0,87 phasef_phasesym_mean_WL3_N5_M0 0,91
tf_LBP_std_R15_P36_M0 0,88 hf_quartile_range_M0 0,91
tf_GLCM_energyd3.0A0.79_M0 0,88 tf_Gabor_0.2A2.36min_M0 0,91
tf_GLCM_energyd3.0A1.57_M0 0,88 vf_Frangi_edge_max_SR(1.0, 10.0)_SS2.0_M0 0,92
tf_Gabor_0.2A2.36skew_M0 0,88 vf_Frangi_full_max_SR(1.0, 10.0)_SS2.0_M0 0,92
tf_Gabor_0.5A1.57std_M0 0,88 vf_Frangi_edge_range_SR(1.0, 10.0)_SS2.0_M0 0,92
tf_GLCMMS_correlationd1.0A2.36std_M0 0,88 vf_Frangi_full_range_SR(1.0, 10.0)_SS2.0_M0 0,92
tf_GLCM_energyd3.0A0.0_M0 0,88 logf_skewness_sigma1_M0 0,92
phasef_monogenic_mean_WL3_N5_M0 0,88 sf_prax_avg_2D_M0 0,92
tf_GLCM_energyd1.0A0.79_M0 0,88 tf_Gabor_0.05A2.36max_M0 0,92
tf_GLRLM_LongRunEmphasis_M0 0,88 tf_GLCMMS_correlationd1.0A1.57mean_M0 0,92
tf_GLCMMS_correlationd1.0A2.36mean_M0 0,88 tf_Gabor_0.2A0.0skew_M0 0,92
tf_Gabor_0.05A0.79max_M0 0,89 hf_max_M0 0,92
tf_GLCM_energyd3.0A2.36_M0 0,89 tf_Gabor_0.2A0.79max_M0 0,93
tf_GLSZM_HighGrayLevelZoneEmphasis_M0 0,89 phasef_phasecong_std_WL3_N5_M0 0,93
tf_GLSZM_LowGrayLevelZoneEmphasis_M0 0,89 phasef_phasesym_std_WL3_N5_M0 0,93
tf_GLCM_energyd1.0A2.36_M0 0,89 tf_GLRLM_RunEntropy_M0 0,93
tf_Gabor_0.2A2.36max_M0 0,89 hf_range_M0 0,93







tf_Gabor_0.5A1.57max_M0 0,89 hf_std_M0 0,93
tf_GLCM_energyd1.0A1.57_M0 0,89 tf_Gabor_0.2A1.57skew_M0 0,94
tf_Gabor_0.2A0.79skew_M0 0,89 sf_rad_dist_std_2D_M0 0,94
tf_Gabor_0.05A0.79skew_M0 0,90 tf_Gabor_0.05A1.57min_M0 0,94
phasef_monogenic_median_WL3_N5_M0 0,90 tf_Gabor_0.05A2.36std_M0 0,94
logf_mean_sigma5_M0 0,90 tf_Gabor_0.2A1.57mean_M0 0,94
tf_Gabor_0.05A2.36min_M0 0,90 tf_Gabor_0.05A2.36kurt_M0 0,94
hf_mean_M0 0,90 tf_Gabor_0.2A0.0std_M0 0,94
tf_Gabor_0.5A0.0min_M0 0,90 tf_Gabor_0.05A0.0max_M0 0,94




tf_Gabor_0.2A0.79min_M0 0,90 logf_min_sigma1_M0 0,95
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Supplemental Table 4. (continued)
Feature label ICC Feature label ICC
tf_Gabor_0.2A2.36kurt_M0 0,95 tf_GLCM_contrastd1.0A1.57_M0 0,97
tf_GLCM_contrastd3.0A2.36_M0 0,95 tf_Gabor_0.2A0.0min_M0 0,97
phasef_monogenic_min_WL3_N5_M0 0,95 tf_Gabor_0.05A0.0mean_M0 0,97
logf_range_sigma1_M0 0,95 tf_GLCM_dissimilarityd1.0A0.0_M0 0,97
tf_GLCM_homogeneityd3.0A0.79_M0 0,95 tf_Gabor_0.5A0.0mean_M0 0,97
hf_peak_M0 0,95 tf_GLCM_dissimilarityd3.0A2.36_M0 0,97
tf_GLCM_homogeneityd3.0A0.0_M0 0,95 phasef_phasesym_entropy_WL3_N5_M0 0,97
tf_Gabor_0.2A0.79mean_M0 0,96 phasef_monogenic_entropy_WL3_N5_M0 0,97




vf_Frangi_full_entropy_SR(1.0, 10.0)_SS2.0_M0 0,96 tf_GLCM_dissimilarityd1.0A1.57_M0 0,98
tf_GLCM_contrastd3.0A0.0_M0 0,96 tf_GLCM_dissimilarityd3.0A1.57_M0 0,98
logf_max_sigma1_M0 0,96 tf_Gabor_0.2A1.57max_M0 0,98
phasef_monogenic_range_WL3_N5_M0 0,96 logf_range_sigma5_M0 0,98
tf_Gabor_0.05A1.57std_M0 0,96 vf_Frangi_inner_skewness_SR(1.0, 10.0)_
SS2.0_M0
0,98
tf_GLCM_homogeneityd3.0A2.36_M0 0,96 tf_GLCM_dissimilarityd1.0A0.79_M0 0,98
tf_GLCM_contrastd3.0A1.57_M0 0,96 tf_GLCM_dissimilarityd3.0A0.79_M0 0,98
tf_Gabor_0.05A2.36mean_M0 0,96 logf_std_sigma5_M0 0,98
tf_GLRLM_RunVariance_M0 0,96 tf_GLCM_dissimilarityd3.0A0.0_M0 0,98
tf_GLCM_contrastd1.0A0.0_M0 0,96 tf_Gabor_0.05A1.57mean_M0 0,98
phasef_phasecong_entropy_WL3_N5_M0 0,96 logf_std_sigma1_M0 0,98
logf_min_sigma5_M0 0,96 logf_mean_sigma10_M0 0,98
logf_max_sigma10_M0 0,96 tf_Gabor_0.5A1.57mean_M0 0,98
tf_GLCM_contrastd3.0A0.79_M0 0,96 hf_energy_M0 0,98
tf_GLCM_homogeneityd1.0A0.79_M0 0,96 logf_entropy_sigma1_M0 0,98
phasef_monogenic_max_WL3_N5_M0 0,96 tf_Gabor_0.05A0.0min_M0 0,98
tf_GLCM_contrastd1.0A2.36_M0 0,96 logf_std_sigma10_M0 0,98
tf_Gabor_0.05A1.57skew_M0 0,96 logf_entropy_sigma10_M0 0,98
tf_GLCM_contrastd1.0A0.79_M0 0,96 logf_median_sigma10_M0 0,98
phasef_phasecong_max_WL3_N5_M0 0,96 tf_Gabor_0.2A0.0mean_M0 0,99
phasef_phasecong_range_WL3_N5_M0 0,96 tf_Gabor_0.2A0.0max_M0 0,99
logf_range_sigma10_M0 0,96 logf_entropy_sigma5_M0 0,99
tf_GLCM_homogeneityd1.0A2.36_M0 0,97 phasef_phasecong_energy_WL3_N5_M0 0,99
logf_min_sigma10_M0 0,97 sf_rad_dist_avg_2D_M0 0,99
phasef_monogenic_std_WL3_N5_M0 0,97 phasef_phasesym_energy_WL3_N5_M0 0,99
phasef_monogenic_quartile_range_WL3_N5_M0 0,97 phasef_monogenic_kurtosis_WL3_N5_M0 0,99




tf_GLCM_homogeneityd1.0A1.57_M0 0,97 vf_Frangi_inner_energy_SR(1.0, 10.0)_SS2.0_M0 0,99
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Supplemental Table 4. (continued)
Feature label ICC Feature label ICC
logf_skewness_sigma5_M0 0,99 logf_energy_sigma5_M0 1,00
logf_quartile_range_sigma10_M0 0,99 phasef_monogenic_peak_WL3_N5_M0 1,00
tf_GLSZM_GrayLevelNonUniformity_M0 0,99 vf_Frangi_inner_peak_SR(1.0, 10.0)_SS2.0_M0 1,00
logf_energy_sigma1_M0 0,99 tf_Gabor_0.5A1.57min_M0 1,00
logf_quartile_range_sigma5_M0 1,00 phasef_phasesym_peak_WL3_N5_M0 1,00
logf_kurtosis_sigma5_M0 1,00 phasef_monogenic_energy_WL3_N5_M0 1,00
logf_kurtosis_sigma10_M0 1,00 phasef_phasecong_peak_WL3_N5_M0 1,00
logf_skewness_sigma10_M0 1,00 vf_Frangi_edge_peak_SR(1.0, 10.0)_SS2.0_M0 1,00
logf_peak_sigma10_M0 1,00 vf_Frangi_full_peak_SR(1.0, 10.0)_SS2.0_M0 1,00
tf_GLSZM_SizeZoneNonUniformity_M0 1,00 tf_GLRLM_GrayLevelNonUniformity_M0 1,00
logf_energy_sigma10_M0 1,00 phasef_phasecong_min_WL3_N5_M0 1,00
logf_quartile_range_sigma1_M0 1,00 phasef_phasesym_min_WL3_N5_M0 1,00
sf_volume_2D_M0 1,00 tf_LBP_median_R8_P24_M0 1,00
tf_GLRLM_RunLengthNonUniformity_M0 1,00 tf_LBP_peak_R15_P36_M0 1,00
logf_peak_sigma1_M0 1,00 tf_LBP_peak_R3_P12_M0 1,00
logf_peak_sigma5_M0 1,00 tf_LBP_peak_R8_P24_M0 1,00
GLCM, gray level co-occurrence matrix; GLCMMS, GLCM multislice; NGTDM, neighbourhood gray tone 
difference matrix; GLSZM, gray level size zone matrix; GLRLM, gray level run length matrix; LBP, local binary 
patterns; LoG, Laplacian of Gaussian; std, standard deviation.
Supplemental Figure 1. Visualization of the 100x random split-cross validation, including a second cross 
validation within the training set.
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This study evaluates the results of the active surveillance (AS) approach in adult patients 
with desmoid-type fibromatosis (DTF), because AS is advocated as a front-line approach 
for DTF in the European consensus guidelines.
Materials and methods
A systematic literature search was conducted (December 19th, 2019, updated on April 14th, 
2020). Studies describing the outcomes of the AS approach were included. The PRISMA 
guidelines were used.
Results
Twenty-five articles were included for data-retrieval. Forty-two percent of reported patients 
(1480 of 3527 patients) received AS, the majority were females and the majority had a 
primary tumour. The median age at diagnosis ranged from 28 to59 years. Common tumour 
sites were; the extremities/girdles (n = 273), the abdominal wall (n = 253), and the trunk 
(n = 153). The median reported percentage of progressive disease, stable disease and partial 
response was 20% (interquartile range [IQR] 13-35%), 59% (IQR: 37-69%) and 19% (IQR: 
3-23%), respectively. In 640 patients, the outcome was not specified. The median reported 
percentage of shifting to an active form of treatment was 29%, most commonly to systemic 
treatment (n=195) and surgery (n=107). The reported median follow-up time ranged between 
8 and 73 months. The reported median time to progression and/or initiation of the subgroup 
shifting from AS to ‘active’ therapy ranged from 6.3 months to 19.7 months.
Conclusions
The majority of patients undergoing AS have either stable disease or a partial response, 
and about one-third of patients shift to an active form of treatment. Selecting patients who 
will benefit from active surveillance upfront should be the priority of future studies.
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Introduction
Desmoid-type fibromatosis (DTF) is an uncommon, soft-tissue tumour arising in 
musculoaponeurotic structures and mainly affecting young adults aged between 20 and 40 
years 1. DTF is characterised by unpredictable, invasive growth. Rapid growth is often seen 
in the early phase of the disease, but also in response to pregnancy or hormonal manipulation 
2, 3. After an initial period of growth, many patients experience prolonged stabilisation of 
the desmoid tumour.
Up to ten years ago, surgical treatment was the mainstay of treating DTF leading to 
significant morbidity and high recurrence rates 4-6. Other forms of active treatments, 
such as radiotherapy and systemic therapy, mainly have a role in case of progressive and 
symptomatic tumours located at sites which are difficult to treat surgically 7. However, these 
therapies can lead to treatment-related toxicities 7. The term ‘active surveillance’ (AS) for the 
management of DTF was introduced in the 1990s. Initially, AS was only offered to patients 
with recurrent tumours, but after 2005 also patients with primary tumours were exposed to 
this approach 8, 9. As a results, a decrease in the use of these ‘active treatments’ over the past 
years has been reported in several nation-wide cohort studies 4, 5. AS for DTF is justified as 
it has no metastatic potential and spontaneous tumour regression is reported in up to 30% 
of patients who undergo initial AS 10. A large retrospective study showed no difference in 
event-free survival (EFS) comparing surgery with the AS approach (53% versus 58%, p = 
0.415) 6. The first European consensus guideline dates from 2015, and advocates using AS 
as an upfront approach, to minimise overtreatment and to prevent unnecessary morbidity 
11. This recommendation was based on the results of several retrospective series 8, 10, 12-14. A 
systematic review to summarise and to evaluate the published results of the AS approach 
can be helpful to select patients who benefit from this approach, while awaiting the results 
of three ongoing, prospective clinical trials from Europe (NCT01801176, NCT02547831, 
and NTR 4714) 15-17.
The aim of the current study was to systematically review published studies reporting the 
results of the AS approach in adult DTF patients. Furthermore, Response Evaluation Criteria 
in Solid Tumors, (RECIST) classification of DTF tumours during the AS approach was 
evaluated, prognostic factors for a successful AS approach were identified, the median time to 
shift to an active form of treatment and the median duration of the AS approach were analysed 
and lastly, the forms of active treatment after the initial AS approach were assessed.
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Material and methods
This study uses the PRISMA guidelines for reporting a systematic literature review.
Information sources
On December 19th 2019, a systematic literature search was performed by an expert librarian. 
The search was updated on April 14th which yielded one additional inclusion. Used databases 
include Embase.com, Ovid MEDLINE, Web of Science, Cochrane CENTRAL, PsychInfo 
Ovid and Google Scholar. Duplicated records were removed. Case reports were excluded 
and an English language filter was applied. There were no constrains on publication dates. 
Supplemental Materials 1 depicts the search strategy.
Eligibility criteria
Studies with sporadic DTF as a main subject and full-text availability were included by two 
researchers (MJMT, AWS). Papers reporting outcomes (either using RECIST 18 or number 
of patients shifting to ‘active treatment’) were included in this systematic literature review. 
Cross-referencing was carried out ensuring inclusion of all relevant articles. The flowchart 
depicting the study selection procedure is available in Supplemental Materials 2.
Study selection
Table 1. Inclusion and exclusion criteria of study selection procedure
Inclusion criteria Exclusion criteria
• Primary and recurrent DTF
• Active surveillance (or other similar terms 
such as wait and see, expectative management 
etc.) as a primary treatment
• Adult (aged ≥ 18 years) patients
• English language
• Reporting the outcomes of active surveillance 
in terms of reporting the success rate of active 
surveillance, numbers of patients needed to 
shift to active treatment, RECIST outcomes 
during active surveillance
• Studies with patients receiving solely active forms 
of treatment such as surgery, systemic treatment, 
local therapy (e.g., cryotherapy), and radiotherapy
• Case reports, case series ≤ 5 patients
• Pre-clinical studies describing molecular features 
of DTF
• Diagnostic studies describing imaging features 
of DTF
• Non-original reports (e.g., editorials, study 
protocols, reviews etc.)
• Non-full text available (e.g., conference abstracts etc.)
• Studies describing solely paediatric cohorts
• Studies describing solely FAP or Garner syndrome
• Other subjects than DTF (e.g., soft tissue sarcoma)
• Language other than English
DTF, desmoid-type fibromatosis; RECIST, Response Evaluation Criteria in Solid Tumors; FAP, familial 
adenomatous polyposis
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The retrieved articles were assessed for potential inclusion by the first and second author 
based on the review of title and abstract. Next, full-text articles were evaluated in accordance 
with the predetermined inclusion criteria and exclusion criteria for this systematic literature 
review (listed in Table 1).
Data Extraction
Data was collected by two researchers (MJMT, AWS) using a pre-defined Excel sheet 
statin the year of publication, the first author, the journal, the publication title, whether the 
publication fulfilled the inclusion criteria, the inclusion period, the type of study, the total 
number of participants, the number of participants receiving AS, the number of patients 
with familial adenomatous polyposis (FAP)/Gardner syndrome, the number of primary 
tumours, and the number of recurrent tumours. Of the AS group, the following variables 
were extracted: the reported mean/median follow-up (range, interquartile range [IQR], 
95% confidence interval [CI]), the reported median/mean age (with range or IQR), the sex 
distribution, the tumour sites, the number of patients with progressive disease (PD), stable 
disease (SD), partial response (PR), complete response (CR), the number of patients who 
shifted to active treatment, reasons for shifting to an active form of treatment, and whether 
RECIST were used for determination of these outcomes. For responses not evaluated by 
RECIST but by using similar terms, tumour response was categorised based on the RECIST 
categories; PD, SD, PR and CR. PD included the terms ‘increase’, ‘evolution’, ‘enlarged’, 
SD included the terms ‘stable’, ‘arrested’, and ‘non-progressive’, PR included the terms 
‘decreased’, ‘regressed’, ‘disease free survival’, ‘responding disease’, and ‘spontaneous 
remission’, and CR included the terms ‘disappeared’, and ‘complete regression’. Not 
specified (NS) was used in case a variable was missing.
Tumour sites were classified as: the extremity/girdle region (including upper extremity, 
lower extremity, shoulder, buttock, thigh and hip), intra-abdominal (including mesenteric), 
trunk (including paraspinal and thoracic wall), abdominal wall, head/neck region and other 
(including inguinal region and not further specified sites). When age and follow-up (in 
months of years) were reported for each individual patient, the median age and median 
follow-up with range were extracted and calculated from these data.
A shift to ‘active treatment’ was defined as ‘ceasing active surveillance’. The following 
therapies were categorised as ‘active treatments’: systemic treatment (including hormonal 
treatment, chemotherapy, and tyrosine kinase inhibitors), surgery, radiotherapy, combination 
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therapies, and local therapies such as radiofrequency or cryotherapy. The category of “NS” 
was used when information was lacking about the type of active treatment. Shift to ‘active 
treatment’ is reported as the percentage of patients shifting to active treatment from each 
separate study, and compiled as an overall median percentage of patients shifting to active 
treatment with IQR, compiling all study results. The same was done for the types of active 
treatments. Variables such as median follow-up of the AS group, the time to intervention, 
the time to progression, the time to stabilisation, the time to regression, progression-free 
survival (PFS), and EFS were extracted in case they were stated by the included studies.
Results
Systematic literature search
The search was performed on December 19, 2019 and updated on April 14, 2020. The 
search strategy yielded a total of 940 papers, after deduplication, 589 papers remained. 
Title and abstract were screened leading to the exclusion of 551 papers. A total of 38 papers 
were reviewed based on full-text and 25 studies were finally included for further analysis. 
The study selection procedure is depicted in Supplemental Materials 2. No randomised 
controlled trials reporting about AS in DTF were identified. Several reviews, discussing 
the current status and treatments of DTF addressed the AS approach, but none of these 
reviews included a systematic literature review solely focussing on the outcomes of the 
AS approach.
Study design and quality assessment.
All included studies were published after 2005. All studies were retrospective case series 
which are generally considered to have a high risk of bias and a low certainty 19, 20. Of note, 
nine studies potentially used overlapping patient cohorts based on author names, affiliations 
and inclusion time period 2, 9, 14&6, 10, 12, 21-23.
6
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Clinical characteristics and outcomes of active surveillance
The clinical characteristics and outcomes of patients treated with AS of the included studies 
are shown in Table 2. Most studies only included sporadic DTF, whilst seven studies also 
included FAP-related DTF. It was mostly unclear whether these FAP-patients were included 
in the AS groups, and no study published separate results for the AS approach in FAP-related 
DTF patients. Treatment strategy comparisons included surgery with or without adjuvant 
radiotherapy, isolated limb perfusion, cryotherapy, radiotherapy, and systemic treatments 
including chemotherapy, tyrosine kinase inhibitors, and hormonal treatment. One study 
compared three groups categorised by surgical margins 28, another study categorised groups 
based on their pregnancy status 2. From the later, only groups A, B and C (representing 
patients with diagnosed during pregnancy [A], diagnosed within 6 months after delivery 
[B], and previously diagnosed and still in situ at the time of pregnancy [C]) were included 
in the analysis. Group D (resected before pregnancy without clinical evidence of residual 
or recurrent disease), was excluded from the results owing to lack of reporting of clinical 
outcome and shift to active treatment. One study only reported the outcome of 37 patients 
with RECIST whilst they had 72 patients undergoing AS (Table 2) 31. Furthermore, one 
study also described a group of patients with resected tumours (group B). This group was 
excluded from analysis and only groups A and C from this study were included 29.
Few studies solely included patients receiving AS 26, 27, 36, 37. Ten studies provided the type and 
interval of imaging during the AS approach. Most studies used intervals of two to six months 
after the first evaluation with either computed tomography (CT) 25 or magnetic resonance imaging 
8, 10, 23, 27, 37, or a combination. Few studies used additional ultrasound 9, 36, 37. Two studies stated 
to ‘change to annual visits’ after tumour stabilisation or after two years of follow-up 30, 36.
Active surveillance as a single treatment
The total number of patients was 3527, of which 1480 (42%) received AS. Three studies 
allowed the use of non-steroidal anti-inflammatory drugs (NSAIDs) in symptomatic patients 
during the AS approach or did not consider shift to hormonal therapy as a “failure of 
AS” (Table 2) 6, 8, 38. As the use of NSAIDs could be under reported by both patients and 
researchers, the results of these studies were included in the analysis of this paper.
The number of patients receiving AS approach ranged from 3 to 388 per included study. 
The total group receiving AS consisted of 205 males and 526 females (reported in fifteen 
studies), for the remaining patients (n = 749), the sex was not further specified. The median 
percentage of females in each reported study was 72% (IQR: 67-78%). The reported median 
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age at diagnosis of the AS group (available in twelve studies) ranged from 28 to 59 years. 
Twenty studies reported the number of primary and recurrent tumours included in their 
AS group (Table 2). In these studies, the majority of patients had a primary tumour with 
a median percentage of primary tumours of 100% (IQR: 68-100%). The remaining had a 
recurrent tumour. Based on the reported information, no distinction in numbers of patients 
needing shift to active treatment could be made between primary and recurrent tumours.
Tumour response to active surveillance
Fourteen out of twenty-five studies stated to use RECIST (either 1.0 or 1.1) 18 to objectively 
measure tumour response 2, 6, 8, 14, 23, 25, 29-33, 35, 36, 38, however only a part of those studies actually 
reported the radiological response per treatment type in accordance with RECIST. Other 
studies used similar approaches describing the disease outcome as PD, SD, PR or CR.
A total of 21 studies reported PD in 322 patients. The median percentage of PD reported 
in these studies was 20% (IQR: 13-35%). A total of eighteen studies reported SD in 382 
patients. The median percentage of SD reported in these studies was 59% (IQR: 37-69%). 
Seventeen studies reported PR in 102 patients. The median percentage of PR reported in 
these studies was 19% (IQR: 3-23%). CR was reported sixteen studies in 34 patients. The 
median percentage of CR reported in these studies was 0% (IQR: 0-6%) (Table 3).
Indications for start of treatment
Table 3. Overview of RECIST outcomes and shift to active treatment





Median % of patients 
(IQR) reported in all 
studies
RECIST outcomes
Progressive disease 21 322 20% (13-35%)
Stable disease 18 382 59% (37-69%)
Partial response 17 102 19% (3-23%)
Complete response 16 34 0% (0-6%)
Active treatment
Shifting to an active form treatment 20 402 29% (17-40%)
Surgery 17 107 41% (11-62%)
Systemic treatment 17 195 33% (0-52%)
Local therapies a 16 4 0% (0%)
Radiotherapy 16 18 0% (0-1%)
Combination of therapies b 20 8 0% (0-3%)
a radiofrequency, cryotherapy; b surgery + radiotherapy, systemic therapy + surgery
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Pain, with or without radiological evidence of progression, functional symptoms, or patient 
request, were frequently mentioned reasons for shifting to an ‘active’ treatment 10. A total of 
402 patients (reported in twenty studies) shifted to ‘active’ treatment. The median percentage 
of patients shifting in these studies was 29% (IQR: 17-40%). The type of ‘active’ treatment 
was systemic treatment in 195 cases, surgery in 107 cases, radiotherapy in 18 cases, a 
combination of therapies (e.g., systemic treatment with surgery, and systemic treatment 
with radiotherapy) in 8 cases and local therapy (e.g., radiofrequency and cryotherapy) in 4 
cases. In 69 cases it was reported that patients shift to an active form of treatment but the 
type was unspecified (Table 3).
Progression and change in treatment strategy
The median follow-up time of patients with the AS approach was reported by twelve studies 
and ranged between 8 months and 73 months (Table 4). Most studies reported the median 
time to progression (n = 5) 9, 22, 28, 29, 32, and solely two studies reported median time to shifting 
from AS to ‘active’ therapy 31, 36. Other studies used PFS 14, 30, 33, 38 or EFS 6, 28 to express the 
success rates of the AS approach. Two studies described time to SD 27, 37.
Van Broekhoven et al. described that the median duration of the AS approach was 22 
months (IQR: 13-46) for patients with CR or PR 32. Kim et al. reported that age younger 
than 40 and a recurrent tumour were significant predictive factors of longer time to disease 
stabilisation (p = 0.014 and p = 0.036, respectively) 37. Penel et al. reported that 30.1% of 
patients in the AS group experienced an event (progression during AS, change in treatment 
strategy and/or disease-related death) 6. Briand et al. reported a cumulative probability of 
dropping out from the AS approach of 5.7% (95% CI 1.5%-14.2%) at one year, and 9.6% 
(95% CI 3.5%- 19.6%) at 2, 5, and 10 years 8. Bonvalot et al. stated that the percentage of 
patients shifting to another treatment was 33% (95% CI 24-43) at 1-year, and 41% at 3 years 
(95% CI 31%-52%) 10. Fiore et al. reported that 89% of patients progressed within the first 
two years after referral, and reported a 5-year PFS rate of 47% (standard error [SE] 10.3%) 
for primary tumours and 54% (SE 11.6%) for recurrent tumours (p = 0.48) 14 (Table 4).
A description of the risk factors for progression or a change in treatment strategy is reported 
in Table 5. A larger tumour size, >5 cm vs. ≤5 cm, was associated with a shorter time to 
intervention (6.9 months versus 32.6 months, p = 0.02) 31, and shift to ‘active’ treatment 
was more likely in patients with “larger” tumours (≥ 7cm) with a hazard ratio (HR) of 2.0 
(95% CI 1.3%- 3.2%, p = 0.002) 36, and >3.5 cm, p = 0.004 10. Furthermore, the initiation 
of ‘active’ treatment was more likely for patients with PD or SD than for patients with PR 
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(p < 0.001) with a HR of 12.4 (95% CI 4.9%- 31.4%), and 4.8 (95% CI 1.8% to 12.6%), 
respectively 36. Patients who experienced pain were also more likely (p < 0.001) to shift 
to an active form of treatment, with a HR of 2.55 (95% CI 1.63%-3.99%) 36. Cassidy et al. 
found no association between intervention (i.e., shift to active treatment) and age (p = 0.22), 
as well as intervention and sex (p = 0.07) 31.
Table 4. Reported time intervals and survival data to express the success rate of the active surveillance approach
Ref. Outcome
Median time to intervention
Cassidy, 2018 31  11.7 months (±6.5)
Van Houdt, 2019 36  6.5 months
Median time to progression
Salas, 2011 22  19.7 months (range: 7.8-46.2 months)
Huang, 2014 28  15.3 months (range 7:.8-41 months)
Colombo, 2015 9  16 months
Van Broekhoven, 2018 32  7.3 months (IQR: 4.1-11.9 months)
Krieg, 2019 34  1.2 years (range: 0.9-1.5 years)
Median time to stable disease
Barbier, 2010 27  13.2 months (range: 6-30 months)
Kim, 2020 37  30.4 months (range: 7-112 months)a
Median time to regression
Briand, 2014 8  54.8 months (range: 21-130 months)
Median progression-free survival
Turner, 2019 38  10 months (range: 2-94 months)
2-year progression-free survival
De Bruyns, 2019 33  71% (95% CI 0.6% to 0.84%)
3-year progression-free survival
Turner, 2019 38  38%
Park, 2016 30  92%
5-year progression-free survival
Fiore, 2009 14  47% (SE: 10.3%) primary tumours
 54% (SE: 11.5%) recurrent tumours
2-year event-free survival
Penel, 2017 6  85.7 (±9.6) core needle biopsy
 52.8 (±4.6) open biopsy
5-year event-free survival
Huang, 2014 28  71.2%
a mean value instead of median
CI, confidence interval; IQR, interquartile range; SE, standard error
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Table 5. Published results regarding variables that are potentially associated with time to disease stabilisation, 




Barbier, 2010 27 Time difference in evolution to stabilisation
 Primary vs. recurrent disease p = 0.0417
Longer evolution time 
before stabilization in 
recurrent tumours
Kim, 2020 37  Age
 Tumour status




Age, < 40 years and 
recurrent tumours are 
predictive factors of 
longer time to disease 
stabilization
Bonvalot, 201310 Change in treatment strategy
 Pregnancy before the development of DTF
 Age
 Tumour size
  3.5-5.0 cm (HR 3.7, 95% CI 1.0% to 14%)
  5-7 cm (HR 4.0, 95% CI 2.4% to 2.8%)




Larger tumour size (>3.5)
Cassidy, 2018 31 Change in treatment strategy
 Age
 Sex




 Tumour size (HR 1,027)
 Tumour site extremities/all other sites
 vs. abdominal wall







p = 0.54/ 
p = 0.38
p = 0.01







Turner, 2019 38 Progression
 Tumour site abdominal wall vs. other sites p = 0.53
Van Houdt, 
2019
36 Change in treatment strategy
 Tumour size >7 cm (HR 2.04, 95% 
 CI 1.29% to 3.21%)
 Reporting pain










Larger tumour size (>7 
cm), reporting pain, 
and stable disease or 
progressive disease are 
associated with a higher 
risk of initiation of an 
active form of treatment
CI, confidence interval; HR, hazard ratio; PD, progressive disease; PFS. Progression-free survival; PR, partial 
response; SD, stable disease
a only available for n = 37 patients with evaluable magnetic resonance imaging
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The influence of tumour site on initiation of active surveillance
Frequent reported tumour sites (available in sixteen studies) were the extremities/girdles (n = 273 
patients, median percentage of incidence in studies 31% [IQR: 3-68%]), the abdominal wall 
(n = 253 patients, median percentage of incidence in studies 9% [IQR: 0-37%]), and the trunk 
(n = 153 patients, median percentage of incidence in studies 17% [IQR: 0-37%]). Intra-abdominal 
(n = 60) and head/neck (n = 15) tumours were less common, with a median percentage of 
incidence in studies of 0% (0-8%) and 0% (IQR: 0-4%) respectively. From a total of 1480 
patients receiving AS, the tumour sites were not specified in 726 (49%) of patients (Table 2).
Cassidy et al. described that patients with abdominal wall tumours were often managed 
with AS (61%), whereas those with chest wall and intra-abdominal tumours more often 
received active treatment (80% and 60%, respectively) 31. Fiore et al. also described that 
patients who received AS commonly had abdominal wall tumours (p < 0.0001) compared 
with patients who received other treatments 14, whilst Park et al. found no difference in 
tumour sites between groups managed with AS or surgery 30.
The influence of the tumour site on disease stabilisation, progression or a change 
of the treatment strategy
No differences in risk of progression during AS were found between abdominal wall 
tumours and other sites (p = 0.53) by Turner et al. 38 nor on a chance of spontaneous 
stabilisation among axial sites or extremity tumours (p = 0.148) by Kim et al. 37 (Table 5). 
The 5-year PFS of primary cases managed with AS of trunk/thoracic wall tumours and 
abdominal wall tumours was similar (53.9% [SE: 16.2%] versus 52.5%, [SE: 14.3%]) in the 
study from Fiore et al. 14. Van Houdt et al. concluded that upper-extremity and chest wall 
DTF tumours have the highest percentage of progression (39% and 47%, respectively), 
although this difference was not significant compared with other locations 36.
Cassidy et al. described that tumours located paraspinal or flank were more commonly 
associated with a change in treatment than abdominal wall tumours (p = 0.01), but no 
differences were found comparing extremity, intra-abdominal or abdominal wall tumours 
31. Van Houdt et al concluded that there was no difference in initiation of active treatment 
between upper extremity and chest wall DTF (p = 0.36) 36. This is in line with the findings 
of Colombo et al. who did not identify the tumour site as a predicting factor for progression 
and/or change in the treatment strategy among tumour sites (p = 0.926) 9. No single 
conclusion could be reached regarding tumour site and the success or failure of the AS 
approach because of the heterogeneity of the cohorts of included studies.
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Discussion
This systematic literature review evaluated the outcomes of the AS approach in sporadic 
DTF. Twenty-five articles, describing the outcomes of the AS in DTF, were identified. The 
majority of the reported patients experienced SD, and about one-third of the patients needed 
to shift to “active” treatment. The median time of follow-up was reported by twelve studies 
and ranged between 8 months and 73 months, and the median time to shift from AS to active 
treatment or to progression ranged from 6.5 months to 19.7 months.
AS has increasingly been advocated in for sporadic DTF 39. This is underlined by the number 
of publications about this subject since the year of 2006. In the most recent European 
consensus paper, published by the Desmoid Tumor Work Group in 2020, AS is advocated 
as a first line treatment in symptomatic patients, independently of the tumour site or size. In 
case of progression, other treatments such as surgery or systemic therapies, and treatments 
(including AS), should preferably take place in an expert clinic with an experienced 
multidisciplinary sarcoma team 7. A study by Eastly et al. showed that almost half of the 
clinicians prefer AS an initial management strategy for primary DTF for which function-
sparing surgery is possible. In case of recurrent DTF after a previous complete resection 
without adjuvant treatment, this rate dropped to 20% 40. This is illustrated by the current 
study as the majority of included patients have primary tumours.
The definition of AS varies widely between studies. Some studies also allowed the usage of 
non-narcotic analgesics, NSAIDs or hormonal treatment in the AS group 6, 8, 38. Especially 
for NSAIDs, which are non-prescription drugs in many countries and mainly used for 
relieving pain symptoms, the usage of these drugs can be severely under-reported by 
patients, clinicians and researchers. Inclusion of these patients in studies evaluating the 
AS approach can distort the true outcomes because NSAIDs and hormonal treatment (e.g., 
tamoxifen) can be beneficial for DTF with a reported response rate of 85% 41.
The current study did not include the results of the phase 3 trial comparing sorafenib to 
placebo 42. Whilst placebo treatment can be considered a form of AS, as patients do not receive 
an active form of treatment, we decided not to include this trial in the current study. This was 
because only patients with progressive, recurrent or primary disease which were deemed 
inoperable or required extensive surgical resection or were symptomatic were included in this 
clinical trial. In daily clinical practice, AS will not be offered as a front-line approach to these 
patients, and therefor3 this study was not included in the current review.
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The selection of patients suitable for the AS approach remains challenging. The results of this 
systematic review suggest that AS is mainly described as a treatment for tumours localised 
in the extremity/girdles and in the trunk. This might be due to the predilection sites of DTF 
tumours to these locations 43, or due to a selection upfront because of the higher risk of 
recurrence after surgery for these groups 12. Based on the current systematic review, drawing 
a single conclusion with regard to tumour sites and the success of AS remains challenging. 
This is mainly due to the inclusion of studies with homogeneous cohorts in terms of tumour 
site (e.g., mesenteric, or breast), or a preselection of patients upfront (e.g., inoperable tumours 
due to localisation adjacent to vital structures [e.g., nerves, blood vessels]). Furthermore, the 
exact tumour site was not specified in a large number of patients.
About one-third of the patients needed a shift to an ‘active’ form of treatment. Although 
no uniform results could be drawn from the current studies, several studies reported that 
larger tumours were more likely to shift 10, 36, whilst age, sex and pregnancy before the 
development of DTF were not associated with this shift 10, 31, 36. Colombo et al. reported 
that the sex, tumour site and tumour size did not predict progression and/or shift to change 
in treatment; the non-surgical group (n = 106) also contained patients receiving medical 
treatments (n = 4) 9. Few studies described β-catenin mutation of the included cohort, and 
none of these studies analysed the influence of these mutations on the success or failure of 
the AS approach 6, 21. The same applies for FAP-related DTF tumours. The variable results 
from these retrospective studies highlight the need for the identification of predictive factors 
for progression and changes in treatment strategies.
In the current study, progression was often reported within two years after diagnosis 14, 
however the length of follow-up of the included studies varied highly. Few studies reported 
the median follow-up duration of the AS subgroup, and time to intervention was often lacking. 
The minimal available information about the type and frequency of follow-up during AS 
underlines the need for standardisation of the AS approach. This includes defining a follow-up 
schedule with the use of MRI or CT, depending on the tumour site. As few studies reported 
progression after stabilisation, a maximum AS term should be discussed with the patient.
The major limitation of the current study is the inclusion of retrospective, small sample-
sized studies, which often evaluate several treatment regimens, with various follow-up 
schedules and limited information about disease outcomes, or reasons for shifting to ‘active’ 
treatment. Only part of the studies used and reported disease response based on RECIST 
18. Some included studies selected patients for the AS approach based on the fact that 
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the patients were unable to tolerate chemotherapy or radiotherapy 28, had unresectable 
asymptomatic mesenteric masses 25 or had masses that were not life-threatening or at risk 
for mutilation 22. Moreover, some studies selected patients based on tumour sites (e.g., 
breast desmoids 21, 23) or were interested in other study endpoints than the results of the 
AS approach (e.g., pregnancy status 2, or imaging characteristics 24, 31). Another limitation 
is the relatively large number of studies included in this systematic review where there is 
potential cohort overlap (based on author names, affiliations and inclusion time period) 2, 9, 
14&6, 10, 12, 21-23. Despite these limitations, this systematic literature review was able to compile 
the available evidence for the use of the AS approach in adult DTF.
Currently, the results of three prospective European studies evaluating the efficacy of AS in 
DTF are awaited. The French study (NCT01801176) and the Italian study (NCT02547831) 
which started in May 2012 and July 2013, respectively, both evaluate 3-year PFS 15, 16. 
The Dutch study (NTR 4714) which started in May 2014, evaluates tumour progression 
at 5-years follow-up 17. These three studies will provide further insights into the natural 
growth of DTF, the differences in growth behaviour between various tumour sites, tumour 
sizes, and β-catenin mutation types as well as the indications and considerations for the 
start of ‘active’ treatment.
Conclusions
Active surveillance is the mainstay of treatment for sporadic DTF. This systematic literature 
review underlined the ongoing trend of the AS approach and indicates that a minority of 
patients need shift to an active form of treatment avoiding overtreatment and minimising 
potential morbidity.
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Supplemental Materials 1. Search strategy used in databases: Embase.com on December 20, 2019 and 
updated on April 14, 2020.
(‘desmoid tumor’/exp OR Fibromatosis/exp OR (desmoid* OR Fibromatos*):ab,ti,kw) AND (‘conservative 
treatment’/de OR ‘active surveillance’/de OR ‘watchful waiting’/de OR ‘expectant management’/de OR 
‘observation’/de OR ‘clinical observation’/de OR (((activ*) NEAR/3 (surveill*)) OR ((conservativ* OR 
non-surgical* OR nonsurgical* OR non-operativ* OR nonoperativ* OR expectant* OR expectativ* OR 
expectiv*) NEAR/3 (treatm* OR therap* OR approach* OR managem* OR intervent*)) OR ((watchful*) 
NEAR/3 (waiting*)) OR ((wait) NEAR/3 (see OR watch)) OR wait-and-see OR ((without) NEXT/2 
(intervent* OR treatm* OR therap*)) OR ((natural*) NEXT/3 (cours* OR behaviour* OR behavior*)) OR 
observation):ab,ti,kw) AND [ENGLISH]/lim NOT ((animal/exp OR animal*:de OR nonhuman/de) NOT 
(‘human’/exp)) NOT (‘case report’/exp OR (case-report*:ti) 
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Supplemental Material 2. Flow diagram of study selection: search performed on December 19, 2019 and 
updated on April 14, 2020
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The majority of sporadic desmoid-type fibromatosis (DTF) tumours harbor a CTNNB1 
(ß-catenin) mutation: T41A, S45F and S45P or are wild-type (WT). Results are conflicting 
regarding the recurrence risk after surgery for these mutation types. This meta-analysis 
(PROSPERO CRD42018100653) uses individual patient data (IPD) to assess the association 
between recurrence and CTNNB1 mutation status in surgically treated adult DTF patients.
Materials and methods
A systematic literature search was performed on June 6th, 2018. IPD from eligible studies 
was used to analyse differences in recurrence according to CTNNB1 mutation status using 
Cox proportional hazards analysis. Predictive factors included: sex, age, mutation type, 
tumour site, tumour size, resection margin status, and cohort. The PRISMA-IPD guideline 
was used.
Results
Seven studies, describing retrospective cohorts were included and the IPD of 329 patients 
were used of whom 154 (46.8%) had a T41A mutation, 66 (20.1%) a S45F mutation, and 
24 (7.3%) a S45P mutation, whereas 85 (25.8%) patients had a WT CTNNB1. Eighty-three 
patients (25.2%) experienced recurrence. Multivariable analysis, adjusting for sex, age and 
tumour site yielded a p-value of 0.011 for CTNNB1 mutation. Additional adjustment for 
tumour size yielded a p-value of 0.082 with hazard ratios (HR) of 0.83 (95% confidence 
interval [CI]: 0.48-1.42), 0.37 (95% CI: 0.12-1.14) and 0.44 (95% CI: 0.21-0.92) for T41A, 
S45P and WT DTF tumours compared S45F DTF tumours. The effect modification 
between tumour size and mutation type suggest that tumour size is an important mediator 
for recurrence.
Conclusions
Primary sporadic DTFs harbouring a CTNNB1 S45F mutation have a higher risk of 
recurrence after surgery compared to T41A, S45P and WT DTF, but this association appears 
to be mediated by tumour size.
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Introduction
Desmoid-type fibromatosis (DTF) was first described 185 years ago by MacFarlane, 
and it was named desmoid in 1838 by Müller who referred to the Greek word “desmos”, 
meaning “a tendon like structure” 1, 2. Ever since, the understanding of this non-
metastasizing and histologically benign tumour has grown remarkably 3. Its potential to 
arise in musculoaponeurotic structures at virtually any body site and to invade surrounding 
structures poses therapeutic challenges. A histological biopsy, with nuclear ß-catenin 
staining, can confirm the diagnosis 4. In recent years, there has been a tendency for an 
active surveillance approach in asymptomatic patients and several prospective clinical trials 
(NCT02547831, Italy, NTR 4714, the Netherlands, and NCT01801176, France) are conducted 
to evaluate the safety of this approach 5-9. For progressive patients, surgical resection, 
isolated limb perfusion, radiotherapy and systemic therapy are available treatment options 
10. The variable growth behaviour with the possibility of tumour progression, growth arrest, 
or regression without treatment, makes this tumour unpredictable 5, 11, 12. Local recurrence 
after surgery, especially in case of tumours located in the extremities, the head/neck region 
and intra-abdominal, occur frequently 13, 14.
The genetic roots of DTF have been extensively studied 15. Desmoid tumours can occur 
as part of the inherited condition Familial Adenomatous Polyposis (FAP) and the FAP 
subtype; Gardner’s syndrome 16. Both conditions are associated with mutations found in the 
adenomatous polyposis coli gene on chromosome 5, and are known for the development of 
hundreds of pre-malignant colonic polyps. The development of mainly intra-abdominal DTF 
tumours is one of the associated manifestations, with a cumulative lifetime risk reaching 
21% 17, 18. Both syndromes will not be further discussed in this meta-analysis since the origin 
and clinical course of these diseases and the DTF tumours for which they predispose, differ 
from the sporadic variant of DTF. The sporadic variant is associated with extra-abdominal or 
abdominal wall desmoid tumours and finds its origin in the CTNNB1 (ß-catenin) gene 15, 19-22. 
β-catenin is involved in several downstream signaling pathways, functions as a transcriptional 
activator and is involved in cell-cell adhesion 19. The mutations are located on exon 3, causing 
mostly the following amino acid changes: T41A, S45F and S45P 19, 23. The remainder of 
tumours, less than 5%, that lack a mutation in the CTNNB1 gene, and of which the underlying 
genetic aberrations are not entirely clear yet, are called wild-types (WT) 15.
The use of the CTNNB1 mutation as a prognostic factor for recurrence after resection has 
been the subject of several studies. Some studies report that S45F-mutated DTF tumours 
exhibit a higher recurrence rate after primary resection than WT or other CTNNB1-mutated 
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tumours 19, 22-24. However, others report conflicting results and could not reveal an impact 
of specific CTNNB1 mutations on outcome 20, 25. These contradictory results are almost 
certainly due to the fact that these are relatively small retrospective studies including 
heterogeneous patient cohorts, which hinders the assessment of the true prognostic value 
of specific CTNNB1 mutations on outcome. Because the insight into prognostic factors 
can be crucial to come to a more personalized treatment approach for DTF patients who 
undergo a resection, we performed a meta-analysis using individual patient data (IPD) to 
study the impact of the CTNNB1 mutation on the risk of local recurrence in a large series 
of sporadic DTF patients. The hypothesis is that S45F mutated DTF tumours have a higher 
risk of local recurrence than WT or other CTNNB1-mutated DTF tumours. The objective 
of this meta-analysis with IPD is to evaluate the impact of the CTNNB1 mutation type on 
recurrence and recurrence-free survival (RFS) in adult patients with primary DTF tumours 
undergoing surgical resection alone.
Materials and methods
Protocol and registration
This study was approved by the local Medical Ethics Committee of the Erasmus Medical 
Center (MC) (MEC-2018-1386) Rotterdam, the Netherlands. The protocol of this meta-
analysis was registered on PROSPERO (CRD42018100653) and can be accessed at www.
crd.york.ac.uk/PROSPERO 26.
Information sources
A systematic literature search was performed by an Erasmus MC librarian expert on June 
6th, 2018. The following databases were used for the search: Embase.com, Medline Ovid, 
Web of science, Cochrane Central, Psych INFO Ovid and Google Scholar. Duplicated 
records were removed. No data or language filters were applied. The search strategy is 
provided in Supplemental Table 1.
Eligibility criteria
Studies with surgically treated sporadic DTF as a main subject were included. Papers 
describing follow-up, risk of recurrence, or recurrence-free survival (RFS) in primary DTF 
tumours with known CTNNB1 mutational type were included for this meta-analysis. The 
flowchart depicting the study selection procedure is available in Supplemental Table 2.
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Study selection
Two independent review authors (M.J.M.T. and M.R.) assessed the retrieved articles of 
the search for potential inclusion by reviewing title and abstract. Next, full articles were 
evaluated according to the predetermined inclusion and exclusion criteria for this meta-
analysis (listed in Supplemental Table 3).
Assessment of study quality and risk of bias
The Oxford levels of Evidence (Oxford Centre for Evidence Based Medicine) were used 
to assess the quality of included articles 27. The quality of included studies was assessed 
using the Quality In Prognostic Studies (QUIPS) tool 28. This tool consists of six domains 
of potential biases: study participation, study attrition, prognostic factor measurement, 
outcome measurement, study confounding, statistical analysis and reporting, rated as “low”, 
“moderate”, or “high” risk of bias. When all domains were considered to be “low” or 
“moderate” risk of bias, the risk of bias was considered to be low. If one or more domains 
were rated as “high” risk of bias, it was considered to be a high risk of bias. Two authors 
scored the risk of bias (M.J.M.T. and M.R.) and resolved discrepancies by discussion.
Data collection process
Two authors (M.J.M.T. and M.R.) independently extracted clinical and genetic information 
from the full text using a predefined extraction sheet. Subsequent cross-checks were 
performed. Inconsistencies were discussed and resolved. Patient overlap was defined as “the 
description of a cohort from one institute with overlapping time periods”. In the latter case, 
the largest cohort was included and IPD was requested from the corresponding author.
Data items
For each eligible article, the corresponding authors were contacted via email to retrieve 
the IPD. They were asked to provide the data either in a template database or by providing 
their database. Requested variables included: sex, date of birth, date of diagnosis, age at 
diagnosis, tumour site (extra-abdominal, intra-abdominal, abdominal wall), tumour site 
specified, tumour size, treatment type (active surveillance, surgery, radiotherapy, systemic 
therapy, or combination therapy), date of surgery, resection margin status, presentation 
(primary or recurrent tumour), FAP status, CTNNB1 mutation (WT, T41A, S45F, S45P or 
other), recurrence (yes or no), manner of identifying the recurrent tumour (radiological and/
or pathological confirmation), date of recurrence on radiology and/or pathology, date of last 
follow-up, vital status (death from disease, death from other cause, alive without evidence of 
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disease, alive with evidence of disease, unknown), date of death, date of the last update of 
the database. Studies for which IPD was not provided were excluded from this analysis.
Inclusion of patients using individual patient data
Inclusion criteria for individual patients to be selected included: primary DTF tumour, age 
above eighteen years at diagnosis, treated with surgery alone, and known CTNNB1 mutation. 
Patients receiving neoadjuvant or adjuvant treatment, patients with rare CTNNB1 mutations, 
patients with intra-abdominal tumours or FAP, patients younger than 18 years, patients with 
missing data about recurrence, and patients with unknown CTNNB1 mutation type were 
excluded from the analysis (Supplemental Table 2). With respect to tumour sites, all papers 
applied different definitions for tumour sites. For data synthesis the following categories of 
tumour sites were applied: trunk/back (including the following terms: trunk, trunk superficial, 
abdominal wall, rectus abdominis, chest aperture, chest wall, flank, back, dorsal, prevertebral, 
scapular area, vertebra), head and neck (including the following terms: head/neck, neck, 
cervical) and extremity (including the following terms: extremity, upper extremity distal, 
upper extremity proximal, ulna, arm, elbow, shoulder, axilla, groin, inguinal, buttock, 
gluteal, calf, knee, lower leg, leg, popliteal, thigh, lower extremity proximal, lower extremity 
distal). One study failed to specify the extra-abdominal tumour site and these patients were 
categorized as having extra-abdominal DTF not specified (NS).
In case the date of surgery was provided, age was calculated using date of birth and date 
of surgery. In case only the date of birth was provided, age was calculated using the date 
of birth and the date of diagnosis. In case age was provided in the cohort, it was defined 
in almost all cases as “age at surgery”. The median and mean age in years, the standard 
deviation (SD), and the interquartile range (IQR) were calculated for the total group and 
per cohort.
Tumour size was obtained from the provided databases; however, specifics on how this 
variable was measured were lacking for every cohort. A single measurement of tumour 
size reported was assumed to be the largest diameter of the tumour. In case tumour size 
was given in multiple dimensions, the largest tumour size was used. All tumour sizes were 
converted into millimetres (mm). The mean tumour size (in mm), SD, median and IQR 
were calculated for the total group and per cohort. In case of non-normal distribution, log 
transformed values were used. Additionally, the percentiles (25th, 50th, and 75th) were used 
to create age and tumour size categories.
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R0 resection was assumed in case the surgical margin was provided as “0”, “R0” or 
“clear”. R1 resection was assumed in case the surgical margin was provided as a “1”, 
or “involvement”. In cases with “2”, R2 resection was assumed and these patients were 
excluded from the analysis. Cases with unknown resection margin, stated as “not applicable” 
(NA), “unknown”, “Rx” or “999” were marked as unknown.
RFS was calculated using the date of surgery and the date of recurrence. In case the date 
of surgery was not provided, the date of diagnosis and the date of recurrence were used 
to calculate this variable as we assumed that most patients underwent surgery within two 
months after diagnosis. End of follow-up was considered as “last date of follow-up”, or 
“date life or death”.
IPD integrity
Data of individual patients were not subjected to data checking since cohorts were from 
various countries and often included patients from various hospitals due to the rarity of 
DTF. Data integrity was checked by comparing published articles with shared databases 
containing data of individual patients.
Statistical analysis
An one-stage approach was used for this meta-analysis with IPD. All variables were collected 
in a single database. Categorical variables are summarized as frequencies and corresponding 
percentages. Continuous variables are summarized as mean values with SD or as median 
with IQR. Analysis of variance and the chi-square test were used to evaluate the associations 
between the variables tumour size, tumour site, sex, mutation type and cohort.
The Kaplan-Meier method was used to calculate RFS, which was defined as the time 
between the date of surgery (or the date of diagnosis in case the date of surgery was not 
available) and the date of recurrence (or the end of follow-up).
Univariable and multivariable Cox proportional hazards analyses were performed to assess 
the association between the outcome (recurrence) and the independent variables (age, sex, 
mutation type, tumour site, tumour size [log-transformed], resection margin status and cohort). 
The proportional hazards assumption was tested for each independent variable by including an 
interaction effect of the independent variable with time since surgery in a Cox regression with 
time-dependent covariates. In case of significance of the interaction effect, the proportional 
hazards assumption was considered not to be met and the variable was included as a stratification 
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variable. An interaction effect between tumour size and CTNNB1 mutation type was tested in 
the multivariable Cox model adjusting for age, sex, mutation type, tumour site and tumour size; 
subgroup analyses based on tumour size were considered in case of considerable interaction. 
Two-sided p < 0.05 was considered statistically significant. SPSS Statistics (version 24) was used 
for all statistical analyses (IBM, Armonk, New York, USA).
Results
Study selection and study characteristics
Results of the search strategy are presented in the flowchart provided in Supplemental 
Table 2. A total of 47 articles were screened based on full text for eligibility. Studies 
were excluded for the following reasons: describing a pediatric cohort (n = 1), no CTNNB1 
mutation type data available (n = 14), no full text available (n = 3), conference abstract 
(n = 1), no recurrence data described (n = 6), no DTF as main subject (n = 1) and a review 
article (n = 3). Based on the origin of the patient cohort, eight studies had to be excluded 
for describing patient sets having a large overlap with series already published 19, 24, 25, 29-33. 
The papers describing the largest cohort were included to request the IPD. From others we 
were not able to receive the IPD 15, 34, 35. All included articles concerned retrospective cohort 
studies and received a score of 2b at the Oxford Levels of Evidence 201127. The QUIPS tool 
was used for assessing the risk of bias (Supplemental Table 4) 28. A detailed description 
of the published reports of the included studies can be found in Supplemental Table 5.
Individual patient data and clinical characteristics
A total of ten corresponding authors were contacted for exchanging IPD. Seven out of ten 
authors were willing to share the data. Data from individual patients were provided in a 
cohort template (n = 1), a database containing a selection of patients (n = 2) or by sharing 
the entire database (n = 4), and the cohorts were analysed by one author (M.J.M.T.). Patients 
were screened using the aforementioned inclusion and exclusion criteria for IPD, leaving 
a total number of surgically treated adult patients with primary DTF tumours of 329. The 
majority of the patients were female (n = 247, 75.1%) with a median age of 38 years (IQR: 
31-50 years), and the most common tumour site was the trunk/back (n = 194, 59%). The 
majority (n = 154, 46.8%) of patients had a CTNNB1 T41A mutated DTF tumour. Other 
clinical characteristics are summarized in Table 1. Missing values included unknown 
resection margin status for 18 (5.5%) patients, missing tumour size (in mm) for 7 patients 
(2.1%), and an extra-abdominal tumour site which was not further specified for 49 patients 
(14.9%). The latter was included as separate category for the variable tumour site.
7
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Follow-up and recurrence
The median follow-up time was 49 months (IQR: 21-94 months). Of 329 patients, 83 patients 
(25.2%) experienced a recurrence. Of these 83 patients, the median time to recurrence was 
16 months (IQR: 10-31 months) and the mean time to recurrence was 26 months (SD: 30 
months). Table 2 summarizes the number and corresponding frequencies of local tumour 
recurrence according to the CTNNB1 mutation type.
Table 2. Cross-tabulation of recurrence and CTNNB1 mutation type
CTNNB1 mutation n S45F T41A S45P WT
No recurrence 246 (74.8%) 38 (58%) 115 (75%) 20 (83%) 73 (86%)
Recurrence 83 (25.2%) 28 (42%) 39 (25%) 4 (17%) 12 (14%)
Total 329 66 154 24 85
WT, wild-type
Survival
There was a statistically significant (p = 0.019) violation of the proportional hazards assumption 
for the variable cohort in the multivariable Cox regression, suggesting that baseline hazards 
differed between studies. Therefore cohort was used as a stratification variable in the Kaplan-
Meier analysis and in the univariable and multivariable Cox regression models. Supplemental 
Figure 1 shows the Kaplan-Meier survival curves with cohort as a stratification variable.
Univariable Cox regression models
In the univariable Cox regression models, CTNNB1 mutation type, tumour site, and tumour 
size (log-transformed) were significant prognostic factors for local tumour recurrence after 
surgical treatment (Table 3).
Multivariable Cox regression models
In the first multivariable analysis, resection margin status was left out to reduce model 
complexity. Since none of the included cohorts indicated tumour size as a prognostic factor, 
the first multivariable model was only adjusted for sex, age, tumour site, and CTNNB1 
mutation, stratified by cohort. In this multivariable analysis, the S45P mutation and WT 
DTF were significantly less likely to recur compared to S45F mutated DTF with a hazard 
ratio (HR) of 0.32 (95% CI: 0.11-0.97), p = 0.043 and a HR of 0.34 (95% CI: 0.17-0.69), 
p = 0.003, respectively. A tumour located in the extremities was shown to be an adverse 
prognostic factor with a HR of 4.09 (95% CI: 2.11-7.92), p < 0.001 compared to trunk/back. 
The results are displayed in Table 4.
7
146460_Timbergen,Milea_BNW-def.indd   195 25-11-2020   08:21
196
Table 3. Univariable Cox proportional hazards regression model for recurrence
Univariable analysis a
Variable n HR (95% CI) p-value
Sex 0.290
Female 247 1.00 (reference) -
Men 82 1.31 (0.80-2.14) 0.290
Age 288 0.99 (0.97-1.01) 0.190
Mutation type 0.006
S45F 66 1.00 (reference) -
T41A 154 0.64 (0.39-1.06) 0.081
S45P 24 0.30 (0.10-0.86) 0.026
WT 85 0.34 (0.17-0.68) 0.002
Tumour site <0.001
Trunk/back 194 1.00 (reference) -
Head/neck 9 2.53 (0.54-11.8) 0.236
Extremity 77 3.81 (1.98-7.35) <0.001
EA NS 49 2.70 (1.33-5.46) 0.006
Tumour size in mm b 283 1.69 (1.16-2.47) 0.007
Resection margin status 0.170
-R0 185 1.00 (reference)
R1 126 1.38 (0.87-2.18) 0.170
HR, hazard ratio; CI, confidence interval; WT, wild-type; EA NS, extra-abdominal not specified
a Cohort was used as a stratification variable due to a violation of the proportional hazards assumption (p = 0.019)
b Used as a log transformed value
Tumour size
Despite the fact that none of the included studies described tumour size as a prognostic 
factor, a significant p-value for tumour size (log-transformed) was found in the univariable 
analysis. To gain more insight into this variable, we tested with an analysis of variance 
whether there were differences in tumour size (as a log transformed variable) between the 
cohorts and we found a statistically significant difference (p < 0.001). The cohort from 
Van Broekhoven et al. and Mussi et al. contained smaller tumours. Next, we investigated 
whether the tumour sizes differed between the various mutation groups and found a 
statistically significant difference (p = 0.001) in tumour size between mutation groups. 
From this analysis we concluded that tumours harbouring a S45F and S45P mutation were 
larger compared to T41A and WT tumours. Additionally, we looked whether the tumour 
size differed between the tumour sites, but this difference was not statistically significant 
(p = 0.392). No significant association could be found between tumour site and CTNNB1 
mutation type (p = 0.261), and between mutation type and sex (p = 0.643), using the chi-
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square test. Taken together these findings indicated an important association between 
tumour size and CTNNB1 mutation and led to the development of a second multivariable 
model (II) including tumour size as a continuous, log transformed variable. This model 
led to non-significant results for the association between CTNNB1 mutation and recurrence 
(p = 0.082). The results of both multivariable analyses are displayed in Table 4.
Table 4. Multivariable Cox proportional hazards regression model for recurrence
Multivariable analysis I a Multivariable analysis II a with 
additional correction for tumour size
Variable n HR (95% CI) p-value n HR (95% CI) p-value
Sex 0.434 0.482
Female 247 1.00 (reference) - 242 1.00 (reference)
Men 82 1.23 (0.73-2.06) 0.434 80 1.21 (0.71-2.04) 0.482
Age 288 0.99 (0.98-1.01) 0.272 283 0.99 (0.98-1.01) 0.405
Mutation type 0.011 0.082
S45F 66 1.00 (reference) - 61 1.00 (reference) -
T41A 154 0.70 (0.42-1.17) 0.178 153 0.83 (0.48-1.42) 0.490
S45P 24 0.32 (0.11-0.97) 0.043 24 0.37 (0.12-1.14) 0.084
WT 85 0.34 (0.17-0.69) 0.003 84 0.44 (0.21-0.92) 0.029
Tumour site <0.001 <0.001
Trunk/back 194 1.00 (reference) - 192 1.00 (reference) -
Head/neck 9 1.67 (0.33-8.45) 0.534 8 1.60 (0.31-8.34) 0.581
Extremity 77 4.09 (2.11-7.92) <0.001 77 4.15 (2.14-8.05) <0.001
EA NS 49 2.42 (1.18-4.95) 0.016 45 2.04 (0.97-4.31) 0.061
Tumour size in mm b - - - 283 1.53 (1.03-2.280) 0.034
HR, hazard ratio; CI, confidence interval; WT, wild-type; EA NS, extra-abdominal not specified
a Cohort was used as a stratification variable due to a violation of the proportional hazards assumption(p = 0.019)
b Used as a log transformed value
To examine the impact of tumour size on recurrence, we tested whether there was an 
effect modification of tumour size and mutation type and found a significant effect 
modification (p interaction = 0.09) between those variables, adjusting for mutation, tumour 
size, tumour site, sex and age. To account for potential effect modification, we used 
the median tumour size (55 mm) as a cut-off value to perform a subgroup analysis of 
multivariable analysis (Supplemental Table 6). Supplemental Figure 2 presents the 
combined estimated effect (in terms of HR) of tumour size and CTNNB1 mutation for 
the multivariable model for all patients with the interaction between tumour size (log-
transformed) and CTNNB1 mutation.
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Discussion
This meta-analysis uniquely combined the IPD of seven studies to determine the effect 
of the CTNNB1 mutation type on recurrence rate in a cohort of surgically-treated DTF 
patients, who did not receive any additional perioperative therapy for their primary tumour. 
Although active surveillance is advocated in asymptomatic patients, a substantial number 
of patients still receive surgical treatment for their DTF during their course of disease 10, 
36. Reported recurrence rates after surgical treatment remain high, between 20% and 68%, 
and highlight the need for prognostic factors to predict recurrence, to inform patients and 
to explore strategies to reduce recurrence risk in high risk groups 14, 24, 30, 37-39. Tumour site, 
age at onset, and CTNNB1 mutation type are most frequently mentioned as important 
prognostic factors 14, 40. Although several studies have reported that CTNNB1 mutation 
type had no prognostic value for recurrence compared to WT DTF, others have identified 
a correlation between the CTNNB1 S45F mutation and a higher risk of recurrence 15, 20, 24, 25, 
41, 42. This study showed that CTNNB1 mutation type is indeed relevant for recurrence, and 
the observed risk of recurrence was highest for S45F tumours, although the association 
was not statistically significant (p = 0.082). We also found that tumour size is a mediator 
for recurrence rate. The findings of this study are remarkable since none of the included 
studies found a significant correlation between recurrence and tumour size, and did not 
identify size as a prognostic marker recurrence 20, 22, 41-43. However, others did report that 
tumour size is an independent predictor of recurrence (Crago et al., p = 0.004) or event 
free survival (Huang et al., p = 0.006), but they did not adjust for CTNNB1 mutation type44, 
45. Other larger series, not included in this meta-analysis because they did not meet our 
inclusion criteria or used overlapping patient cohorts, did not find a correlation between 
tumour size and progression free survival 31, time to recurrence 19, mutation type 34, and 
progression or recurrence 30. Although the variable tumour size is prone to inter-observer 
and intra-observer variability, the current multivariable model suggests that both tumour 
size and mutation type should be considered as predictors for recurrence in patients with 
primary, extra-abdominal, surgically treated DTF.
Tumour site, especially the extremity, is reported as a significant prognostic factor for 
recurrence in the univariable analysis of multiple studies. However, this statement often does 
not hold in the multivariable analysis 19, 24, 37, 45. These conflicting results could be explained 
by the fact that most of these studies comprise relatively small case series or cohort studies 
and include patients who received neoadjuvant/adjuvant chemotherapy, or radiotherapy, 
which influences the recurrence rates and impairs the assessments of the true prognostic 
value of these parameters 46. The current study shows that a tumour located in one of the 
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extremities, is an adverse prognostic factor (p < 0.001) for recurrence compared to tumours 
located on the trunk/back.
Females represented the majority of patients in the current cohort (75%). This is in line with 
previous reports describing nationwide cohorts by Broekhoven et al.47 (71.3% females) and 
Penel et al. 36 (72.6% females). In the current study, no statistically significant association 
between sex and mutation type (p = 0.643) could be found. Additionally univariable analysis 
did not identify sex as a prognostic marker for recurrence (p = 0.290).
The added value and the strength of the current study is the use of individual patient data, 
which created a relatively large cohort of patients that receive the same treatment for their 
primary DTF, but there are some limitations to take into account. The use of IPD demanded 
the formation of new variables, for example, T0 which was defined as date of surgery. 
Unfortunately, this variable was not available for all patients and was solved by the use of 
“date of diagnosis” in a small part of patients. Another example of a new variable which 
had to be created was tumour site. Although a statistically significant result was found 
in both univariable and multivariable analyses, one should keep in mind that there is a 
relatively large group of patients having an extra-abdominally located tumour without any 
further specification (extra-abdominal NS). A major limitation, considering the present 
knowledge, is the relatively large number of patients with WT tumours in the current 
cohort. Multiple studies report that CTNNB1 mutations are not always detected by Sanger 
sequencing due to the low frequency of mutant alleles and the relatively low sensitivity of 
the technique. This can lead to incorrect allocation to the WT group while having CTNNB1 
or other, novel, mutations 15, 48, 49. The CTNNB1 genotyping protocols, used in the included 
studies (Supplemental Table 5), focused on the presence of a CTNNB1 mutation in exon 3 
and provided no information about the presence of other mutations that may be present in 
the tumours. Another limitation is the heterogeneity of included studies which differed in 
primary outcome and differences in follow-up procedures, possibly leading to missing a 
certain number of recurrent tumours. This is also reflected by the variable recurrence rates 
reported by the included studies. Moreover, the rarity of DTF is reflected by the limited 
number of available studies with available CTNNB1 type assessing recurrence, and led to 
the inclusion of studies with a high risk of bias. As the aim of the current study was to gain 
insight into the prognostic values of the CTNNB1 mutation, every study, regardless of their 
sample size, was included in this meta-analysis. Several studies could not be included in 
this meta-analysis due to potential cohort overlap and due to the impossibility to acquire the 
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IPD 15, 19, 23-25, 29-35. Although there might be a selection, this is the largest cohort describing 
the correlation between CTNNB1 mutation type and recurrence risk to date.
Despite these limitations, using the IPD of several international cohorts created a large 
pooled cohort of patient that received the same treatment, unique for a rare disease like DTF. 
The pooled data provided new insights into the prognostic value of the CTNNB1 mutation 
type in predicting local recurrence in surgically treated DTF patients, with tumour size as 
an important mediator. Currently, there are no prospective studies examining the value of 
adjuvant therapy after surgical resection of DTF. Future studies investigating the role of 
adjuvant therapy in patients with an S45F mutation, in whom re-resection would result in 
unacceptable morbidity, are recommended. Additionally, mechanistic studies, exploring 
how the different CTNNB1 mutations affect DTF tumour biology are warranted, especially 
since an increasing number of patients is being treated with active surveillance. Data from 
the three studies, that are currently investigating the active surveillance approach, will give 
valuable information regarding the association between CTNNB1 mutation type and DTF 
tumour behaviour.
Conclusions
Tumour size and mutation type should be considered as predictors for recurrence in patients 
with extra-abdominal, surgically treated primary sporadic DTF. Ongoing studies about 
upfront active surveillance, are evaluating whether mutation type can predict the risk of 
progression, to anticipate the need for treatment in patients who received an initial active 
surveillance approach. If the predictive value of mutation type for the risk of progression is 
proven, mutation type should be included in the algorithm for managing DTF.
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Supplementary Table 1. Electronic search, Embase.com, conducted on June 6, 2018
(‘desmoid tumor’/de OR ‘desmoid type fibromatosis’/de OR ‘desmoid fibromatosis’/de OR ‘abdominal 
fibromatosis’/de OR (desmoid* OR ((fibromatos*) NEAR/3 (aggressive OR abdom* OR extra*))):ab,ti) 
AND (‘mutation’/exp OR ‘beta catenin’/de OR ‘ctnnb1 gene’/de OR ‘ctnnb1 protein human’/de OR ‘ctnnb1 
protein’/de OR ‘gene frequency’/de OR ‘molecular genetics’/exp OR ‘molecular diagnosis’/de OR ‘DNA 
microarray’/de OR ‘tissue microarray’/de OR ‘microarray analysis’/de OR ‘nucleotide sequence’/de OR ‘DNA 
sequence’/de OR ‘tumor marker’/de OR ‘biological marker’/de OR ‘genetic analysis’/exp OR ‘threonine’/de 
OR ‘phenylalanine’/de OR ‘alanine’/de OR ‘proline’/de OR ‘serine’/de OR (mutation* OR gene OR genes 
OR genetic* OR genotyp* OR molecular OR biomarker* OR ((tumor OR tumour OR biologic*) NEXT/1 
(marker*)) OR ‘beta catenin’ OR ‘b-catenin’ OR ‘β-catenin’ OR ctnnb1 OR ((tissue) NEXT/1 (array OR 
analys*)) OR microarray* OR DNA OR ‘nucleic acid’ OR RNA OR S45f OR T41A OR S45P OR threonin* 
OR phenylalanin* OR alanine* OR proline* OR serine*):ab,ti) NOT ([animals]/lim NOT [humans]/lim) 
NOT (‘Conference Abstract’)
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Supplementary Table 2. Flowchart of the systematic literature search conducted on June 6th, 2018 and 
study selection
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a Reason for exclusion n = 29
n = 1 paediatric cohort
n = 14 no CTNNB1 mutation type data available
n = 3 no full text available
n = 1 conference abstract
n = 6 no recurrence data described
n = 1 no DTF as a main subject
n = 3 review, no original article
b Number of eligible studies for which IPD were not sought (give reasons) n=8
n = 8 overlapping databases (defined as using a cohort from the same institute(s))
c Number participants for whom no data were provided
n = 385 patientsw
• n = 270 corresponding authors not willing to participate
• n = 115 unknown reasons, possible exclusion by the corresponding authors due to our inclusion criteria
d Number of studies for which IPD were not provided
n = 3 corresponding authors not willing to participate
e Number participants excluded n = 350
Colombo et al.23 (n = 179)
Total excluded patients: n = 68
Total included patients: n = 111
n = 32 intra-abdominal DTF
n = 29 other treatment than surgery alone
n = 7 age <18 years
Mussi et al.41 (n=25)
Total excluded patients: n = 8
Total included patients: n = 17
n = 1 other treatment than surgery alone
n = 4 wait and see only
n = 1 R2 resection
n = 2 recurrent tumours
van Broekhoven et al.22 (n = 101)
Total excluded patients: n = 54
Total included patients: n = 47
n = 40 adjuvant radiotherapy
n = 4 other treatment than surgery alone
n = 6 age <18 years
n = 1 other mutation
n = 3 intra-abdominal DTF
Mullen et al.20 (n = 115)
Total excluded patients: n = 52
Total included patients: n = 63
n = 8 pre-/ post-operative radiotherapy
n = 2 pre-/ post-operative photon therapy
n = 13 intra-abdominal DTF
n = 10 systemic treatment
n = 2 second gross resection
n = 1 other mutation
n = 6 age <18 years
n = 10 recurrent tumours
Nishida et al.42 (n = 11)
Total excluded patients: n = 8
Total included patients: n = 3
n = 8 other treatment than surgery alone
Salas et al.49 (n = 89)
Total excluded patients n = 50
Total included patients: n = 39
n = 1 other mutation
n = 14 age <18 years
n = 1 recurrence unknown
n = 31 recurrent tumours
n = 3 unknown tumour status
Kim et al.43 (n = 159)
Total excluded patients: n = 110
Total included patients: n = 49
n = 20 other treatment than surgery alone
n = 10 age <18 years
n = 6 other mutation
n = 15 intra-abdominal DTF
n = 1 unknown tumour status
n = 18 recurrent tumours
n = 40 other diagnosis (Dupuytren’s contracture, plantar 
fibromatosis)
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Supplementary Table 3. Inclusion and exclusion criteria of the literature search, applied at study level
Inclusion criteria Exclusion criteria
• Human subjects
• Studies only reporting data on patients with a 
histologically proven primary DTF
• Studies with at least one participant with age ≥ 
18 years.
• Studies with at least one participant having extra-
abdominal or abdominal-wall DTF
• Studies with at least one participant who received 
only surgical treatment for their DTF
• Studies with at least one participant from which 
the CTNNB1 (β-catenin) mutation type is known.
• Studies that report recurrence, recurrence rate, 
follow-up time, recurrence free survival, event-
free survival, disease free-survival, report of a 
local recurrence rate, progression free survival, 
local recurrence rate, overall recurrence rate, and 
overall survival time.
• Non-human models
• Studies reporting about familial adenomatous 
polyposis exclusively
• Studies reporting about intra-abdominal 
(mesentery) fibromatosis exclusively
• Studies reporting about surgery in combination 
with other treatments exclusively
• Studies describing a pediatric cohort (solely 
patients of 18 years and younger)
DTF, desmoid-type fibromatosis























Moderate Moderate Moderate Low Low Low Low risk
Salas
et al. 49
High High Low Low High Low High risk
Nishida
et al. 42
High Moderate Moderate Low Low Low High risk
Mullen
et al. 20
Low Low Low Low Low Low Low risk
Mussi
et al. 41
Low Moderate Moderate Low High Low High risk
Van Broek-
hoven et al. 22
Low Moderate High Low Low Low High risk
Colombo et al. 23 Low Moderate Moderate Low Moderate Low Low risk
When all domains were rated as low or moderate risk, a study was considered to be of low risk of bias
When at least 1 domain was rated as high risk, a study was considered to be of high risk of bias
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Supplementary Table 6. Cox proportional hazards regression multivariable analysis for recurrence, 
categorized according to tumour size




Female 1.00 (reference) -
Male 1.81 (0.72-4.48) 0.203
Age 0.98 (0.96-1.01) 0.177
Mutation type 0.020
S45F 1.00 (reference) -
T41A 0.32 (0.12-0.87) 0.026
S45P 0.07 (0.01-0.77) 0.030
WT 0.31 (0.11-0.92) 0.035
Tumour site 0.107
Trunk / back 1.00 (reference) -
Head / neck 11 (1.44-86.91) 0.021
Extremity 1.64 (0.55-4.92) 0.375
EA NS 1.9 (0.53-6.89) 0.324






Male 1.08 (0.50-2.33) 0.853
Age 0.99 (0.97-1.01) 0.390
Mutation type 0.294
S45F 1.00 (reference)
T41A 1.46 (0.69-3.13) 0.326
S45P 0.76 (0.20-2.87) 0.687
WT 0.56 (0.18-1.73) 0.316
Tumour site 0.001
Trunk / back 1.00 (reference)
Head / neck 0 (0) 0.982
Extremity 6.25 (2.43-16.07) <0.001
EA NS 2.06 (0.81-5.29) 0.132
Tumour size b 1.80 (0.77-4.20) 0.173
HR, hazard ratio; CI, confidence interval; WT, wild-type; EA NS, extra-abdominal not specified
a Cohort was used as a stratification variable due to a violation of the proportional hazards assumption (p=0.019)
b Used as a log transformed value
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Supplementary Figure 1. Recurrence-free survival curve per included cohort calculated with the log rank test.
Supplementary Figure 2. Estimated Hazard Ratios per CTNNB1 mutation type for the  total effect of 
tumour size in mm based on the multivariable model including the interaction between tumour size (log 
transformed) and CTNNB1 mutation.
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Identification and assessment of 
health related quality of life issues
in patients with sporadic desmoid-
type fibromatosis: A literature 
review and focus group study
Milea J.M. Timbergen, Lonneke V. van de Poll-Franse, Dirk J. Grünhagen, 
Winette T. van der Graaf, Stefan Sleijfer, Cornelis Verhoef, Olga Husson




Sporadic desmoid-type fibromatosis (DTF) is a rare, chronic, non-metastasizing, disease of 
the soft tissues. It is characterised by local invasive and unpredictable growth behaviour and 
a high propensity of local recurrence after surgery thereby often having a great impact on 
health related quality of life (HRQoL). This study aims to review currently used HRQoL-
measures and to asses HRQoL-issues among DTF patients.
Materials and methods
A mixed methods methodology was used consisting of (1) a systematic literature review, 
according to the PRISMA guidelines (2009), using search terms related to sporadic DTF 
and HRQoL in commonly used databases (e.g., Embase, Medline Ovid, Web of science, 
Cochrane Central, Psyc Info, and Google scholar), to provide an overview of measures 
previously used to evaluate HRQoL among DTF patients; (2) focus groups to gain insight 
into HRQoL issues experienced by DTF patients.
Results
The search strategy identified thirteen articles reporting HRQoL-measures using a wide 
variety of cancer-specific HRQL tools, functional scores, symptom scales (e.g., NRS), and 
single-item outcomes (e.g., pain and functional impairment). No DTF specific HRQoL-tool 
was found. Qualitative analysis of three focus groups (6 males, 9 females) showed that 
participants emphasised the negative impact of DTF and/or its treatment on several HRQoL-
domains. Six themes were identified: 1) diagnosis, 2) treatment, 3) follow-up and recurrence, 
4) physical domain, 5) psychological and emotional domain and 6) social domain.
Conclusions
A DTF-specific HRQoL-tool and consensus regarding the preferred measurement tool 
among DTF patients is lacking. Our study indicates that HRQoL of DTF patients was 
negatively affected in several domains. A DTF-specific HRQoL-measure could improve 
our understanding of short- and long-term effects and, ideally, can be used in both clinic 
and for research purposes.
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Introduction
Desmoid-type fibromatosis (DTF) is a soft tissue tumour that arises from musculoaponeurotic 
structures. It is incapable of metastasizing and is often described as a benign tumour in 
clinical practice. However, due to its local aggressive behaviour and its known tendency of 
local recurrence after initial surgical resection, it is categorized as a borderline tumour 1. 
Desmoid-type fibromatosis is rare, with a reported incidence of 5.4 new cases per million 
persons per year in the Dutch population 2. Symptoms vary, depending on tumour location 
and size, and can be very severe. Roughly two types can be distinguished: sporadic DTF 
with extra-abdominal or abdominal wall tumour formation and familial adenomatous 
polyposis (FAP) related DTF with intra-abdominal tumour formation 3, 4.
The aetiology of sporadic DTF remains doubtful although a history of trauma has been 
reported, as well as specific hormonal status (such as pregnancy) and genetic predisposition 
5-8. With local recurrence rates up to 50%, potential treatment benefits and adverse effects of 
treatment should be considered carefully 9-11. Nowadays, active surveillance is recommended 
in asymptomatic patients, while treatment options for symptomatic patients include 
surgical resection, radiation therapy, and systemic therapy 12-16. Determination of treatment 
effectiveness is currently mainly evaluated by tumour size or recurrence free survival 11, 17, 
18. Although such end-points can be appropriate in malignant diseases, the unpredictable 
growth behaviour including spontaneous regression and the low mortality rate of sporadic 
DTF renders such outcomes less appropriate for this borderline disease 16. Consequently, 
the question rises whether health related quality of life (HRQoL) assessment could be a 
more appropriate outcome measure in DTF 10, 14, 19, 20. The definition of HRQoL is ‘a patients’ 
evaluation of the impact of a health condition and its treatment on all relevant aspects of life’. 
Patient-reported outcome measures (PROMS) can be used to measure HRQoL with various 
purposes: as screening tools, as a method for identifying patient preferences, to guide 
clinicians for informed decision making, to improve patient-provider communication, and 
to assess the efficacy of treatments in the context of clinical trials 21. In DTF, few researchers 
have sought to understand patient’s perceptions on the disease, and HRQoL is not (yet) 
widely accepted as an appropriate outcome measure. The aim of this mixed-method study 
is to explore currently used HRQoL-tools and identify HRQoL-issues of DTF patients.
8




The literature review was conducted in accordance with the PRISMA guidelines 22. A 
systematic literature search with terms related to sporadic DTF and HRQoL (Supplemental 
Materials 1) was conducted by an expert research librarian on November 6th, 2017 to 
identify HRQoL-tools currently used among DTF patients. No language or publication 
limitations were applied. Used databases were Embase, Medline Ovid, Web of science, 
Cochrane Central, Psyc Info, and Google Scholar. The resulting publications were analysed 
using inclusion and exclusion criteria at two levels: title/ abstract (1) and full text (2) by two 
reviewers (MJMT and OH). Data from papers that met the inclusion criteria at full text 
level were extracted for final inclusion by one reviewer (MJMT) (Supplemental Materials 
2). Corresponding authors were contacted in case of lack of availability of full text, three 
authors granted our request. Variables that were identified in included papers were number 
of patients, number of patients for which PROMs were available, tumour location, treatment, 
PROM outcome pre-treatment, and PROM outcome post-treatment. The outcome of each 
study was reported according to the specific PROM used in the study.
Patient recruitment
To identify the HRQoL issues of DTF patients, focus group sessions were organised. Patients 
diagnosed with sporadic DTF were recruited from the Erasmus Medical Centre (MC) in 
Rotterdam, the Netherlands. As FAP-associated DTF patients are also confronted with many 
other issues compared to patients with sporadic DTF, these patients were excluded. Eligible 
patients were diagnosed with DTF, regardless of their stage of disease (e.g., pre-treatment 
or during follow-up), previous or current treatments and site of disease. Additionally, they 
had to be above the age of 18 at the time of the focus group and participation required 
sufficient Dutch language skills. Patients with a recent diagnosis of cancer were excluded 
since this diagnosis might influence their HRQoL. Potential participants were approached 
by telephone, with a maximum of four attempts to explain the study objectives and received 
a written invitation and information letter. In total, three focus groups were organised in 
July and August 2017; one with male participants, one with female participants and one 
mixed sex group. The decision to organize separate sessions for both sexes was based on 
the assumption that patients would be more likely to share personal experiences or feelings 
with the same sex. The third, mixed sex group was organized separately because of logistic 
reasons. The focus group sessions took place in the Erasmus MC. Written informed consent 
(including permission for making field notes and audio recording for anonymous processing) 
and background information was obtained at the start.
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Data collection
The focus group sessions were supervised by the first author (MJMT), a second independent 
researcher kept written records and was not actively involved in the discussions. A pre-prepared 
protocol, based on the protocol of Husson et al. 23 was used for guidance (Figure 1).
Figure 1. Focus group guideline
Opening question
• Can you introduce yourself by telling your name, age and place of residence and tell us shortly 
about the location of your DTF tumour, which treatments you had and what the current status is. 
(This question was asked in to every participant at the start of the focus group)
Transition questions
Moment of diagnosis
• Can you share your experience around the moment of diagnosis?
• Can you share your experience about the referral to this specialised centre?
• What kind of feelings did you experience when you were first diagnosed?
• How was the information about DTF in the first period?
• Can you remember the expectations that you had when you visited the specialist for the first time?
• How did your family and friends react? Did you need any support? Did you receive this support?
• Can you explain how you were informed about the treatment?
Symptoms
• Did you experience any problems on physical, emotional, social and/or financial level?
• How do / did you cope with your symptoms?
• Did you have to adjust your way of life? I yes, in what manner?
• Did you receive any support from your family and friends?
• How did you experience your contact with your treating specialist?
• How did you experience the professional support during the course of disease?
• How did you experience the amount of information about the disease and the treatment(s)?
Treatment
• Can you tell us what kind of treatment(s) you received?
• Can you tell us how the treatment(s) affected your life?
Work/ finances
• How did the disease effect your work and financial situation?
Key questions
• Which symptoms do you associate with your primary treatment(s)?
• Which symptoms do you experience during your follow-up?
• Which symptoms, caused by the desmoid tumour, do you experience on the long term?
• Which symptoms, caused by the desmoid tumour, have the most impact on your life?
Exit questions
• Can you describe your feelings when we are discussing your disease?
• Can you describe your feelings about this discussion?
8
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Participants received a brief introduction with the explanation of the study objectives and 
an opening question for introduction was answered by each participant. Next, pre-prepared 
exploratory questions developed specific for the objectives of this study were asked to 
encourage conversation and discussion. Transition questions were asked to explore several 
aspects of HRQoL-issues around the time of diagnosis, treatment and follow-up. The focus 
groups lasted 1.5-2 hours, and an exit question was used to terminate the focus group. 
Participants received an evaluation form and 15 euro gift certificate in order to express 
our appreciation for their participation Focus group sessions were audio recorded, and 
transcribed by the first author (MJMT) ATLAS.ti 8.0© (Scientific Software Development 
GmbH, Berlin, Germany) was used for generating codes for themes and subthemes. The 
field notes were used as complementary data to transcripts as they described non-verbal 
communication of participants. Data was ordered into relevant code terms and then 
categorised into themes by two researchers (MJMT and OH) and analysed independently. 
Consensus was reached through continuous discussion. Relevant quotes of focus group 
participants were selected to support findings.
Approval from the Medical Ethics Committee of Erasmus Medical Centre (MC) in 
Rotterdam, the Netherlands was obtained for this study (file number MEC-2017-269). All 
patients gave written informed consent before the start of the focus groups and patient’s 
anonymity and confidentiality were ensured throughout the study by the use of study codes 
replacing identifying information. Only the first author had direct access to the digital record 
of study codes and patient information.
Results
Literature review
A systematic literature search (Supplemental Materials 1) showed 3114 articles after 
deduplication. In total, 3067 articles were excluded based on title or abstract. Full-text 
reviewing, took place for the remaining 47 articles excluding another 34 articles (flow 
chart Supplemental Material 2). Thirteen articles, describing seven validated scoring 
systems were identified. No DTF-specific questionnaires were identified in this literature 
review (Table 1).
8
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The Disabilities of the Arm, Shoulder and Hand (DASH) score is a 30-item questionnaire 
designed to evaluate disability of the upper limb region by measuring symptoms and 
physical functions with 5 response options and higher scores reflecting greater disability 
24, 25, 36, 37. The Enneking/ Musculoskeletal Tumor Society (MSTS) score comprises six 
categories: pain, function and emotional acceptance of both lower and upper extremities, 
support, walking and gait of the lower extremities and hand positioning, dexterity and lifting 
ability in the upper extremity, for which patients have to assign values ranging from 0 to 
5 points. Higher values indicate better functioning 25-27, 38, 39. The European Organisation 
for Research and Treatment of Cancer quality of life questionnaire C30 (EORTC QLQ-
C30) is a 30-item, cancer-specific questionnaire designed for evaluating quality of life 
incorporating five functional scales, symptom scales and global health and quality of life 
scales 19, 40. The MD Anderson Symptom Inventory (MDASI) measures the severity of 13 
cancer-related symptoms experienced by the patient during the previous 24 hours. The 
score rates symptoms on an 11-point scale; higher scores reflect more severe symptoms 29, 
41. The (modified) Johnstone scale provides a functional grading system with grades ranging 
from 0 to 4, higher scores reflect fewer limitations 30, 42. The Numerical Rating Scale (NRS) 
is used for self-reporting subjective conditions, currently in use for several symptoms. 
Symptoms are rated on a 0 to 10 scale; higher scores reflect more severe symptoms 31, 32, 
43. The Toronto Extremity Salvage score (TESS) is internationally used for measuring 
functional outcome and physical disability in patients with extremity tumours undergoing 
limb preservation surgery. This questionnaire consists of 29 (upper extremity) or 30 (lower 
extremity) questions regarding daily activities. Each item is rated on a scale from 1-5, higher 
values represent better function 38, 44, 45.
Other identified measures and questionnaires included items related to functional 
impairment, pain and cosmetic outcome (Table 1.) 33-35.
Focus group
In total, 45 patients were approached to participate; 22 patients agreed to receive written 
information, 15 patients could not be reached by telephone. Reasons for refusal included 
not willing to participate in a group experience but willing to do a personal interview, not 
available at pre-set dates, language barrier or not willing to participate because of minimal 
symptoms. A total of 15 patients participated in the focus groups. The first group consisted 
of five female participants with a median age of 37 years (range: 25-60 years), the second 
group consisted of five male participants with a median age of 62 (range: 37-75 years), the 
third group was a mixed sex group with a median age of 37 years (range: 36-53 years). 
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Participants differed in age at diagnosis, education level and treatment (Table 2.). None of 
the participants knew another person with the same condition before the focus group. Most 
participants were treated surgically (n = 8) or received a conservative management (n = 4). 
Three participants received a combination of therapies. A minority of the participants 
sought support in the paramedic field (e.g., physiotherapist, occupational therapist, social 
worker, and dietician).
Table 2. Characteristics of fifteen focus group participants
Age in years at time of focus group














































Location of DTF Head / neck
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Table 2.  (continued)
Contact with health care 
professionals















Self-reported symptoms c Lump with obvious growth
Pain
Tumour complains during daily 
activities






Self-reported medical history c Surgery related desmoid
Desmoid related to hormonal status
6
3
a n = 1: surgical resection with post-operative radiotherapy, n = 1 surgical resection, radiotherapy and isolated 
limb perfusion (ILP) ; n = 1 surgical resection (with final amputation of the lower leg, radiotherapy, isolated limb 
perfusion, hormonal therapy, experimental chemotherapy.
b lymphatic therapy; c obtained during the focus group sessions as reported by the patients
Qualitative analysis
HRQoL-issues were categorised into six themes 1) diagnosis, 2) treatment, 3) follow-up 
and recurrence, 4) physical domain, 5) psychological and emotional domain and 6) social 
domain. The themes were further categorised into subthemes. An overview of themes, 
subthemes, key issues and quotes is provided in Table 3.
Diagnosis
Almost all participants reported feelings of uncertainty and anxiety of having cancer 
during the period of waiting on their final diagnosis. They described this as having a 
great impact on their overall life. Upon diagnosis, feelings of relief are described due 
to the borderline nature of this disease. Participants with more symptoms and a more 
aggressive clinical course of DTF mentioned being frustrated about underestimation of the 
consequences since the disease is categorised as a borderline tumour and can act in a more 
malignant way with sometimes severe sequelae compared to benign tumours. The opinion 
on receiving information about DTF varied amongst participants. Some participants felt 
they did not receive enough information from their treating physician, some participants 
searched for more information on internet or asked their general practitioner, and some 
deliberately did not search on the internet because of fear to find unpleasant information. 
Most participants agreed that the amount and depth of information they found in general was 
8
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not satisfying. This observation was substantiated by multiple questions from participants 
about DTF during the group sessions.
Treatment
Participants with minor symptoms and solely treated with surgery reported being glad 
or relieved that the tumour was removed as they had the feeling that it ‘did not belong to 
their body’. One participant with major symptoms from an intra-abdominal tumour felt 
that surgery was the only treatment option, but feared for a stoma or dying during surgery. 
Participants with a conservative management reported to be satisfied since they had minor 
symptoms and potentially mutilating surgery could be avoided.
Follow-up and recurrence
A common theme in the qualitative study was fear of recurrence or worries about the 
future and future health. Not all participants were correctly informed about the risk on 
local recurrence. Feelings of uncertainty remained present during follow-up because of 
the knowledge that the tumour may be able to recur. One participant with DTF localised in 
the lower extremity, reported struggle with weakness in the leg due to previous treatments, 
which made her fearful of the future.
Physical domain
The most common symptoms before diagnosis are described in Table 2. Complications 
of treatment included infection of the surgical wound, and severe neuropathic pain due to 
nerve damage. Residual issues after treatment regarded scars, being asymmetrical, having 
function restrictions, oedema, stiffness, lack of sensibility and muscle weakness. One 
participant used a wheelchair and crutches due to a lower leg amputation, another patient 
used an electric wheelchair due to severe neuropathic pain after being treated surgically. 
One participant reported that physical therapy was not offered to her, but in retrospect she 
would have appreciated it since she experiences weakness of the affected limb.
Emotional / psychological domain
Participants expressed that ‘they felt they did not have a choice’ and ‘they will face 
the situation as it comes’ and learned how to deal with their problems over time. Life-
style changes included minor adjustments because of functional limitations and major 
adjustments including movement to a ground floor apartment. One participant reported that 
DTF restricted her from having another child, which had a major impact on her family. One 
participant reported a low self-esteem and problems with body image due to scars. Another 
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participant reported the feeling that he missed out on starting a family because of extensive 
treatments which started at a young age. One participant was treated by a psychologist. 
Several participants stressed that they felt differently about life after diagnosis and stated 
to be more grateful for their life compared to the time before the diagnosis.
Social domain
Participants reported that DTF had influenced their working life, as they had to stop working 
temporarily after treatment. This period ranges from a couple of weeks to two years and in 
one case not being able to work at all. Participants reported that the uncertainty during the 
time of diagnosis and the fear of cancer influenced their family life. Several participants 
mentioned to downstage their problems since they did not want to be a burden to their 
families or they wanted to protect their loved ones. One participant reported that social 
relationships changed after the diagnosis. Some friendships became closer and some 
friendships had ended due to lack of support. She specifically mentioned that her friends 
paid less attention to her disease and health status because of the term ‘benign disease’ 
which implies minor disease related issues or short course of disease.
Discussion
With this study, we aimed to gain more insight in HRQoL-issues and currently used 
HRQoL-tools in the setting of DTF. The results of this study can be seen as the first step 
towards developing a disease specific HRQoL-tool that can be used in clinical practice or 
research. The literature review identified several non-disease specific HRQoL-tools; no 
tool currently exists that assesses all issues relevant for DTF patients. Functional scores 
like the DASH score 24, the Enneking score / MSTS 25-27, 38, the TESS38, and the Johnstone 
scale 30 are used for extremity diseases but are not suitable for patients who have sites of 
disease other than the extremities. Symptoms scores including the MDASI score 29 and the 
NRS 31, 32 are quite specific for measuring the severity of symptoms, and could be useful in 
combination with HRQoL-tools measuring issues like emotional or social wellbeing. The 
EORTC QLQ-C30 19 is designed to cover issues relevant for cancer patients and may be a 
good generic measure to be completed by an item list consisting of the key DTF-specific 
issues identified in our focus groups, in order to create a more holistic perspective of 
HRQoL-issues in patients with DTF.
The results of the literature review show that researchers are interested in measuring the 
effect of DTF and its treatment on functioning or pain, but no consensus exists with respect 
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to the preferred tool, as a DTF specific tool has not been developed yet. One could argue that 
a combination of the aforementioned scores could be sufficient to get a clear view of relevant 
issues of DTF patients. A downside to this might be that patients are exposed to a large 
number of questions, which could be non-relevant and give patients an additional burden. 
A carefully developed DTF-specific tool could be effective in measuring HRQoL.
There are limitations to the current systematic literature review. Since DTF is a rare 
soft tissue tumour, included studies comprise retrospective, small sized studies with low 
methodologic quality. Additionally, risk of bias could not be assessed properly.
To create a HRQoL-tool which is suitable for DTF patients and to achieve at least satisfying 
content validity, focus groups were used which encouraged participants to discuss their 
views on HRQoL-issues 46. Our focus group results suggest that patients with DTF often face 
problems with recognition and management because of the lack of diagnostic awareness, as 
a result of its rarity, and because of the striking discrepancy between its benign histological 
appearance and its local aggressive behaviour. This study identified key issues in six themes; 
1) diagnosis, 2) treatment, 3) follow-up and recurrence, 4) physical domain, 5) psychological 
and emotional domain and 6) social domain, which will be the basis of a future DTF-
specific tool. The first three themes (diagnosis, treatment and follow-up) can be clustered 
as ‘the process of healthcare’ and the last three themes (physical domain, psychological and 
emotional domain and social domain) can be clustered as ‘symptoms and function’. We do 
acknowledge the overlap that can occur between themes.
The need to gain more insight into HRQoL of DTF patients is reflected by several attempts 
made around the world. In the USA, the Desmoid Tumor Research Foundation (DTRF) 
patient registry opened recently (September 2017) to register clinical, pathological and 
geographical variables of DTF patients. Additionally, a survey, based on both validated 
and non-validated HRQoL-questionnaires, was put together to gain more insight in HRQoL 
of DTF patients 47. The latter, a PRO specific DTF-tool, was presented on the Annual 
Meeting of the American Society of Clinical Oncology of 2017 48. In the Royal Marsden 
UK, two focus group sessions took place in March 2017 23. This resulted in four key themes 
(diagnostic pathway; treatment pathway; living with DTF; supportive care). We found 
an interesting difference in the impact of DTF between the Dutch and UK focus group 
participants. Apart from the selection bias, which could be explained by the selection of 
patients and the willingness of patients to participate in such a study, and differences in 
the way patients had been treated with more often chemotherapy (Caelyx) in the UK focus 
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group, other factors may play a role, which are beyond the individual patient level of these 
focus groups participants. An international desmoid population-based questionnaire study 
could ideally give more detailed information. Such a study could also examine which 
patients are particularly at risk for poor disease related outcomes on their quality of life.
Our focus group study has several limitations. First; the recruitment of participants for 
focus group sessions might have led to selection bias. Patients who are introvert, or who 
have minor symptoms, or received successful treatment might have been less likely to 
agree to participate in a focus group session and vice versa. A frequently heard response, 
when being approached for participation, was the worry about being influenced by negative 
experiences of other patients. However, in that case, most patients were willing to do a 
private face-to-face interview with the author to share their experiences. This suggests that 
not all patients feel comfortable to join a group session. The second limitation involves the 
small number of DTF patients. Due to the rarity of DTF larger sample sizes are difficult 
to obtain in a single centre study. Nevertheless the small sample size gave all participants 
enough time to share their experiences 46. The third limitation comprises the heterogeneity 
of the focus group participants, since we did not select participants based on their stage of 
disease or their treatment. Only one out of fifteen participants received previous systemic 
treatment, which might be an underestimation of the total percentage of patients in the DTF 
population receiving medication. We do acknowledge that every treatment modality (e.g., 
surgery, radiotherapy, chemotherapy) could impact HRQoL on the short- and the long-term. 
However, regardless of previous treatments, patients, included in the focus groups, shared a 
wide variety of experiences coinciding with the chronic nature of the disease. This resulted 
in the report of various HRQoL-issues, which we believe do represent the entire spectrum 
of HRQoL-issues experienced by the DTF population.
To our knowledge this is one of the few studies that explored currently used HRQoL-tools 
and the experience of HRQoL-issues in the setting of sporadic DTF. The strength of our 
study is the approach according to the EORTC guidelines for developing questionnaire 
modules 49. By conducting the systematic literature review we revealed the necessity for 
measuring HRQoL-outcomes in clinical practice and exposed a deficit in suitable HRQoL-
tools for this patient group. The focus group approach elicits patients to explore and to 
clarify individual and shared perspectives. This resulted in the identification of key issues 
experienced by DTF patients and ensures the achievement of high content validity.
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The results of the systematic literature review and the focus group sessions will be used 
to create a provisional list of issues which will be ranked by both patients and healthcare 
professionals for their relevance. Next, an item list will be created which will form the basis 
of the DTF specific tool. This tool could complement the EORTC QLQ-C30 questionnaire 
with questions capturing issues raised from the focus groups such as concerns about 
recurrences and emotional or psychological problems and, site specific issues (i.e., extremity, 
abdominal wall etc.). This questionnaire is much needed in order to understand effects of 
DTF and its treatment on patient reported outcomes and provide support for patients who 
experience problems regarding physical, emotional, social and psychological well-being. 
Also, knowledge about HRQoL-outcomes can be used for informed decision making during 
the diagnosis and treatment trajectory of this patient group.
Conclusions
A DTF-specific tool and consensus regarding the preferred measurement tool for measuring 
HRQoL in DTF patients is lacking in the literature. Used questionnaires either focus on single 
items, excluding possible items of significance, or are too generic. Existing questionnaires 
could be complemented with questions regarding key HRQoL-issues, identified during the 
focus group sessions, which DTF patients experience in various HRQoL-domains. This 
DTF-specific tool, validated in a large population study, would provide guidance for clinical 
practice, can compare treatment effects on HRQoL and raise awareness of the impact of 
DTF on patients’ life.
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Supplemental Materials 1. Literature search, Embase.com, November 6th, 2017
(‘desmoid tumor’/exp OR Fibromatosis/exp OR ‘familial colon polyposis’/exp OR (desmoid* OR Fibromatos* 
OR ((familial* OR heredit* OR genetic* OR Adenomatous*) NEAR/6 polypos*)):ab,ti) AND (‘quality of 
life’/exp OR ‘quality of life assessment’/exp OR ‘functional assessment’/exp OR ‘general health status 
assessment’/exp OR ‘health status’/exp OR ‘health impact assessment’/de OR ‘daily life activity’/exp OR 
‘ADL disability’/exp OR ‘patient satisfaction’/exp OR ‘distress syndrome’/exp OR ‘stress’/exp OR emotion/
exp OR ‘sexuality’/exp OR ‘self concept’/exp OR ‘family relation’/exp OR ‘family life’/exp OR ‘coping 
behavior’/exp OR ‘disability’/de OR invalidity/de OR ‘immobility’/de OR ‘esthetics’/de OR ‘pain assessment’/
exp OR ‘pain measurement’/de OR ‘social interaction’/exp OR ‘social life’/exp OR ‘social environment’/
de OR ‘psychosocial environment’/de OR ‘social support’/de OR ‘social stress’/de OR ‘social rejection’/de 
OR ‘mental health’/exp OR ‘wellbeing’/exp OR ‘interview’/exp OR ‘questionnaire’/exp OR ‘assessment of 
humans’/exp OR ‘psychological aspect’/exp OR ‘psychology’/exp OR ‘marriage’/exp OR ((quality NEAR/3 
life) OR hrql OR qol OR (Functional* NEAR/3 (outcome* OR asses*)) OR (daily NEAR/3 (life OR living) ) 
OR ADL OR (patient NEAR/3 satisf*) OR ((health OR function*) NEAR/3 status*) OR eortc OR ((short-form 
OR sf) NEXT/1 (12 OR 20 OR 36)) OR sf12 OR sf20 OR sf36 OR distress OR (stress NEAR/3 (patient* OR 
personal* OR psycho* OR mental* OR life)) OR emotion* OR anxi* OR sexual* OR (self NEXT/1 (concept* 
OR esteem OR satisf* OR percept*)) OR body-image* OR burden* OR ((impact* OR problem* OR issue*) 
NEAR/6 (function* OR disease* OR personal* OR psycholog* OR body OR clinical* OR health* OR life 
OR daily OR tumor* OR tumour* OR social* )) OR psychosocial* OR worry* OR worrie* OR ((family 
OR interpersonal OR partner* OR spous*) NEAR/6 (relation* OR communicat* OR life OR involve*)) OR 
coping OR ((adaptive* OR adjustment* ) NEAR/6 (behav* OR psycho*)) OR impairment* OR disabilit* 
OR invalidit* OR esthetic* OR aesthetic* OR cosmetic* OR beauty OR fitness OR (physical* NEAR/3 
(condition* OR mobility)) OR immobility OR (pain* NEAR/6 (assess* OR inventor* OR measure*)) OR 
attractiveness* OR (social* NEAR/3 (isolat* OR distan* OR interact* OR life* OR support OR reject* 
OR participat* OR environment*)) OR feeling* OR (mental NEAR/3 (health OR status OR suffer*)) OR 
wellbeing OR well-being OR insecur* OR resilien* OR (symptom* NEAR/6 (assess* OR inventor* OR 
check*)) OR karnofsk* OR (karno* NEXT/3 (score* OR scale* OR perform* OR function* OR stat* 
OR index* OR rating)) OR (focus NEAR/3 group*) OR interview* OR questionnaire* OR (assessment* 
NEAR/3 human*) OR hopeless* OR fear OR frustrat* OR hopeless* OR helpless* OR unhapp* OR mood 
OR uncertaint* OR (lack NEAR/3 informat*) OR disturb* OR concerned OR deficit* OR ((self OR patient*) 
NEXT/1 report*) OR marriage*):ab,ti) NOT ([animals]/lim NOT [humans]/lim)
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Supplemental Material 2. Flow chart showing the selection of studies for the inclusion in the literature review
Inclusion criteria:
• patients with sporadic DTF
• original articles
• availability of full text
• the use of (non)validated tool or measurement to measure HRQoL
• language: Dutch, English, German or French.
Exclusion criteria:
• case reports, reviews
• FAP patients
DTF, desmoid-type fibromatosis; FAP, familial adenomatous polyposis HRQoL: health related quality of life; n, 
number of studies; STS, soft tissue sarcoma
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Assessing the desmoid-type 
fibromatosis patients’ voice: 
Comparison of health-related quality 
of life experiences from patients of 
two countries
Milea J.M. Timbergen,  Winette T.A. van der Graaf, Dirk J. Grünhagen, Eugenie Younger, 
Stefan Sleijfer, Alison Dunlop, Lucy Dean, Cornelis Verhoef, 
Lonneke V. van de Poll-Franse, Olga Husson




Desmoid-type fibromatosis (DTF) is a rare, non-metastasising soft tissue tumour. Symptoms, 
unpredictable growth, lack of definitive treatments, and the chronic character of the disease 
can significantly impact health-related quality of life (HRQoL). We aimed to identify the 
most important HRQoL-issues according to DTF patients in two countries, in order to 
devise a specific HRQoL-questionnaire for this patient group.
Methods
DTF patients and health care providers (HCPs) from the Netherlands and the United 
Kingdom individually ranked 124 issues regarding diagnosis, treatment, follow-up, 
recurrence, living with DTF, healthcare and supportive care experiences, according to 
their relevance. Descriptive statistics were used to calculate priority scores.
Results
The most highly ranked issues by patients (n = 29) were issues concerning ‘tumour growth’, 
‘feeling that there is something in the body that does not belong there’, and ‘fear of tumour 
growth into adjacent tissues or organs’ with mean (M) scores of 3.0, 2.9 and 2.8 respectively 
(Likert scale 1-4). British patients scored higher on most issues compared to Dutch patients 
(M 2.2 vs. M 1.5). HCPs (n = 31) gave higher scores on most issues compared to patients 
(M 2.3 vs. M 1.8).
Conclusions
This study identified the most relevant issues for DTF patients, which should be included 
in a DTF-specific HRQoL-questionnaire. Additionally, we identified differences in 
priority scores between British and Dutch participating patients. Field-testing in a large, 
international cohort is needed to confirm these findings and to devise a comprehensive and 
specific HRQoL-questionnaire for DTF patients.
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Introduction
Sporadic desmoid-type fibromatosis (DTF) is a rare, borderline tumour of the soft tissues 
1-3. Most patients are females, aged between 20 and 40 years at primary diagnosis 3. 
Sporadic DTF arises in musculoaponeurotic structures with the most common sites being 
the abdominal wall and the extremities 4. Symptoms vary, depending on tumour site, size 
and infiltration of adjacent structures, resulting in pain and/or functional impairment. 
DTF does not metastasize, rarely has fatal outcomes, often displays long periods of 
spontaneous stabilisation, and can undergo spontaneous regression 5. Surgical resection, 
radiotherapy, non-cytotoxic and cytotoxic systemic therapies may be considered in patients 
with symptomatic disease but unfortunately, these “traditional” treatment options do not 
guarantee tumour reduction and/or clinical response 6. Local recurrence after surgery 
remains high 7, 8, leading to a reduction in surgical treatments for DTF over recent decades 
3, 4. Additionally, “active” forms of treatment can be debilitating, causing greater morbidity 
than the tumour itself. For these reasons, active surveillance is now recommended as a first 
line management for most patients with DTF 6, 9. Therefore, DTF has obtained a “chronic” 
status and its impact on patients should be evaluated accordingly.
Health-related quality of life (HRQoL) provides information beyond traditional measures 
of efficacy in oncology such as overall survival, and is increasingly used as an endpoint in 
clinical trials 10, 11. We previously performed a systematic literature review to evaluate which 
HRQoL-measures were used in research to assess HRQoL in DTF 12. Generic HRQoL-
measures (e.g., the cancer specific core questionnaire from European Organisation for 
Research and Treatment of Cancer; the EORTC quality of life core questionnaire (EORTC 
QLQ-C30)) may not consider disease-specific issues in DTF patients. Site-specific tools 
(e.g., Toronto Extremity Salvage Score), may not be relevant to certain groups (e.g., those 
with an abdominal wall, or head and neck tumours).
At present, there is no validated DTF-specific HRQoL-tool, and this was illustrated by a 
systematic literature review published by our group 12, 13. In order to gain greater insight 
into the issues that patients with DTF experience in their daily lives, and to evaluate their 
experiences of health care including the supportive care system, we previously organised 
focus groups and semi-structured interviews, in the United Kingdom (UK) and in the 
Netherlands (NL) 12, 13. These studies identified issues covering various domains including 
the diagnostic pathway, the treatment pathway, daily limitations (e.g., physical and 
psychological symptoms), and experiences with the current health care system.
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The main goal of this study was to determine the relative importance of each issue and 
receiving feedback on appropriateness of content and breadth of coverage. In the present 
study, we used the previously identified issues to 1) identify the most relevant issues to 
patients with DTF in two health care settings (UK and NL) and to 2) identify differences 
in scores between both countries.
Materials and Methods
Identification of issues
The EORTC Quality of Life group methodology for developing a questionnaire was used 
for the selection of relevant issues based on previous focus groups and patients interviews 14. 
Issues, that had previously been identified to be of concern to DTF patients, were listed per 
country (UK and NL). A total of 188 issues were identified in the UK group and 110 issues 
were identified in the Dutch group. Next, issues were grouped into categories and duplicate 
issues, covering the same topics were removed. A total of 124 issues were converted into 
a provisional list of issues. All issues were reviewed by two authors (M.J.M.T. and O.H.). 
All issues were translated by native English and Dutch speakers.
Patient selection
Patients with DTF were approached for participation by their treating physician. Inclusion 
criteria were; histologically proven DTF, age ≥18 years, Dutch or English language skills 
and a “recent” visit (<2 years) to the hospital. Exclusion criteria were; participation in one 
of the previous focus groups or patient interviews, and patients with a diagnosis of cancer 
or familial adenomatous polyposis (FAP). Patients received an information letter which 
explained study objectives. Baseline characteristics and details about the individual disease 
trajectory of participants were obtained. Patients were only invited to participate once and 
did not have to provide a reason if they declined. No reminders were send. All data from 
patients were collected and processed anonymously.
Selection of health care providers
To examine whether HCPs, with expertise and experience in sarcomas and DTF have the 
same perspectives as patients with DTF about key HRQoL-issues, an e-survey of the same 
124 issues was created using Lime Survey Servicebedrijf© software. The issue list was 
available in two languages (Dutch and English) and issues were presented in a random 
order. In the Netherlands, HCPs from the multidisciplinary team (e.g., surgeons, oncologists, 
radiologists, radiotherapists, sarcoma clinical nurse specialists, and physiotherapists) were 
9
146460_Timbergen,Milea_BNW-def.indd   248 25-11-2020   08:21
249
identified using the website Orphanet, which provides information on centres of expertise 
dedicated to the medical management for rare diseases (https://www.orpha.net/consor/cgi-
bin/Clinics_Search.php?lng=EN). In the UK, HCPs of the aforementioned disciplines were 
identified using the sarcoma network group of the Royal Marsden Hospital, London, UK. 
Every HCP received an invitation email with a token and link to the e-survey. A reminder 
was sent after one week if the HCP had not responded.
Sociodemographic and clinical characteristics
Age at time of diagnosis was either stated by the patient or calculated using the date of 
birth and date of the first pathology report. Age at the time of questionnaire completion was 
either stated by the patient or calculated using the date of informed consent and the date 
of birth. Education levels were categorized into “high” (PhD, university, higher education 
postgraduate/undergraduate degree), “intermediate” (professional qualification, vocational 
work, work related qualification, general secondary education, further/intermediate 
education), and “low” (primary education [with a higher, but not completed education] 
and secondary education). Continuous variables were presented as a mean with a standard 
deviation (SD) or as a median with an interquartile range (IQR). Categorical variables were 
presented as numbers (n) using frequencies and percentages.
Presentation of issues to patients and health care providers
A total of 124 issues were presented to patients and health care providers (HCPs) in a 
random order (Supplemental Table 1). Patients and HCPs scored 124 issues by relevance 
on a Likert scale from 1 to 4 ((1) not at all, (2) a little, (3) quite a bit, and (4) very much) 
and ranked the top ten most important issues. The frequency that each issue appeared in 
the top ten most important issues was converted into the mean priority score (M-score) per 
issue. The frequency of top ten priority score of each issue was calculated and ranked in 
overall priority score. Where questions were left blank by the participant, they were coded 
as a “missing value” and not incorporated in the total score. Space for general remarks was 
available at the end of the questionnaire.
EORTC QLQ-C30 questionnaire
In addition to the issue list, patients were asked to fill out the 30-item EORTC QLQ-
C30 questionnaire (version 3) to assess HRQoL 15. Norm data was obtained from the 
EORTC, which recently collected data from the general population in Europe and North 
America 16. Only data from the general population in the Netherlands and the UK were 
used for the current study. The EORTC QLQ-C30 questionnaire contains five functional 
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scales (physical, role, cognitive, emotional and social functioning), a global health status 
scale, three symptom scales (fatigue, nausea and vomiting, and pain), and six single items 
(appetite loss, diarrhoea, dyspnea, constipation, insomnia, and financial difficulties). The 
questionnaire has a 1-week time frame and uses a four-point response format (“not at all”, 
“a little”, “quite a bit”, and “very much”), with the exception of the global health status 
scale, which has a seven-point response format. The scores were calculated using linear 
transformation to a score between 0 and 100. For the functional scales and the global health 
status, a high score represents a high (healthy) level of functioning. A high score for the 
symptom scales represents a high level of symptoms (greater symptom burden) 17. The 
EORTC QLQ-C30 summary score was calculated using the mean scores of the function 
scales and the reversed mean scores of the symptom scales and single items (financial impact 
and global health status excluded), and are summarized as the mean of the combined 13 
QLQ-C30 scale scores A higher summary score represented a better outcome 18, 19. The 
summary score was only calculated when all of the required 13 scale and item scores were 
available. Data analysis and handling of missing items were done according to the scoring 
manual of the EORTC 17.
Statistical analysis
Patients were matched, using a 1:10 nearest-neighbour match method, with the general 
population based on nationality, age, and sex using Rstudio (RStudio, version 1.0.153, 
Boston, MA, package MatchIt). Patients with missing values (lacking information regarding 
age or sex) were excluded from the analysis. Differences in priority scores (Dutch versus 
British participating patients, and HCPs versus participating patients), and differences in 
scores of the EORTC QLQ-C30 scales between groups (Dutch versus British participating 
patients, and Dutch and British participating patients versus the Dutch and British general 
population) were tested for their significance using the Mann-Whitney U test. SPSS 
Statistics (version 24) was used for the Mann-Whitney U tests (IBM, Armonk, New York, 
USA). Two-sided p < 0.05 was considered statistically significant.
Results
Patient cohort
Forty-one patients from the Erasmus MC, Rotterdam, the Netherlands, and 32 patients 
from the Royal Marsden Hospital, London, UK, were approached during July and August 
2018. Out of 73 patients, 29 patients (total response rate of 39.7%) gave written informed 
consent (Figure 1). The cohort comprised of 10 males and 19 females with DTF most 
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commonly localized in the extremities, flank and chest wall (n = 15, 52%). Nine participants 
had received active treatment at the time of the questionnaire. The median, self-reported 
age at diagnosis was 38 years (IQR: 30-48) (Table 1). Sociodemographic characteristics are 
summarized in Supplemental Table 1. All participants completed the issue list, and sixteen 
participants ranking their top 10 most relevant issues.
Figure 1. Flow diagram of participating patients and health care providers’ responses to this survey
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Table 1. Clinical characteristics of 29 participating patients
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Ranking of priority of the issues
Ranking of HRQoL-issues revealed that 13 out of 124 issues (10.5%) were chosen to be the 
most relevant (prevalence ratio of >30%) (Table 2). Patients considered the following issues 
as relevant and missing on the current issue list; “problems with health care insurances”, 
“coverage of costs related to the disease such as traveling costs”, “lack of adequate online 
information”, “lack of knowledge about treatment options outside the region or country”, 
“lack of information about pain management and referral to pain professionals” and “lack of 
advice regarding dietary restrictions or playing sports”. A list of the missing items, general 
remarks and quotes is provided in Supplemental Table 2 and Supplemental Table 3.
British versus Dutch patients
Table 2. Top 10 most important issues according to number of participating patients (n)





Worries about tumour growth
Fear of the tumour growth 
and/or tumour growing into 
adjacent tissues or organs
Feeling that there is 
something in your body that 
does not belong there
Stress around check-ups 
during the follow-up
Pain
Reaching a definite diagnosis 
is time consuming
Not being able to sleep 
because of pain
Feeling frustrated about the 
“benign” diagnosis with 
malignant features
Desmoid-type fibromatosis is 



















Worries about tumour 
growth
Experience of uncertainty 
during the course of disease
Pain
Lack of optimal treatment 
options and /or uncertainty 
about preferred treatment











a n = 13 participating patients failed to provide a top 10
The cut-off value for inclusion in the DTF-specific HRQoL-questionnaire is a prevalence ratio of > 30%
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Overall, British patients gave higher scores for each issue compared to Dutch patients 
(M-score 2.2 (UK) vs M-score 1.5 (NL)) (Supplemental Table 4). Differences in score of 
more than 1 point between Dutch and British patients are displayed in Supplemental Figure 
1. Additionally, priority scores of Dutch and British HCPs, and scores of participating 
patients and HCPs from the Netherlands and the UK were compared (Supplemental Table 
4). The total cohort of patients was too small to identify any differences between subgroups 
(e.g., initial treatment type, tumour location, and age at diagnosis).
Health care providers
In the Netherlands, HCPs were invited at six sarcoma centres. All HCPs from the UK were 
employees at the Royal Marsden Hospital, London. Twenty-one Dutch and ten British 
HCPs responded. Professional backgrounds included; surgical oncologist (n = 12), medical 
oncologist (n = 6), radiation oncologist (n = 5), specialized sarcoma nurse (n = 5), and other 
professions including a radiologist, physiotherapist and pain specialist (all n = 1). Seventeen 
professionals had more than 10 years of experience, three had 6-10 years of experience, 
and eleven had 5 or less years of experience working with desmoid patients. Frequency of 
contact with DTF patients varied between once a week (n = 9, 29%) to rarely (less than 
once every 3 months) (n = 1, 3%).
Issues with the highest scores according to HCPs included; “worries about tumour growth” 
(M-score 3.4), “stress about the diagnosis” (M-score 3.2), “the experience of uncertainty 
during the course of the disease” (M-score 3.2), “pain” (M-score 3.2), “concerns about the 
future” (M-score 3.0), “stress around check-ups during the follow-up” (M-score 3.0), “fear 
of recurrence after treatment” (M-score 3.0), “fear of tumour growth/tumour growth into 
adjacent tissues or organs” (M-score 2.9) and “the feeling that patients do not have a clear 
prognosis” (M-score 2.9). Overall, HCPs from the UK gave higher scores, compared to 
Dutch HCPs with M-scores of 2.8 and 2.0 respectively (Supplemental Table 4).
Participating patients versus health care providers
There was considerable overlap between the highest ranked issues according to patients 
and HCPs, particularly regarding the unpredictable growth pattern of DTF tumours 
(Supplemental Table 4). HCPs scored significantly higher (p < 0.05) on 77 out of a total of 
77 of 124 issues. HCPs also gave a higher mean overall score on the issues list (total M-score 
2.3) compared to patients (total M-score 1.8) (Supplemental Table 4).
9
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EORTC QLQ-C30 - Dutch versus British participating patients
Overall, the mean summary score for the EORTC QLQ-C30 for all DTF patients together 
was 78.1, with a mean global health score of 68.7 (Table 3). Statistically significant 
differences between scores of British and Dutch patients were found for “global health”, 
“insomnia”, for the symptom scales “pain” and “fatigue”, and for the following functioning 
scales “cognitive functioning”, “emotional functioning”, “social functioning” and “role 
functioning” (Table 3).
EORTC QLQ-C30 - Participating patients versus the matched general population
After 1:10 nearest-neighbour matching based on nationality, sex and age, data of 170 people 
from the Dutch general population and data of 80 people from the British general population 
were selected to compare scores between DTF patients and the general population. Four 
British patients were excluded from this analysis due to missing data regarding their age 
at the time of questionnaire completion. Dutch patients had a score of 77 for global health 
and a summary score of 87.2, whereas scores for the matched Dutch population were 78.7 
and 89.8 for global health and the summary score respectively. British patients (n = 8) had a 
score of 59.4 for global health and a summary score of 68.2, whereas scores for the matched 
British population were 60.2 and 76.7 for global health and the summary score respectively 
(Table 3) 16. Dutch participating patients scored lower on all functioning scales compared to 
the general Dutch population, although only the physical functioning score (p = 0.019) and 
the role functioning score (p = 0.021) showed a statistically significant difference (Table 
3). No statistically significant differences were found comparing EORTC QLQ-C30 scores 
between the British patients and British general population.
Discussion
The purpose of this study was to identify the most important HRQoL-issues for patients 
with sporadic DTF and rank them according to relevance. The most highly ranked HRQoL-
issues by patients with DTF were related to the unpredictable disease trajectory of DTF. 
Additionally, issues regarding the rarity, aggressiveness and the benign classification of 
DTF received high scores. From the patient perspective, this benign classification was 
seen as misleading, as DTF can display aggressive growth. In terms of the health care 
system, the benign disease classification, not being cancer, can have both pros and cons 
as it can have consequences for insurances and covering of expenses, depending on the 
country of residence. As the aforementioned items are not included in the EORTC QLQ-C30 
questionnaire, a tailored DTF HRQoL-tool could capture these issues. Physical symptoms 
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such as pain, fatigue and loss of muscle strength also received high priority scores of 
2.4, 2.3 and 2.3 respectively. Although these items are covered by the EORTC QLQ-C30 
questionnaire, the results of this study highlight the importance of physical symptoms, 
caused by the tumour or as a side effect of treatment, and their impact on HRQoL. Patients 
identified several important issues that were not covered by other questionnaires. These 
could be considered in the development of a future DTF-specific HRQoL-tool.
In a rare and heterogeneous disease, such as DTF, measuring the impact of the disease for 
patients can be challenging. This can be due to the variable disease presentation, course and 
response to treatment, and due to the knowledge gap of the natural history of the disease 
20. Moreover, the limited number of responses challenges research in this field. Our cohort 
may not be representative of the entire DTF population as the majority of patients in this 
cohort had an intra-abdominal tumour and many patients received one or multiple active 
forms of treatment.
In addition to physical, emotional and psychological problems, patients with DTF might 
also experience social isolation due to lack of peers with the same condition 20. This was 
reflected in the current study by a relatively high score for the issue “not knowing peers 
with the same disease”. Furthermore, lack of information was identified as a relevant topic 
as the following issues “DTF is unknown among most doctors”, and “lack of information 
received about DTF”, received M-scores of 2.6, and 1.8 respectively.
HCPs may treat a limited number of patients with this rare disease, therefore patients may 
receive an incorrect diagnosis or delay in diagnosis due to lack of experience in recognizing 
and treating the disease 20. The comparison in relevance scores between patients and HCPs 
show that HCPs scored significantly higher on a large number of issues, suggesting that they 
recognize and acknowledge problems that faced by this patients group. The issue “reaching 
a definite diagnosis is time consuming” received an M-score of 2.3, showing that this is a 
relevant problem for this patient group. Whilst the future DTF-specific HRQoL tool will 
be available upon diagnosis, it is important for HCPs to consider that patients may have 
encountered difficulties reaching the correct diagnosis and so provision of clear information 
and support at this time is essential. Accessing specialists with knowledge of DTF can be 
challenging, as they may be located in regional specialist centres. This can result in patients 
receiving multiple treatment recommendations before seeing a specialist.
9
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Financial consequences, due to insurance problems, the need to take time off work or 
increasing traveling costs can also affect HRQoL, although the issues regarding these 
subjects all received relatively low scores in the current study 21. Social problems, such as 
the burden of having a rare disease on family and carers, as well as having this diagnosis 
at a young age, can also have a negative impact on HRQoL 20, 21.
This unique study identified important issues for DTF patients and compared the views of 
British and Dutch patients. Most issues were scored higher by British patients compared 
to Dutch patients (indicating a higher relevance for the specific issue). This phenomenon 
was also seen comparing EORTC QLQ-C30 scores, as British patients scored statistically 
significantly lower (indicating worse functioning) on four out of five function scales, 
and for the symptom scales insomnia, pain and fatigue. Although both participating 
centres are tertiary centres visited by patients with more complex or advanced disease, 
the catchment area of the Royal Marsden Hospital (London, UK) is larger than of the 
Erasmus MC (Rotterdam, NL) possibly creating selection bias during this study. Norm data 
obtained by the EORTC of the general Dutch and British population showed a comparable 
trend with higher scores on symptom scales and single items scales (indicating greater 
symptom burden) and lower scores on functioning scales (indicating worse functioning) 
comparing the data from the general Dutch and British population. Data from 2017 of The 
Organisation for Economic Co-operation and Development show similar results with lower 
scores (indicating a lower well-being) of British participants compared to Dutch participants 
on several measures of well-being (e.g., housing, income, education and health and life 
satisfaction) 22. This suggest that, although our data might show differences between both 
countries of “impact of disease” on HRQoL, baseline scores in the normal population differ 
and that the experience of HRQoL-issues depends on where you live 16, 22.
Comparisons between patients and a matched cohort of the general population based on 
nationality, sex and age, did not yield significant results, except for “physical functioning” 
and “role functioning” comparing the Dutch patients with the Dutch general population. 
Additionally, we compared the scores of HCPs and participating patients. An important 
finding of this study was the clear overlap of issues that were important to patients and 
HCPs. The HCPs rated various issues higher than patients particularly with regard to pain, 
stress about the diagnosis, and concerns about the future.
We acknowledge that this study has several limitations. The small sample size is explained 
by the rarity of DTF. A larger cohort is needed to test the psychometric aspects of a DTF-
9
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specific HRQoL-tool in future studies. The response rate was lower than we had hoped for, 
but similar response rates have been published in studies describing more common diseases 
such as cancer 23. In the current study the relatively low response rate may have been due to 
the length of the questionnaire, the single centre setup (one centre in each country), the timing 
of sending out the questionnaire (mid-summer) and/or the overall reluctance to participate in 
a survey study. Furthermore, many patients also need to complete questionnaires as part of 
their regular health care; therefor patients might be less willing to complete questionnaires 
for research purposes. Sending out a reminder to patients would have been a valid option 
to increase the response rate. Selection bias may have led to an overestimation of HRQoL-
problems in our cohort. As the primary aim was to identify the most relevant issues in this 
patient group, the effect of this overestimation is less relevant. A population-based cohort 
is required to determine true prevalence of issues and perhaps a more representative result. 
Lastly, interpretation of the questions is influenced by the current health situation of each 
patient. We tried to eliminate such influencing factors by excluding patients with a diagnosis 
of cancer and FAP-associated DTF. However, patients HRQoL might also be influenced 
by disease stage, tumour location and treatments, and by other comorbidities and personal 
circumstances. This impact on HRQoL-issues could be evaluated in a future population-based 
cohort study and stresses the need for validation of our findings in a large, international DTF 
cohort to evaluate the prevalence of HRQoL-issues.
Today, solely one DTF-specific questionnaire, the Gounder/DTRF Desmoid Symptom / Impact 
Scale, is available, and currently mainly used in the setting of clinical trials 24-26. The findings 
of our study will be used for the development of a DTF-specific tool, according to the EORTC 
guidelines, which can be used accompanied by the EORTC QLQ-C30 HRQoL-instrument and 
will be useful for observational studies, clinical trials and clinical care. Implementation of this 
tool and action on abnormal findings, concerns or poor experiences of patients might improve 
satisfaction with health care, symptom management and HRQoL 27. Health care providers 
may benefit from being able to anticipate and identify problems earlier, thereby improving 
work efficiency and promoting patient-centred care through shared decision-making 28-30. In 
order for a tailored HRQoL-tool to work in clinical practice, this tool should add value to the 
clinical workflow without disrupting it 31. Our results will be used in the development of an 
international, multicentre, population-based study in line with the EORTC guidelines for 
developing a questionnaire 14. This study includes pre-testing and content validation of a DTF-
specific questionnaire. This questionnaire will assess the prevalence of HRQoL-issues and 
will identify risk factors for the development of HRQoL-issues patients experience. Patients 
will receive an invitation to participate in an online survey and one reminder for completing 
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the questionnaire. When this tool has been developed and validated, it will reflect overall 
patient experience and its multidimensional contributing factors by including important non-
symptom, disease specific areas regarding the unpredictable course of this rare disease. The 
tool could be used alongside the EORTC QLQ-C30, to gain more insight into HRQoL-issues 
of the patient at diagnosis. Additionally, longitudinal studies could evaluate HRQoL-issues 
of DTF patients during their disease trajectory and the questionnaire can potentially be used 
in both clinical and research setting.
Conclusions
This study identified relevant issues for DTF patients to be considered in the future 
development of a DTF-specific HRQoL-questionnaire. Issues regarding the unpredictable 
growth behaviour and rarity of DTF were the most highly ranked by patients and HCPs. 
Additionally, this study identified differences in priority scores between British and Dutch 
patients. Although this could be due to selection-bias, field-testing in a large, international 
cohort is needed to confirm any potential cultural findings.
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Current living situation Living with child(ren) and 
spouse /partner
Living with child(ren)

















































































Employed full-time (including 
self-employed)
Employed part-time (including 
self-employed)
Unemployed
































Physical demanding job Not applicable



























Mentally challenging job Not applicable









































a Percentages may not add up to 100% due to rounding up of decimals
9




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































146460_Timbergen,Milea_BNW-def.indd   265 25-11-2020   08:21
266
Supplemental Table 3. General remarks and quotes from patients
Remarks Quotes
Difficult to interpret some of the questions 
since many issues change over time
Due to multiple recurrences; ‘fear for a new 
tumour rather than recurrent tumours’
Psychological support at the beginning of 
the disease
• “I would have loved at the beginning is psychological 
support. Being a very active and confident person, 
adjusting to initial limitations was very hard and I really 
struggled both physically and mentally”
Some issues are caused by the operation 
rather than the tumour itself which is 
difficult to distinguish from each other
Having a benign tumour which is 
aggressive, but no cancer
• “The biggest problem is having an aggressive recurrent 
tumour treated by oncologist with cancer treatment 
being less than cancer”
• “It’s benign so it’s not going to kill you; the only thing 
it could do to kill you would be to suffocate you if it 
overwhelms your organs”
A good band with your treating physician • “I learned thinking positive from my treating physician”
Fear of tumour growth during and after 
pregnancy
• “Especially post pregnancy with fear of further desmoid 
developing from scar from the caesarean section”
9
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Supplemental Figure 1. Differences in score of more than 1 point between Dutch and British patients
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General Discussion
The knowledge about desmoid-type fibromatosis (DTF) has grown significantly over the 
past decades. Various, often patient-initiated, projects have led to more awareness for this 
rare disease. Today the research community still faces many challenges in DTF research; 
gathering knowledge about tumour genetics, biology, growth behaviour, and risk prediction. 
The efficacy of existing treatments are evaluated and the search for novel therapeutic 
targets continues. Lastly, the impact of the disease on patients’ health-related quality of 
life (HRQoL) is increasingly acknowledged and incorporated in both research and clinical 
decision-making. The aim of this thesis was to describe the many faces of desmoid-type 
fibromatosis, to contribute to the current knowledge of this peculiar disease.
Genetics and Molecular Biology
DTF is rare with an incidence of 5 patients per million people per year in the Netherlands 
1. Several treatments options are currently available including active surveillance, surgery, 
and several systemic treatments 2. In Chapter 2, we evaluate existing biological evidence 
for the activity of common cell-signalling pathways in DTF including Wnt/β-catenin, JAK/
STAT, Notch, PI3 kinase/AKT, mTOR, Hedgehog, the oestrogen pathway, and the growth 
regulatory pathway in order to identify potential therapeutic opportunities. Furthermore, 
we summarized the results of completed clinical trials studying targeted drug regimens 
in the DTF setting. The evidence for most of these treatment regimens are based on small 
sized, retrospective cohort studies with heterogeneous study populations, and the biological 
rationale for the use of these targeted therapies is often limited. The variable efficacy of 
systemic treatments in DTF may also be caused by the absence of recommendations on the 
sequence of systemic treatments in international treatment guidelines 3. This leaves room 
for individual physicians to follow their preferred indication for starting systemic treatment 
and their drugs of choice 4. Thus many current treatments, administered to DTF patients 
lack the solid evidence base for efficacy that is preferred. Nevertheless, initiation of systemic 
treatments in a stepwise fashion, starting with the least toxic agent, is recommended 3.
The current systemic regimens include traditional chemotherapy such as methotrexate 
alone 5 or combined with vinblastine/vinorelbine 6, anthracycline-containing regimens (i.e., 
dacarbazin and/or (liposomal pegylated) doxorubicin) 5, 7, but also targeted therapies. The 
later encompasses non-steroidal anti-inflammatory drugs, such as celecoxib or sulindac, 
alone 8 or in combination with selective oestrogen receptor modulators (i.e., tamoxifen, 
toremifene, or raloxifene 9-13), and tyrosin kinase inhibitors (i.e., imatinib, nilotinib, and 
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pazopanib) 14-18. The evidence for most of these treatment regimens are based on small sized 
retrospective cohort studies with heterogeneous study populations. 
Drugs that form an attractive therapeutic option include gamma-secretase inhibitors. These 
drugs interfere with the Notch signalling pathway by inhibiting the final Notch processing 
step by which intra-cellular domain is released to act in the nucleus, consequently blocking 
Notch signalling 19. The gamma-secretase inhibitor PF-03084014, later named Nirogacestat, 
was developed based on the positive results of decreased Notch target protein expression 
in in vitro studies. This led to the development of several clinical trials 21-23. The results 
of the phase 3 trial (Nirogacestat vs. placebo) are currently awaited and will determine if 
Nirogacestat can be seen as a valid treatment option for DTF 24. 
Other randomized data regarding systemic treatments for DTF that is currently available 
include two tyrosin kinase inhibitors: sorafenib and pazopanib. The first trial reported an 
advantage for sorafenib in the 2-year progression-free survival (PFS) over placebo (81% 
(95% confidence interval [CI], 69-96) versus 36% (95% CI, 22-57). The second trial reported 
an advantage for pazopanib over methotrexate-vinblastin in progression-free proportion of 
patients measured at 6 months (83.7% (95% CI 69.3–93.2) versus 45% (95% CI 23.1–68.5) 
25, 26. The result of these trials suggest that there seems to be a beneficial effect of tyrosin 
kinase inhibitors on DTF tumours. These drugs could therefore be seen as a valid treatment 
option, taking potential side effects and clinical benefits into account 27.
The increased level of β-catenin and consequent aberrant Wnt/β-catenin signalling are 
characteristics of DTF, but so far they have not yielded any therapeutic opportunities 28. 
The cause of nuclear β-catenin accumulation are specific, non-synonymous mutations in the 
CTNNB1 gene. About 85% of DTF tumours contain a mutation located in exon 3 causing one 
of the following substitutions: a replacement of threonine to alanine at codon 41 (T41A), a 
replacement of serine for phenylalanine (S45F), or a replacement of serine for proline (S45P) 
at codon 45. The relevance for these mutations and their impact on prognosis and clinical 
growth behaviour remains uncertain. Clinical studies demonstrate clear differences in tumour 
behaviour between the most common mutation types. S45F-mutated DTF tumours exhibit a 
higher recurrence rate after primary resection than wild-type (WT) and T41A mutant tumours 
29-32. Several studies demonstrate that S45F tumours have an increased resistance to systemic 
treatments such as meloxicam 33, sorafenib  34, or doxorubicin 35 and that they are more resistant 
to apoptosis and exhibit deregulation of apoptotic-related genes 35. 
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The biological explanation for the aforementioned differences remains unclear. In pre-
clinical research studying liver cancer, different CTNNB1 mutations are linked to different 
levels of β-catenin activation: an S45F mutations led to a weaker activation compared to 
T41A, but the duplication of weak S45F alleles resulted in a final higher β-catenin activity 
36.  In desmoid cells, Hamada et al. reported that S45F desmoid cells have a stronger 
nuclear β-catenin staining and observed an upregulation of Wnt target genes AXIN2 and 
CCND1 compared to WT and T41A cells 37. In this thesis we sought to explain these clinical 
differences based on mRNA expression data and DNA methylation patterns. In Chapter 3, 
we compared Wnt signalling activity between the mutation types based on the expression 
of Wnt target genes. We were not able to identify differences comparing the different 
mutations types. In Chapter 4, we used a novel technique to uncover whole genome DNA-
methylation patterns. No distinct DNA-methylation patterns were found between DTF with 
a S45F or T41A mutation. From this research we tentatively conclude that S45F and T41A 
are biologically similar and that observed clinical differences may be caused by other factors 
such as tumour location or size 38. A possible confounder in our studies is that the WT 
group, now defined by the absence of mutations in exon 3 of CTNNB1, needs to be screened 
more thoroughly for CTNNB1 mutations. This group of DTF tumours remain peculiar, as 
previous studies show that a large part of these “wild-type” contain other mutations in APC 
or CTNNB1 which can be detected using more sensitive methods than Sanger Sequencing 
(e.g., Next Generation Sequencing) 39, 40. In this group, other genomic alterations can occur 
like APC loss, chromosome 6 loss and alterations such as BMI1 mutations are seen. All of 
these alterations are linked to Wnt/β-catenin activation 40 and this pathway seems to play a 
pivotal role in the development of DTF tumours. More insight into the genes that drive this 
subgroup of tumours and their biological and clinical differences with the more common 
mutation is encouraged.
Diagnosis and Treatment
About one third of DTF patients is misdiagnosed at the first presentation 41. Early recognition 
and referral to a sarcoma centre with a medical specialist with affinity for DTF, is vital 
for a patient to establish a correct diagnosis and treatment plan 3. Magnetic resonance 
imaging (MRI) is the preferred imaging modality for extra-abdominal or abdominal 
wall soft tissue sarcomas (STS) and DTF. However, these two entities can display similar 
imaging characteristics such as fascial crossing and invasive growth 42. As DTF is rare, 
there are no established imaging protocols and diagnosing can be challenging. Radiomics 
is a promising technique that links large amounts of quantitative imaging features with 
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clinical outcome 43-47. In Chapter 5, we used radiomics to create a prediction model for 
the differential diagnosis of DTF (DTF versus STS) and the different genetic mutations 
(S45F, T41A, and WT) observed in DTF. We showed that our radiomics model was capable 
of distinguishing DTF from STS based on T1-weighted and T2-weighted MR images, and 
the model outperformed the two experienced radiologists. Unfortunately, the model was 
not able to predict the CTNNB1 mutation type of the included DTF tumours. The results 
of our study encourages the use of computer-aided models in the diagnostic trajectories of 
rare diseases.
After establishing the correct diagnosis, treatment decisions are based on the patients’ 
preferences, comorbidities, symptoms, tumor site and tumour size. Treatment decisions 
are preferably made in a multidisciplinary team meeting in the presence of a radiologist, 
a pathologist, a surgeon, an oncologist, and a radiotherapist, all with relevant expertise 
regarding soft tissue sarcomas and DTF. The increasing knowledge about the biology of 
DTF has taught us that active surveillance can be a safe approach 3, 48. Consequently, the 
rate of surgery as an initial treatment therefore decreased from 55% to 42% between 2010 
and 2015 in a French nationwide cohort study 49. Three prospective clinical trials (NTR 
4714, the Netherlands, NCT02547831, Italy, and NCT01801176, France) are conducted in 
Europe to evaluate the percentage of patients that do not need to receive an active form of 
treatment 50-52. The results of those trials are still awaited. In an attempt to systematically 
evaluate the results of the active surveillance using retrospective data, we performed a 
systematic literature review in Chapter 6. This study showed that a majority of patients 
undergoing active surveillance have either stable disease or partial response. The overall 
median percentage of patients with partial response in the included studies was 20% (95% 
CI 10-24) which demonstrates the capacity of DTF tumours of undergoing spontaneous 
regression. About one-third of patients shift to an active form of treatment. Although the 
active surveillance approach avoids the complications seen in active treatments, patients 
should be made aware of the benefits and risks to increase the chance of a successful active 
surveillance. Moreover, there is a need for identification of patients that will benefit from 
this approach.
A way of stratifying the patients that will benefit from a certain treatment approach is 
to determine the CTNNB1 mutation type. Several studies implicate a prognostic role for 
these mutations specifically after surgical resection 29-32. These studies imply that the 
S45F mutated desmoid tumour has an increased risk of recurrence compared to other 
CTNNB1 mutations and WT desmoid tumours. However, these studies were all small-sized 
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heterogeneous retrospective studies and other report contradictory results 53, 54. To assess 
the true prognostic value of the S45F mutation for recurrence in a homogeneous group of 
patients, we performed a meta-analysis with individual patient data of patients with primary 
DTF treated with surgery only (reported in Chapter 7). We found that S45F mutated 
tumours do have a higher chance of recurrence compared to WT and T41A mutations. 
However, this risk of recurrence appeared to be mediated by tumour size and a higher 
chance of recurrence for S45F tumours was only valid for small tumours (<5 cm). This study 
suggests that a prognostic nomogram should not only focus on tumour site, size and age, but 
should also include CTNNB1 mutation status when predicting the risk of recurrence 38.
Health-related Quality of Life
Whilst decreasing the risk of recurrence or achieving tumour stabilization or regression are 
the goal of many treatments, the effect of lowering symptoms must not be underestimated 
55. DTF remains a tumor with many faces; varying from a small, asymptomatic lump to a 
large infiltrative debilitating tumour and multiple recurrences. Especially in an unknown 
disease with a wide variety of clinical outcomes, evaluating HRQoL can be relevant to 
meet a patients’ need. To achieve this, more knowledge about the impact of the disease on 
a patients’ life is a necessity. Furthermore, a tool, designed specifically for DTF required. 
In Chapter 8, 9 and 10 we describe the development of a DTF-specific questionnaire, the 
DTF-QOL, according to the guidelines of the European Organization for Research and 
Treatment for Cancer (EORTC) 56. In Chapter 8, we conducted a systematic literature 
review and organized patient focus groups to identify relevant HRQoL-issues. In Chapter 
9, the issues are ranked and prioritized by patients and health-care professionals. These two 
studies showed the impact of the disease on various domains of DTF patients and led to the 
initiation of the QUALIFIED study (The evaluation of health-related quality of life issues 
experienced by patients with desmoid-type fibromatosis), of which the protocol is described 
in Chapter 10. This study includes the DTF-specific questionnaire, the ‘DTF-QOL’ which 
covers all HRQoL-domains. The results of this study will hopefully provide insight into 
the prevalence of HRQoL-issues and can be used to identify patients at risk for impaired 
HRQoL to improve our DTF care.
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Investing in in Vivo and in Vitro Models to  
Understand DTF Biology
The clinical course of DTF tumours varies widely. Although several factors have been 
mentioned to influence risk of recurrence or to reflect tumour aggressiveness such as tumour 
site, size and type of CTNNB1 mutation, up until now, for a large part, DTF biology is still 
unknown. The current thesis focuses mainly on the hypothesized biological differences 
between the most common mutation types of DTF. Our translational research was mainly 
challenged by the limited number of available biomaterials and corresponding clinical 
data. Therefore, inevitably given the rarity of DTF, the used study sample sizes were small, 
potentially contributing to inconclusive or negative results. Moreover, types of analysis 
were restricted by the use of FFPE material and lack of fresh frozen tissues and micro-array 
data. Commercially available desmoid cell lines are scarce and culturing of DTF tumour 
tissue remains challenging. This is mainly due to overgrowth of fibroblastic cells without 
a CTNNB1 mutation.
Currently, clonal expansion techniques to separate tumour cells (containing an CTNNB1 
mutation) from stromal cells are being exploited 1. Although cell lines are a corner 
stone of many translational studies, one should also consider the role of the tumour 
microenvironment in DTF pathogenesis and growth. DTF tumours are known to be 
heterogeneous, and unpublished work from M. Al-Jazrawe and B.A. Alman showed that 
there is a large variation in the proportion of stromal cells and mutated cells per tumour 
1. The clinical consequences of these differences are still not clear but could explain the 
observed differences in tumour behaviour in culture, and possibly in patients. The role of 
the tumour microenvironment is well recognized in cancer, and the cross talk between 
stromal and neoplastic cells are thought to play an important role in tumour initiation, 
progression, and invasion 2, 3. Future studies should therefore acknowledge the contribution 
of the tumour microenvironment for example by using representative animal models rather 
than cell lines. A murine model; APC+/APC1638N1638N and a Xenopus tropicalis model have 
been developed. Unfortunately, both models are APC-based and may not be representative 
for the sporadic DTF 4,5. Currently, mouse models with a mutation in CTNNB1 (T41A and 
S45F) are being developed for research purposes 6. These animal models could be of use 
to study the DTF pathogenesis, microenvironment, and tumour growth. Furthermore, they 
could be of value when testing the efficacy of existing treatments in vivo.
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(Inter)national Case Registration
In order to increase the availability of biomaterials accurate identification and registration of 
patients is a necessity. As the disease is not classified as a cancer 7, cases are not registered 
in the Dutch national cancer registry. Currently, our research is depending on the Dutch 
national pathology database: Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief 
(PALGA) 8. This registry provides pathology reports, but contains little clinical information, 
and results can be distorted due to the use of general terms like “fibrosis”. Furthermore, 
obtaining clinical data is challenging as patients are often referred to their local hospitals 
for initial diagnosis before referral to one of the seven Dutch sarcoma-expertise clinics. This 
could lead to fragmentation of patient data, as the first diagnostic specimen remains in the 
local hospital, whilst data of additional molecular analysis and the clinical data are localized 
in the expert clinic. Currently, both pathological analysis (first diagnosis and additional 
molecular analyses) are registered separately in PALGA, and patient linkage is not always 
possible. This type of registration leads to missing data or incorrect data interpretation. 
Especially due to the rarity of the disease, a complete registration system to identify patients 
and their diagnostic pathways on a national level must be possible. This national registry 
could be complemented by an imaging database, such as the radiomics platform, in order 
to recognize patters on imaging, to predict clinical behaviour.
Several worldwide initiatives have been made to improve the registration process of DTF 
cases. For example, the American patient association, the Desmoid Tumor Research 
Foundation (DTRF), developed the DTRF registry 9. This patient registry is an online 
system completed by patients, and designed to understand patients’ experiences and the 
natural history of DTF. The French sarcoma network has also made tremendous efforts to 
improve registration by including DTF patients in the national sarcoma registry 10. This 
effort decreased the number of misdiagnosis, shortened the diagnostic delay, and increased 
the number of patients treated in an expert centre 11. Accurate case registration would 
aid translational research projects by identification of biomaterial available for research 
purposes. Clinical research would benefit by quick identification of eligible patients for both 
retrospective and prospective studies. Additionally, such a registration would be helpful 
for quick and clear communication about important research updates and it will assist 
international collaborations. Therefore, a national DTF registration system is advised.
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The Usefulness of RECIST in DTF
Tumour size in DTF remains an ambiguous variable since DTF can display variable shapes 
with irregular margins and infiltrative growth 12, 13. Currently, Response Evaluation Criteria 
in Solid Tumors (RECIST, version 1.1) 14, 15 is used for determining treatment success using 
the categories; complete response (CR), partial response (PR), stable disease (SD), and 
progressive disease (PD) 15. However, these criteria assumes spherical-shaped tumours 
and a uniform decrease in size 16. To obtain a “partial response” status, a 30% tumour 
size reduction has to be achieved. This may not always be feasible in DTF; hence, the 
relatively high number of reported SD in retrospective trials evaluating systemic treatments 
and active surveillance. Furthermore, distinction of natural DTF tumour behaviour and 
the true efficacy of treatment can be challenging 17, 18. This is illustrated in the phase 
3 sorafenib versus placebo trial, in which 20% of patients on placebo display a partial 
response 19. Therefore, we encourage to use a volumetric parameter, alongside RECIST, to 
evaluate treatment response and/or to observe the natural growth of DTF 16. Our radiomics 
model might provide a platform to obtain such volume measurements as it uses semi-
automatic segmentation of the entire tumour in multiple dimensions. Moreover, it can 
be used in various imaging modalities such as ultrasound, computed tomography, and 
magnetic resonance imaging (MRI). It can also provide insights into changes in histological 
activity, reflected by hyperintense signals on T2 weighted MRI, which can be diminished 
without changes in tumour size 20. We encourage efforts to improve the radiomics platform, 
exploring automatic segmentation options to make the process less time consuming, and 
to include volumetric parameters when evaluating treatment response or natural growth of 
DTF. This radiomics platform could also be used in a longitudinal manner to map tumour 
growth, and to predict tumour behaviour.
Health-Related Quality Of Life
HRQoL is increasingly used as an endpoint in clinical trials for DTF (e.g., NCT04195399 
21, NCT01876082 22, and NCT03966742 23). Measuring HRQoL in DTF is relevant as the 
mortality rate is low and traditional oncologic endpoints are less relevant. However, there 
are some factors to consider. First, appropriate time points for assessing HRQoL have 
to be identified so that treatment arms are evaluated in a fair and similar manner. The 
accurate choosing of time points to assess HRQoL can be challenging by the unpredictable 
response of DTF to certain treatments, for example delayed response or late recurrences 
24-26. Additionally, measurable response does not necessarily mean a decrease in symptoms 
26-28. Choosing accurate time points depends on the treatment type, the type and timing of 
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expected effects of the treatment and this should be individually established for each clinical 
trial. Second, trial information should be presented as objective as possible to minimize 
influence on treatment decisions and HRQoL-issues. This could be established by using 
standardized information videos to inform patients about the study design, potential adverse 
effects and trial endpoints. Third, the balance between accurate assessment of HRQoL and 
patient response burden must be evaluated carefully; as too many questionnaires and/or 
to many questions can lead to a decrease in response rates and missing data 29. Fourth, the 
research team should establish a baseline HRQoL-value for their cohort and have consensus 
on the definition of the desirable ‘effect’ on HRQoL of the investigated treatment strategy. 
Insight into common HRQoL-problems can serve as a source of information for new patients 
and their loved ones. Despite the aforementioned challenges, incorporation of HRQoL as a 
clinical endpoint will provide evidence for the efficacy of a certain treatment on symptom 
relieve and improvement of HRQoL. The use of a DTF-specific measurement is encouraged 
as such as tool captures disease-specific problems.
Final Remark
The knowledge about desmoid-type fibromatosis (DTF) has grown significantly over the past 
decades and it continues to grow. Strengthened collaborations, accurate case registration, 
and the use of new technologies and representative tumour models will lay the foundation 
towards of a global consensus for the optimal treatment of this rare disease. Such a network 
will accumulate valuable insights, experiences and knowledge from all over the world and it 
will act as a powerful platform for health care providers committed to this rare disease.
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Summary
This thesis consists of four parts. Part I of this thesis aims to gain insight into the genetics 
and biology of desmoid-type fibromatosis (DTF). The first chapter describes the role of the 
various cell signalling pathways. The other chapters aim to explain potential differences in 
clinical behaviour by comparing Wingless (Wnt)/ β-catenin signalling and DNA methylation 
patterns of the most common CTNNB1 mutation types. Part II describes a novel technique 
named radiomics, evaluates the success of the active surveillance approach and investigates 
whether primary S45F-mutated DTF tumours have an increased risk on recurrence after 
surgery. Part III describes the health-related quality of life (HRQoL) in the setting of DTF.
Part I - Genetics and Molecular Biology
Chapter 2 describes the current evidence for the use of targeted therapies in the treatment of 
DTF. Specific attention was paid to in vivo/in vitro studies. This literature review aimed to 
review the common cell signalling pathways Wnt/β-catenin, JAK/STAT, Notch, PI3 kinase/
AKT, mTOR, Hedgehog, the oestrogen pathway, and the growth regulatory pathway, which 
might play a role in the pathogenesis of DTF. Additionally, an overview on the currently 
available targeted therapies targeting the aforementioned pathways is provided. This 
review underlined the existing evidence for activation of the Wnt/β-catenin cell signalling 
pathway, but currently there are no clinically available treatments targeting this pathway. 
The evidence for activation of the other signalling pathways is weak and mainly based on 
the expression of certain genes or reports of observed clinical response after treatment 
with available targeted therapies. Currently, few randomized clinical trials investigate the 
effect of targeted therapies. This study raises awareness to the need to better understand 
the biology of DTF and identify novel therapeutic drug targets.
Chapter 3 describes the role of the Wnt/β-catenin cell signalling pathway. β-catenin is a 
major player in this pathway and this chapter investigated the differences in expression of 
Wnt-related genes between the different mutation types of DTF (S45F, T41A, S45P and 
wild-type (WT)). This study uses mRNA data of 128 desmoid patients from an Affymetrix 
dataset (gene Expression Omnibus series matrix file, GSE58697). Additionally, the 
expression of AXIN2, CCND1, and DKK1 was calculated in 64 desmoid patients by real-time 
polymerase chain reactions (RT-PCR). There were no statistically significant differences 
in relative expression levels of the Wnt-related genes AXIN2, CCND1, and DKK1 between 
the β-catenin mutants. Hierarchical cluster analyses using selected Wnt targets did not 
discriminate between different CTNNB1 mutation types.
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Chapter 4 examines the genome-wide DNA methylation profiles of S45F and T41A 
mutated DTF. MeD-seq analysis was performed on 29 primary DTF tumours including 15 
T41A samples and 14 S45F samples. In total, 365 regions were identified as differentially 
methylated regions (DMRs). Clustering analysis yielded no clear separation was observed 
between the two mutation groups. Only few DMRs had a fold change of ≥ 1.5 implicating 
no difference in methylation between mutation types. No differences in expression of the 
corresponding genes of those DMRs between the two mutation types were confirmed in an 
independent mRNA Affymetrix dataset. Immunoprecipitation did not reveal an association 
of wild-type β-catenin or mutant variants with DNMT1.
Part II - Diagnosis and Treatment
Chapter 5 describes the use of a new technology: radiomics that related large amounts of 
quantitative imaging features to clinical outcome. In this chapter we used radiomics in an 
effort to simplify the diagnosis of DTF by creating a model that could distinguish extremity 
DTF from other extremity soft tissue sarcoma (STS) on a pre-treatment T1-weighted (T1w)
magnetic resonance imaging (MRI) scan. Furthermore a prediction model was created 
for determining the CTNNB1 mutation type. The MRI data encompassed tumours from 
203 patients and included 72 patients with DTF and 131 patients with STS. Tumours were 
semi-automatically annotated on the T1w images, from which 424 features were extracted. 
The T1w radiomics model showed a mean area under the curve (AUC) of 0.79 on the full 
dataset. Addition of T2w and post-contrast sequences did not improve the performance. On 
the location matched cohort, the T1w model had a mean AUC of 0.88 while the radiologists 
had an mean AUC of 0.80 and 0.88, respectively. For the prediction of the mutations (S45F, 
T41A and wild-type), the T1w model showed an mean AUC of 0.61, 0.56, and 0.74. From 
this research we have to conclude that the radiomics model was able to distinguish DTF 
from STS with high accuracy similar to two radiologists, but was not able to predict the 
CTNNB1 mutation status.
In Chapter 6 we performed a systematic literature search to systematically evaluate the 
results of retrospective studies describing the active surveillance approach. A total of 
24 articles were included describing a total of 3541 patients of which 40.7% (n = 1404) 
received active surveillance. The majority were females and the majority had a primary 
tumour. About 20% of patients had progressive disease, 58% had stable disease and 20% 
of patients had a partial response. About 30% of patients needed shift to an active form of 
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treatment most commonly surgery and systemic treatment. The reported median follow-up 
time ranged between 8 and 73 months, and the reported median time to progression and/or 
initiation of the subgroup shifting from active surveillance to ‘active’ therapy ranged from 
6.5 months to 19.7 months. Selecting patients who will benefit from this active surveillance 
approach upfront should be the priority of future studies.
Chapter 7 describes a meta-analysis of seven retrospective studies with individual patient 
data of 329 patients to analyse differences in risk of recurrent according to the CTNNB1 
mutation status. From the total group of patients, 154 had a tumour with a T41A mutation, 
66 patients presented tumours with a S45F mutation, 24 tumours displayed a S45P mutation 
and 85 contained WT CTNNB1 tumours. Eighty-three patients (25.2%) experienced a 
tumour recurrence after surgery. Multivariable analysis, adjusting for sex, age and tumour 
site yielded a p-value of 0.011 for CTNNB1 mutation and risk of recurrence after surgery. 
Additional adjustment for tumour size yielded a p-value of 0.082 with hazard ratio’s (HR) 
of 0.83 (95% confidence interval [CI] 0.48-1.42), 0.37 (95% CI 0.12-1.14) and 0.44 (95% CI 
0.21-0.92) for T41A, S45P and WT DTF tumours compared to S45F DTF tumours. From 
this study we concluded that primary, sporadic DTFs harbouring a CTNNB1 S45F mutation 
have a higher risk of recurrence after surgery compared to T41A, S45P and WT DTF, but 
this association appears to be mediated by tumour size.
Part III - Health-Related Quality of Life
Chapter 8 investigated the impact of DTF on HRQoL. A mixed methods methodology 
was used consisting of a systematic literature review to provide an overview of measures 
previously used to evaluate HRQoL among DTF patients and focus groups, to gain insight 
into HRQOL-issues experienced by DTF patients. Thirteen articles reporting HRQoL-
measures using a wide variety of cancer-specific HRQoL tools, functional scores, symptom 
scales, and single-item outcomes (e.g., pain and functional impairment) were identified 
but no DTF specific HRQoL-tool was found. Qualitative analysis of three focus groups (6 
males, 9 females) showed that participants emphasised the negative impact of DTF and/or 
its treatment on several HRQoL-domains. Six themes were identified including diagnosis, 
treatment, follow-up and recurrence, the physical domain, the psychological and emotional 
domain and the social domain. This study indicates that HRQoL of DTF patients was 
negatively affected in several domains. A DTF-specific HRQoL-measure could improve 
our understanding of short- and long-term effects and, ideally, can be used in both clinic 
and for research purposes.
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In Chapter 9, we used the results of chapter 8 and the corresponding study from the 
United Kingdom (UK) of Husson et al. (2018, Support Care Cancer) to create a list of 
issues regarding diagnosis, treatment, follow-up, recurrence, living with DTF, healthcare 
and supportive care experiences. DTF patients and health care providers (HCPs) from the 
Netherlands and the UK individually ranked 124 issues according to their relevance. The 
most highly ranked issues by 29 patients were issues concerning “tumour growth”, “feeling 
that there is something in the body that does not belong there”, and “fear of tumour growth 
into adjacent tissues or organs”. British patients scored higher on most issues compared to 
Dutch patients and 31 HCPs gave higher scores on most issues compared to patients. Field-
testing in a large, international cohort is needed to confirm these findings and to devise a 
comprehensive and specific HRQoL-questionnaire for DTF patients.
Chapter 10 describes the protocol of the QUALIFIED study (The evaluation of health-
related quality of life issues experienced by patients with desmoid-type fibromatosis), an 
international, multicentre, cross-sectional, observational cohort study. The DTF-specific 
questionnaire, the DTF-QOL supplements existing questionnaires such as the European 
Organization for Research and Treatment for Cancer Quality of Life Questionnaire (EORTC 
QLQ-C30), and the EuroQol 5D (EQ-5D) and questionnaires compiled specifically for this 
study to gather sociodemographic and clinical characteristics. All adult (≥18 years) patients 
diagnosed between January 1990 and October 2019, with pathologically proven, sporadic 
DTF and a recent (between October 2014 and October 2019) visit to the hospital for their 
DTF are eligible for inclusion. Questionnaires will be completed using PROFILES (Patient 
Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship), 
a system to electronically capture questionnaire responses. It aims to gain insight into 
DTF-specific HRQoL-problems, to compare HRQoL-scores of DTF patients in the general 
Dutch and British population; and to identify subgroups at risk for impaired HRQoL.
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Samenvatting
Dit proefschrift bestaat uit vier delen. In Deel I van dit proefschrift wordt gepoogd inzicht 
te geven in de genetica en de biologie van desmoïd-type fibromatose (DTF). Het eerste 
hoofdstuk beschrijft de rol van verschillende signaaltransductie cascades. De andere 
hoofdstukken proberen het verschil in klinisch gedrag van desmoïd tumoren te verklaren 
door de Wingless (Wnt)/β-catenine signaaltransductie cascade en DNA methylatie patronen 
tussen de verschillende veel voorkomende CTNNB1 mutatie types te vergelijken. Deel II 
beschrijft de toepassing van een nieuwe techniek, genaamd radiomics, om het diagnostische 
proces van DTF te optimaliseren. Verder wordt het succes van de actieve observatie (in het 
Engels: active surveillance) geëvalueerd en wordt er onderzocht of primaire tumoren die een 
S45F mutatie bezitten een hoger risico op een recidief hebben na chirurgische resectie. Deel 
III beschrijft de gezondheid-gerelateerde kwaliteit van leven van patiënten met DTF.
Deel I – Genetica en Moleculaire Biologie
In hoofdstuk 2 is de huidige bewijslast voor het geven van doelgerichte, oftewel “targeted” 
therapieën voor DTF. Samengevat werd hierbij gelet op de bewijslast van in vivo en in vitro 
experimenten. Voor deze studie werd er middels een literatuuronderzoek een overzicht gegeven 
van bekende signaaltransductie cascades welke mogelijk een rol spelen in de pathogenese van 
DTF. De volgende signaaltransductie cascades werden bekeken: Wnt/β-catenine, JAK/STAT, 
Notch, PI3 kinase/AKT, mTOR, Hedgehog, de oestrogeen signaaltransductie cascade en de 
groeifactor signaaltransductie cascade. Ook werd er een overzicht gegeven van de beschikbare 
therapieën door aan te geven op welke manier zij mogelijk op deze signaaltransductie cascades 
inwerken. Er zijn veel aanwijzingen dat activatie van de Wnt/β-catenine signaaltransductie 
cascade een belangrijke rol speelt in DTF, maar helaas is er tot op heden nog geen klinisch 
beschikbaar middel op de markt dat hierop ingrijpt. Voor de andere genoemde cascades is 
het bewijs dat zij geactiveerd zijn in DTF schaars en met name gebaseerd op expressie van 
bepaalde genen of gebaseerd op werkzaamheid van reeds bestaande middelen die in de setting 
van DTF werden uitgeprobeerd. Tevens zijn er momenteel weinig medicamenteuze studies 
die het effect van bepaalde medicamenten in gerandomiseerde studies hebben onderzocht. Op 
basis van de resultaten van deze studie kan er mogelijk meer onderzoek gedaan worden naar de 
biologische rationale voor de werkzaamheid van reeds beschikbare medicamenten in DTF.
Hoofdstuk 3 beschrijft de rol van de Wnt/β-catenine signaaltransductie cascade. β-catenine 
is een belangrijk eiwit in deze signaaltransductie cascade en in dit hoofdstuk werd er 
onderzocht of er verschillen zijn tussen de expressie van Wnt-gerelateerde genen tussen de 
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verschillende CTNNB1 (β-catenine) mutaties die voorkomen in desmoïd tumoren. Voor 
deze studie werd er gebruik gemaakt van mRNA expressie data van 128 desmoïd patiënten 
uit een openbare Affymetrix dataset. Aanvullend werd er gekeken naar de expressie van 
AXIN2, CCND1 en DKK1 in 64 andere DTF-patiënten met real-time polymerase chain 
reaction (RT-PCR). Uit deze studie blijkt dat er geen verschil is in de expressie van de Wnt-
gerelateerde genen AXIN2, CCND1 en DKK1 tussen β-catenine mutanten. Tevens bleek 
uit clusteranalyse, op basis van expressieprofielen van genen die het product zijn van de 
Wnt/β-catenine signaaltransductie cascade, dat de verschillende mutanten niet van elkaar 
konden worden onderscheiden.
Hoofdstuk 4 onderzoekt DNA methylatie profielen van S45F en T41A mutaties in DTF. 
MeD-seq analyse werd uitgevoerd op 29 primaire DTF tumoren waarvan 14 een T41A 
mutatie en 15 een S45F mutatie hadden. In totaal werden 365 regio’s geïdentificeerd als 
“anders gemethyleerde regio’s” (in het Engels: differentially methylated regions (DMR’s)) 
echter hadden slechts zes DMR’s hadden een fold-change van ≥1.5. Een cluster analyse 
liet zien dat er geen duidelijk te onderscheiden methylatiepatronen per mutatie groep zijn. 
Ook in een onafhankelijke mRNA expressie dataset konden er geen duidelijke expressie 
verschillen gevonden worden tussen mutanten waarbij er specifiek gekeken is naar de genen 
die aan de DMR’s gerelateerd zijn. Immunoprecipitatie liet geen associatie zien tussen wild-
type β-catenine of gemuteerde β-catenin varianten en DNMT1.
Deel II – Diagnose en Behandeling
Hoofdstuk 5 beschrijft het gebruik van een nieuwe technologie; radiomics welke grote 
hoeveelheden beeldeigenschappen relateert aan klinische uitkomsten. In dit hoofdstuk 
werd radiomics ingezet om te kijken of het diagnosticeren van DTF versimpeld kon 
worden door het creëren van een radiomics model. Met dit model wordt er gekeken of 
DTF in de extremiteiten onderscheiden kan worden van andere wekedelen sarcomen in de 
extremiteiten op T1-gewogen magnetic resonance imaging (MRI) beelden welke vóór de 
start van de behandeling vervaardigd werden. Verder werd er een voorspel model gemaakt 
om te voorspellen welke CTNNB1 mutatie een desmoïd tumor bezit. In totaal werden 203 
patiënten geïncludeerd; 72 patiënten hadden een desmoïd tumor, 131 patiënten hadden een 
wekedelen sarcoom. Tumoren werden semiautomatisch geannoteerd op T1-gewogen MRI-
beelden. In totaal werden hier 424 beeld karakteristieken uit onttrokken. Het T1-gewogen 
radiomics model had een gemiddeld gebied onder de curve (in het Engels Area Under the 
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Curve (AUC)) van 0.79 op de volledige dataset. Toevoeging van T2-gewogen en post-
contrast beelden verbeterde de prestaties van het model niet. In het locatie gematchte-cohort, 
waarin alleen patiënten met extremiteit tumoren werden geïncludeerd, had het T1-gewogen 
model een gemiddelde AUC van 0.88 terwijl de radiologen een gemiddelde AUC van 0.80 en 
0.88 hadden. Voor het voorspellen van de mutaties (S45F, T41A en WT, liet het T1-gewogen 
model een gemiddelde AUC van 0.61, 0.56 en 0.75 respectievelijk zien. Uit deze studie 
concluderen we dat het radiomics model in staat is om DTF van wekedelen sarcomen van 
de extremiteiten te onderscheiden met een hoge accuratesse, welke gelijk staat aan twee 
radiologen. Het model was niet in staat om het type CTNNB1 mutatie te voorspellen.
In Hoofdstuk 6 werd een systematisch literatuuronderzoek uitgevoerd om de resultaten 
van actieve observatie (in het Engels: active surveillance) beschrijven, die werd beschreven 
in verschillende retrospectieve studies, samen te vatten. In totaal werden 24 artikelen 
geïncludeerd welke een totaal van 3541 patiënten beschreven. 40.7% van deze patiënten 
(n = 1404) ondergingen actieve observatie. De meerderheid was vrouw en de meerderheid 
had een primaire tumor. Ongeveer 20% van de patiënten had progressieve ziekte, 58% 
had stabiele ziekte en 20% van de patiënten had een gedeeltelijke regressie van de tumor. 
Circa 30% van de patiënten moest veranderen van behandelingsvorm, dit betrof meestal 
chirurgische resectie of systemische behandeling. De gerapporteerde mediane follow-up 
tijd varieerde tussen de 8 en 73 maanden en de gerapporteerde mediane tijd tot progressie 
en/of initiatie van een actieve behandeling varieerde tussen 6.5 maanden tot 19.7 maanden. 
Selectie van patiënten die van deze actieve observatie profiteren moet de prioriteit worden 
bij het ontwerpen van toekomstige studies.
Hoofdstuk 7 beschrijft een meta-analyse van zeven retrospectieve studies met individuele 
patiënten data van 329 patiënten om de verschillen in het risico op het krijgen van een 
recidief na chirurgie te analyseren tussen de verschillende CTNNB1 mutaties. Van een totale 
groep hadden 154 patiënten een T41A mutatie, 66 patiënten een S45F mutatie, 24 patiënten 
een S45P mutatie en 85 patiënten een WT DTF tumor. Van de totale groep had uiteindelijk 
83 patiënten (25.2%) een recidief. Een multivariabele analyse, waarbij er gecorrigeerd werd 
voor geslacht, leeftijd en tumor locatie toonde een p-waarde van 0.011 voor de CTNNB1 
mutatie. Een additionele correctie voor tumor grootte toonde echter een p-waarde van 
0.082 voor CTNNB1 mutatie met hazard ratio’s van 0.83 (95% betrouwbaarheidsinterval 
[BI] 0.48-1.42), 0.37 (95% BI 0.12-1.14) en 0.44 (95% BI 0.21-0.92) voor T41A, S45P en 
WT DTF tumoren in vergelijking met S45F DTF-tumoren. Uit deze studie concluderen we 
dat primaire, sporadische DTF-tumoren die een CTNNB1 S45F mutatie hebben een hoger 
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risico hebben op recidief na operatie in vergelijking met T41A, S45P en WT, maar dat deze 
associatie gemedieerd wordt met door tumor grootte.
Deel III – Gezondheids-Gerelateerde Kwaliteit Van Leven
In Hoofdstuk 8 wordt de impact van deze zeldzame ziekte op gezondheid gerelateerde 
kwaliteit van leven beschreven. Een systematisch literatuuronderzoek geeft een overzicht 
van de kwaliteit-van-leven-instrumenten die op dit moment ingezet worden om de kwaliteit 
van leven van patiënten met DTF te beoordelen. Daarnaast werden er focus groepen 
georganiseerd om te evalueren welke problemen er bij deze patiënten spelen. Dertien 
artikelen rapporteren kwaliteit-van-leven-instrumenten met een variëteit aan kanker-
specifieke instrumenten, functie scores, symptoom schalen en lijsten die een enkele uitkomst 
(vb. pijn of functionele beperking) meten. Er werd geen DTF-specifiek kwaliteit-van-leven 
instrument gevonden. Kwalitatieve analyse van 3 focusgroepen waar 6 vrouwen en 9 
mannen aan deelnamen toonden dat de ziekte een negatieve impact had op de volgende 
domeinen: 1) diagnose, 2) behandeling, 3) follow-up en recidief, 4) het fysieke domein, 5) het 
psychologische en emotionele domein 6) en het sociale domein. Deze studie impliceert dat 
de gezondheid gerelateerde kwaliteit van leven van DTF-patiënten negatief wordt beïnvloed 
in verschillende domeinen. Een DTF-specifiek meetinstrument kan het begrip van korte- 
en lange termijneffecten van de ziekte verbeteren en kan zowel in de kliniek als in het 
onderzoek gebruikt worden.
In Hoofdstuk 9 gebruikten we de resultaten van hoofdstuk 8 en de soortgelijke studie 
uit het Verenigd Koningrijk van Husson et al. (2018, Support Care Cancer) om een lijst 
met problemen te ontwikkelen. DTF-patiënten en zorgprofessionals uit Nederland en 
het Verenigd Koningrijk scoorde de relevantie van elk probleem. In totaal deden 29 
patiënten mee en 31 zorg professionals. De meest relevante problemen gingen over: 
“tumorgroei”, “het gevoel dat er iets in het lichaam zit wat daar niet thuishoort”, en 
“angst van tumorgroei in omliggend weefsel en organen”. Britse patiënten scoorde hoger 
op de meeste problemen in vergelijking met Nederlandse patiënten. Zorgprofessionals 
gaven hogere scores aan de meeste problemen in vergelijking met patiënten. Op basis 
van de meest relevante problemen werd een vragenlijst samengesteld. Deze vragenlijst, 
de DTF-QOL, zal in een groot internationaal cohort getest worden om de bevindingen 
van deze studie te bevestigen en om de specifieke kwaliteit van leven vragenlijst voor 
desmoïd patiënten verder te ontwikkelen.
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In Hoofdstuk 10 wordt het protocol van de QUALIFIED studie (The evaluation of health-
related quality of life issues experienced by patients with desmoid-type fibromatosis), 
beschreven. Dit is een internationale, multicentrische, cross-sectionele, observationele 
cohortstudie. De DTF-specifieke vragenlijst, de DTF-QOL, die ontwikkeld is op basis van 
de data uit Hoofdstuk 8 en 9, wordt samen met bestaande vragenlijsten zoals de European 
Organization for Research and Treatment for Cancer Quality of Life Questionnaire (EORTC 
QLQ-C30) en de EuroQol 5D (EQ-5D) en vragenlijsten special samengesteld voor deze 
studie voorgelegd aan patiënten om socio-demografische en klinische karakteristieken te 
verzamen. Alle volwassen (≥18 jaar) patiënten, gediagnosticeerd tussen Januari 1990 en 
Oktober 2019 met een pathologisch bewezen, sporadische DTF-tumor en een recent bezoek 
(tussen oktober 2014 en oktober 2019) aan het ziekenhuis voor hun desmoïd zijn geschikt 
voor inclusie. Vragenlijsten worden ingevuld via PROFIEL (PROFILES: (Patient Reported 
Outcomes Following Initial treatment and Long term Evaluation of Survivorship ) een 
systeem dat elektronisch vragenlijsten kan verzamelen. De QUALIFIED studie beoogt 
inzicht te krijgen in DTF-specifieke gezondheid gerelateerde kwaliteit van leven problemen 
door scores van DTF patiënten met scores van de populatie te bekijken en door subgroepen 
die risico lopen op kwaliteit van leven problemen te identificeren.
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